# Obstetric consequences of female genital mutilation/cutting (FGM/C)

Report from Kunnskapssenteret (Norwegian Knowledge Centre for the Health Services)

No 6-2013

Systematic review



Background: Female genital mutilation/cutting (FGM/C) is a traditional practice that involves the partial or total removal of the external female genitalia or other injury to the female genital organs for non-medical reasons. This systematic review aimed to fill a gap in synthesized evidence of the obstetric sequelae of FGM/C. We included 44 primary studies, 28 of which compared groups of women with FGM/C to women with no or different types of genital modifications. Main findings: • Women who have undergone FGM/C seem to be more likely than non-cut women to experience prolonged labor, obstetric tears, instrumental delivery, obstetric hemorrhage, and difficult delivery. • Women with FGM/C type III (infibulation) seem to be more likely than women with FGM/C type I-II (clitoridectomy or excision) to experience problems during delivery. • There was not found a significant difference in risk of cesarean section or episiotomy between women with FGM/C and women without FGM/C. • There was not found a significant difference in risk of obstetric tears, cesarean section, or episiotomy between women with FGM/C type I and women with FGM/C type II. (continued)

Norwegian Knowledge Centre for the Health Services (Kunnskapssenteret)
PO Box 7004, St. Olavs plass
N-0130 Oslo
(+47) 23 25 50 00
www.kunnskapssenteret.no
Report: ISBN 978-82-8121-526-9 ISSN 1890-1298

no 6-2013

# kunnskapssenteret

• There were insufficient data for us to conclude whether the risk of other obstetric complications is higher among women with FGM/C compared to women with no FGM/C and whether various FGM/C types differentially affect the risk of other obstetric complications. • These findings are based on very low quality of evidence and preclude us from drawing conclusions regarding causality. However, while the exact size of the greater risk from FGM/C is unclear, the findings provide evidence of serious harmful consequences from FGM/C.

**Title** Obstetric consequences of female genital mutilation/cutting (FGM/C)

**Norwegian title** Obstetriske konsekvenser av kvinnelig kjønnslemlestelse

**Institution** Norwegian Knowledge Centre for the Health Services (NOKC)

(Nasjonalt kunnskapssenter for helsetjenesten)

Magne Nylenna, Director

Authors Berg, Rigmor C, (Project leader), researcher, NOKC

Underland, Vigdis, researcher, NOKC

ISSN 1890-1298

**ISBN** 978-82-8121-526-9

**Report** No. 6 – 2013

**Project number** 693

**Type of report** Systematic review (Systematisk oversikt)

**No. of pages** 98 (130 including appendices)

**Client** World Health Organization, Norwegian Agency for Development

Cooperation

**Subject heading** 

(MeSH)

Genital mutilation, female; Circumcision, female

**Citation** Berg RC, Underland V. Obstetric consequences of female genital mutilation/cutting (FGM/C). Report from Kunnskapssenteret no.

6-2013. Oslo: Norwegian Knowledge Centre for the Health Services,

2013.

Norwegian Knowledge Centre for the Health Services summarizes and disseminates evidence concerning the effect of treatments, methods, and interventions in health services, in addition to monitoring health service quality. Our goal is to support good decision making in order to provide patients in Norway with the best possible care. The Centre is organized under The Norwegian Directorate for Health, but is scientifically and professionally independent. The Centre has no authority to develop health policy or responsibility to implement policies.

We would like to thank Tove Ringerike, Ingeborg B. Lidal, Owolabi Bjälkander, Vanja Berggren, and Staffan Bergström for their expertise in this project. Norwegian Knowledge Centre for the Health Services assumes final responsibility for the content of this report.

Norwegian Knowledge Centre for the Health Services Oslo, April 2013

# **Key messages**

Female genital mutilation/cutting (FGM/C) is a traditional practice that involves the partial or total removal of the external female genitalia or other injury to the female genital organs for non-medical reasons. This systematic review aimed to fill a gap in synthesized evidence of the obstetric sequelae of FGM/C. We included 44 primary studies, 28 of which compared groups of women with FGM/C to women with no or different types of genital modifications. The main findings are:

- Women who have undergone FGM/C seem to be more likely than non-cut women to experience prolonged labor, obstetric tears, instrumental delivery, obstetric hemorrhage, and difficult delivery.
- Women with FGM/C type III (infibulation) seem to be more likely than women with FGM/C type I-II (clitoridectomy or excision) to experience problems during delivery.
- There was not found a significant difference in risk of cesarean section or episiotomy between women with FGM/C and women without FGM/C.
- There was not found a significant difference in risk of obstetric tears, cesarean section, or episiotomy between women with FGM/C type I and women with FGM/C type II.
- There were insufficient data for us to conclude whether the risk of other obstetric complications is higher among women with FGM/C compared to women with no FGM/C and whether various FGM/C types differentially affect the risk of other obstetric complications.

These findings are based on very low quality of evidence and preclude us from drawing conclusions regarding causality. However, while the exact size of the greater risk from FGM/C is unclear, the findings provide evidence of serious harmful consequences from FGM/C.

#### Title:

Obstetric consequences of female genital mutilation/cutting (FGM/C)

# Type of publication: Systematic review

A review of a clearly formulated question that uses systematic and explicit methods to identify, select, and critically appraise relevant research, and to collect and analyse data from the studies that are included in the review. Statistical methods (meta-analysis) may or may not be used to analyse and summarise the results of the included studies.

# Doesn't answer everything:

- Excludes studies that fall outside of the inclusion criteria
- No health economic evaluation
- No recommendations

### Publisher:

Norwegian Knowledge Centre for the Health Services

### Updated:

Last search for studies: January, 2012.

### Peer review:

Tove Ringerike, researcher, NOKC (Norway)

Ingeborg B. Lidal, researcher, NOKC (Norway)

Owolabi Bjälkander, Ph.D candidate, Karolinska Institute (Sweden)

Vanja Berggren, RN, Ph.D, researcher, Karolinska Institute (Sweden)

Staffan Bergström, MD, Ph.D, professor, Karolinska Institute (Sweden)

# **Executive summary**

### **Background**

Female genital mutilation/cutting (FGM/C) is a traditional practice that involves the partial or total removal of the external female genitalia or other injury to the female genital organs for non-medical reasons. To clarify understanding of the prevalence as well as consequences of the practice, WHO has classified FGM/C into four categories: type I (clitoridectomy), type II (excision), type III (infibulation), and type IV (other). It is widely recognized that FGM/C violates a series of human rights principles – including the Universal Declaration of Human Rights – yet, the practice is found among diverse ethnic groups in about 28 countries in Africa as well as some countries in the Middle East and Asia, and among immigrant communities in Western countries. A range of reasons, which vary across countries, regions and cultural groups, exist for FGM/C, but the practice is generally carried out as a matter of social convention. FGM/C is typically performed on pre-pubescent girls, often without anaesthetics, thus, it is reasonable to assume that it is a traumatic event that may cause short-term as well as long-term harm. WHO writes that, on the physiological level, the procedure causes permanent, irreparable changes in the external female genitalia and that there are no known health benefits to FGM/C. It is estimated that across the world, between 100-140 million girls/women are presently living with FGM/C.

The question addressed in the present systematic review is whether women who have been subjected to FGM/C are more likely than women without FGM/C to experience obstetric complications. Obstetrics is the medical specialty area dealing with the care of women and their children during pregnancy, childbirth, and the first six weeks after delivery.

### **Objective**

This systematic review aimed to fill a gap in synthesized evidence of the obstetric sequelae of FGM/C. The overall aim of the systematic review is to support well-informed decisions in health promotion and health care that inform work to reduce the prevalence of FGM/C and improve quality of services related to the consequences of FGM/C.

The main research question was: What are the obstetric consequences of FGM/C?

### Method

The systematic review was conducted in accordance with the NOKC Handbook for Summarizing Evidence and the Cochrane Handbook for Systematic Reviews of Interventions. The main literature search strategy was searches in 15 international databases. Studies eligible for inclusion were systematic reviews, cohort studies, case-control studies, cross-sectional studies, case series, and case reports. The population of interest was girls and women who have been subjected to any type of FGM/C. It follows that the event or intervention was FGM/C, and the comparison was no- or an alternative type of FGM/C. In this report, we summarized the obstetric consequences of FGM/C. These outcomes included, but were not limited to, prolonged labor, tears/lacerations, caesarean section, episiotomy, instrumental delivery, and post-partum hemorrhage.

Two reviewers assessed studies for inclusion according to pre-specified criteria, considered the methodological quality of the studies using appropriate checklists, and extracted data from the included sources using a pre-designed data recording form. These steps were done independently and then jointly by the two reviewers. Because results from studies which compare groups of women are most valid for evaluating risk of experiencing complications, we prioritized presenting results from comparative studies. We summarized the study level results in texts and tables and calculated effect estimates (relative risk and mean difference). When studies were sufficiently similar, we used the statistical technique of meta-analysis to estimate risk. We applied the instrument Grading of Recommendations Assessment, Development and Evaluation (GRADE) to assess the extent to which we could have confidence in the effect estimates.

#### **Results**

We identified 5,109 publications and after having assessed titles, abstracts, and publications in full text we included 44 primary studies. All included studies were observational studies, of which 28 were comparative, i.e. they compared groups of women with FGM/C to women with no- or a different type of genital modification. The methodological study quality was generally low, with only seven of the 28 comparative studies (25%) judged as having high or moderate methodological study quality. In our assessment, using the GRADE instrument, the quality of the evidence was very low with regards to documenting a causal relationship between FGM/C and obstetric consequences.

Collectively, the studies involved almost 3 million participants. This was due to the inclusion of seven registry studies. Women with FGM/C made up 2.4% of the total sample (n= 70,495). There were eight main outcomes reported across the included studies: Prolonged labor, obstetric tears/lacerations, cesarean section, episiotomy, instrumental delivery, obstetric hemorrhage, dystocia/difficult delivery, other obstetric and antenatal complications.

The main findings are:

- Women who have undergone FGM/C seem to be more likely than non-cut women to experience prolonged labor, obstetric tears, instrumental delivery, obstetric hemorrhage, and difficult delivery.
- Women with FGM/C type III (infibulation) seem to be more likely than women with FGM/C type I-II (clitoridectomy or excision) to experience problems during delivery.
- There was not found a significant difference in risk of cesarean section and episiotomy between women with FGM/C and women without FGM/C.
- There was not found a significant difference in risk of obstetric tears, cesarean section, and episiotomy between women with FGM/C type I and women with FGM/C type II.
- There were insufficient data for us to conclude whether the risk of other obstetric complications is higher among women with FGM/C compared to women with no FGM/C and whether various FGM/C types differentially affect the risk of other obstetric complications.

### Discussion

This systematic review identified a number of disparities in obstetric outcomes for women with FGM/C relative to women who have not undergone FGM/C. Meta-analysis results show that deliveries to women who have undergone FGM/C are more likely to be complicated by prolonged labor, perineal tears/lacerations, instrumental delivery, obstetric hemorrhage, and obstructed labor than deliveries by comparable women who have not undergone FGM/C. Given the studies included in the meta-analyses included women with various types of FGM/C, genital cutting of any type seems to be associated with obstetric complications. Although the available data do not allow for obstetric complications to be causally attributed to FGM/C and the exact size of the greater risk from FGM/C is unclear, the data clarify the obstetric improvements that may be anticipated with the halting of FGM/C. These results could be used as arguments for campaigning against the practice.

### **Conclusion**

The low quality of the body of evidence means that it is unclear whether the documented association of FGM/C with obstetric complications reflects true causality. However, the evidence base suggests that women who have undergone FGM/C are more likely than women who have not been subjected to FGM/C to experience obstetric complications.

It is questionable whether intensified research efforts would meaningfully change the results described here. If further research on the association between FGM/C and obstetric outcomes are considered ethically and financially justified, such studies should be based on the best possible methodological study design, which is case-control studies.

# **Hovedfunn** (norsk)

Kjønnslemlestelse er en tradisjonell praksis som innebærer at hele eller deler av de eksterne kvinnelige kjønnsorganene fjernes eller skades av ikke-terapeutiske grunner. Denne systematiske oversikten hadde som mål å besvare: hva er de obstetriske konsekvensene (fødselskomplikasjoner) av kjønnslemlestelse? Vi inkluderte 44 primærstudier, hvorav 28 studier sammenlignet kvinner utsatt for kjønnslemlestelse med kvinner uten kjønnslemlestelse, eller sammenlignet ulike typer kjønnslemlestelse. Hovedfunnene er:

- Det ser ut til at kvinner med kjønnslemlestelse har større risiko enn kvinner uten kjønnslemlestelse for å oppleve forlenget fødsel, obstetriske rifter, instrumentell forløsning, store blødninger og vanskelig fødsel.
- Det ser ut til at kvinner med kjønnslemlestelse type III (infibulasjon) har større risiko enn kvinner med kjønnslemlestelse type I-II (klitoridektomi eller eksisjon) for å oppleve problemer under fødselen.
- Resultatene viste ingen statistisk signifikant forskjell mellom kvinner med og uten kjønnslemlestelse i risiko for keisersnitt og episiotomi.
- Resultatene viste ingen statistisk signifikant forskjell mellom kvinner med kjønnslemlestelse type I og type II i risiko for obstetriske rifter, keisersnitt og episiotomi.
- Det er ikke grunnlag for å konkludere om risikoen for andre obstetriske komplikasjoner er høyere blant kvinner med kjønnslemlestelse enn uten, og om ulike typer kjønnslemlestelse i ulik grad påvirker risikoen for andre obstetriske komplikasjoner.

Disse resultatene er basert på et kunnskapsgrunnlag av svært lav kvalitet, slik at vi kan ikke dra kausale slutninger. Men selv om den nøyaktige størrelsen på økt risiko av kjønnslemlestelse er uklar, viser resultatene likevel evidens for at kvinner med kjønnslemlestelse i større grad opplever obstetriske problemer enn kvinner uten kjønnslemlestelse.

### Tittel:

Obstetriske konsekvenser av kvinnelig kjønnslemlestelse

### Publikasjonstype:

### Systematisk oversikt

En systematisk oversikt er resultatet av å

- innhente
- kritisk vurdere og
- sammenfatte relevante forskningsresultater ved hjelp av forhåndsdefinerte og eksplisitte metoder.

### Svarer ikke på alt:

- Ingen studier utenfor de eksplisitte inklusjonskriteriene
- Ingen helseøkonomisk evaluering
- Ingen anbefalinger

# Hvem står bak denne rapporten?

Kunnskapssenteret har skrevet rapporten på oppdrag fra Verden Helseorganisasjon og NORAD.

# Når ble litteratursøket utført?

Søk etter studier ble avsluttet Januar, 2012.

### Fagfeller:

Tove Ringerike, forsker, Kunnskapssenteret (Norge)

Ingeborg B. Lidal, forsker, Kunnskapssenteret (Norge)

Owolabi Bjälkander, Ph.D kandidat, Karolinska Institutet (Sverige)

Vanja Berggren, RN, Ph.D, forsker, Karolinska Institutet (Sverige)

Staffan Bergström, MD, Ph.D, professor, Karolinska Institutet (Sverige)

# **Sammendrag** (norsk)

### Obstetriske konsekvenser av kvinnelig kjønnslemlestelse

### **Bakgrunn**

Kjønnslemlestelse er en tradisjonell praksis som innebærer at hele eller deler av de eksterne kvinnelige kjønnsorganene fjernes eller skades av ikke-terapeutiske grunner. For å klargjøre forståelsen av forekomst og konsekvenser av praksisen har verdens helseorganisasjon klassifisert kjønnslemlestelse i fire kategorier: type I (klitoridektomi), type II (eksisjon), type III (infibulasjon) og type IV (andre former). Kjønnslemlestelse er anerkjent som en skadelig praksis som krenker menneskelige rettigheter – inkludert verdenserklæringen om menneskerettigheter – likevel fins praksisen blant ulike etniske grupper i ca 28 land i Afrika, samt noen land i Midtøsten og Asia og blant innvandrere i vestlige land. Begrunnelsene for kjønnslemlestelse varierer på tvers av land, regioner og kulturelle grupper, men praksisen er vanligvis grunnet i at det er en sosial konvensjon. Kjønnslemlestelse utføres vanligvis før pubertetsalderen, ofte uten bedøvelse og det er derfor rimelig å anta at det er en traumatisk hendelse som kan føre til kortsiktige så vel som langsiktige skader. Ifølge verdens helseorganisasjon fører inngrepet til vedvarende, uopprettelige endringer i de ytre kvinnelige kjønnsorganene, og ingen helsemessige gevinster. Det anslås at det på verdensbasis i dag er ca 100-140 millioner jenter/kvinner som lever med kjønnslemlestelse.

### **Problemstilling**

Denne systematiske oversikten hadde som mål å besvare: hva er de obstetriske konsekvensene av kjønnslemlestelse?

### **Metode**

Den systematiske oversikten ble utført i henhold til Kunnskapssenteret metodehåndbok og Cochrane Handbook for Systematic Reviews of Interventions. Den viktigste strategien for identifisering av litteratur var litteratursøk i 15 internasjonale databaser. Vi kunne inkludere følgende studiedesign: systematiske oversikter, kohortestudier, kasuskontrollstudier, tverrsnittstudier, kasus-serier og kasustikker. Populasjonen av interesse var jenter/kvinner som var kjønnslemlestet. Hendelsen ('tiltaket') var kjønnslemlestelse. Sammenligningen var med versus uten kjønnslem-

lestelse, eller én type versus en annen type kjønnslemlestelse. Obstetriske konsekvenser av kjønnslemlestelse kunne inkludere, men var ikke begrenset til: forlenget fødsel, obstetriske rifter, keisersnitt, episiotomi, instrumentell forløsning og post partum-blødning. To medarbeidere, først uavhengig og så sammen, vurderte studier for inklusjon i henhold til forhåndsbestemte kriterier, vurderte den metodiske kvaliteten på studiene ved bruk av egnede sjekklister og hentet ut data fra de inkluderte studiene ved hjelp av et datauttrekkingsskjema. Resultater fra studier som sammenligner grupper gir de mest gyldige svarene på risiko for å oppleve komplikasjoner, derfor prioriterte vi å presentere resultater fra komparative studier. Vi oppsummerte resultater på studienivå i tekst og tabeller og beregnet effektestimat (relativ risiko og gjennomsnittsforskjell). For resultat fra studier som var tilstrekkelig like benyttet vi meta-analyser for å beregne risiko. Vi vurderte den samlede dokumentasjonen for endepunktene ved hjelp av Grading of Recommendations, Assessment, Development and Evaluation (GRADE).

### Resultat

Vi identifiserte 5109 publikasjoner og etter å ha vurdert titler, sammendrag og artikler i fulltekst fant vi 44 studier som oppfylte inklusjonskriteriene. Alle studiene var observasjonsstudier, hvorav 28 var komparative, dvs. de sammenlignet kvinner utsatt for kjønnslemlestelse med kvinner uten kjønnslemlestelse, eller de sammenlignet kvinner med ulike typer kjønnslemlestelse. Den metodiske studiekvaliteten var generelt sett lav; kun syv av de 28 komparative studiene (25 %) hadde høy eller moderat metodisk studiekvalitet. Vi vurderte kvaliteten på den samlede dokumentasjonen for endepunktene ved hjelp av GRADE til svært lav. Det betyr at effektestimatene er for usikre til å kunne dokumentere en kausal sammenheng mellom kjønnslemlestelse og obstetriske konsekvenser. Studiene involverte totalt nesten 3 millioner deltakere. Dette var på grunn av at vi inkluderte syv registerstudier. Kvinner med kjønnslemlestelse utgjorde 2,4 % av det totale utvalget (n= 70 495). Åtte hovedutfall ble rapportert: forlenget fødsel, obstetriske rifter, keisersnitt, episiotomi, instrumentell forløsning, obstetrisk blødning, dystoci/vanskelig fødsel, andre obstetriske komplikasjoner. Hovedfunnene er:

- Det ser ut til at kvinner med kjønnslemlestelse har større risiko enn kvinner uten kjønnslemlestelse for å oppleve forlenget fødsel, obstetriske rifter, instrumentell forløsning, store blødninger og vanskelig fødsel.
- Det ser ut til at kvinner med kjønnslemlestelse type III (infibulasjon) har større risiko enn kvinner med kjønnslemlestelse type I-II (klitoridektomi eller eksisjon) for å oppleve problemer under fødselen.
- Resultatene viste ingen statistisk signifikant forskjell mellom kvinner med og uten kjønnslemlestelse i risiko for keisersnitt og episiotomi.
- Resultatene viste ingen statistisk signifikant forskjell mellom kvinner med kjønnslemlestelse type I og type II i risiko for obstetriske rifter, keisersnitt og episiotomi.

 Det er ikke grunnlag for å konkludere om risikoen for andre obstetriske komplikasjoner er høyere blant kvinner med kjønnslemlestelse enn uten, og om ulike typer kjønnslemlestelse i ulik grad påvirker risikoen for andre obstetriske komplikasjoner.

### Diskusjon

Denne systematiske oversikten identifiserte en rekke forskjeller i obstetriske utfall for kvinner med kjønnslemlestelse i forhold til kvinner som ikke har blitt utsatt for kjønnslemlestelse. Meta-analysene viser at kvinner med kjønnslemlestelse, sammenlignet med kvinner uten kjønnslemlestelse, har større risiko for å oppleve fødselskomplikasjoner som: forlenget fødsel, perinealrifter, instrumentell forløsning, store blødninger, og vanskelig fødsel. Studiene som meta-analysene var basert på inkluderte kvinner med ulike typer kjønnslemlestelse, derfor ser det ut til at enhver type kjønnslemlestelse er assosiert med obstetriske komplikasjoner. Kunnskapsgrunnlager er av såpass lav kvalitet at vi kan ikke dra kausale slutninger og den nøyaktige størrelsen på økt risiko av kjønnslemlestelse er uklar. Likevel avklarer resultatene obstetriske fordeler som kan forventes med at praksisen stopper. Resultatene kan brukes som argumenter i kampanjer mot praksisen.

### Konklusjon

Disse resultatene er basert på et kunnskapsgrunnlag av svært lav kvalitet, slik at vi ikke kan dra kausale slutninger. Men resultatene gir sterkt uttrykk for at kvinner med kjønnslemlestelse har større risiko for å oppleve obstetriske komplikasjoner enn kvinner uten kjønnslemlestelse. Det er usikkert om ytterligere studier vil gi meningsfulle endringer i resultatene vi har sammenfattet her. Hvis videre forskning på sammenhengen mellom kjønnslemlestelse og obstetriske utfall anses som etisk og økonomisk forsvarlig bør slike studier være basert på best mulig design, som er kasuskontrollstudier.

Nasjonalt kunnskapssenter for helsetjenesten fremskaffer og formidler kunnskap om effekt av metoder, virkemidler og tiltak og om kvalitet innen alle deler av helsetjenesten. Målet er å bidra til gode beslutninger slik at brukerne får best mulig helsetjenester. Kunnskapssenteret er formelt et forvaltningsorgan under Helsedirektoratet, men har ikke myndighetsfunksjoner og kan ikke instrueres i faglige spørsmål.

Nasjonalt kunnskapssenter for helsetjenesten PB 7004 St. Olavs plassN-0130 Oslo, Norway

Telefon: +47 23 25 50 00

E-mail: post@kunnskapssenteret.no

Hele rapporten (pdf): www.kunnskapssenteret.no/Publikasjoner

# **Table of contents**

KEY MESSAGES	2
EXECUTIVE SUMMARY	3
Background	3
Objective	3
Method	4
Results	4
Discussion	5
Conclusion	5
HOVEDFUNN (NORSK)	6
SAMMENDRAG (NORSK)	7
Bakgrunn	7
Problemstilling	7
Metode	7
Resultat	8
Diskusjon	9
Konklusjon	9
TABLE OF CONTENTS	10
PREFACE	12
OBJECTIVE	13
BACKGROUND	14
FGM/C	14
Obstetrics	17
METHOD	20
Literature search	20
Inclusion criteria	21
Exclusion criteria	22
Selection of studies	22
Data extraction and analysis	23
RESULTS	27
Description of included literature	27

Methodological quality assessment	34
Obstetric consequences of FGM/C	35
DISCUSSION	67
Discussion of main results	67
Quality of the evidence	70
Strengths and limitations	72
CONCLUSION	74
Need for further research	74
REFERENCES	76
APPENDIX	99
Appendix 1: Glossary	99
Appendix 2: Search for literature	102
Appendix 3: Excluded studies	107
Appendix 4: Quality assessment	114
Appendix 5: Outcome tables	119
Appendix 6: GRADE Evidence profile tables	125

### **Preface**

The World Health Organization (WHO) and the Norwegian Agency for Development Cooperation (NORAD) commissioned a summary of available research on the physical health consequences following female genital mutilation/cutting (FGM/C) from the Norwegian Knowledge Centre for the Health Services (NOKC). This evidence review will make up the background documentation for supporting organizations like the WHO and NORAD's work concerning FGM/C among girls/women subjected to and at risk for the practice in countries where FGM/C may occur.

Given the enormous scope of the documentation identified we prepared three reports. The present report concerns the obstetric consequences of FGM/C. The other two reports will examine the immediate (acute) consequences and the gynecological consequences following FGM/C. These are planned to be completed by the end of 2013.

The project group consisted of:

- Project coordinator: researcher, Rigmor C Berg, NOKC
- Researcher: Vigdis Underland, NOKC

The literature search was conducted by search specialist Sari Ormstad, Jan Odgaard-Jensen provided statistical support, and Eva Denison assisted with methodological quality assessment. All three are with the NOKC. We are also indebted to Elise R. Johansen (WHO) for her efforts to locate full text of studies and data. We are grateful for peer review by two internal and three external reviewers:

- Tove Ringerike, researcher, NOKC, Norway
- Ingeborg B. Lidal, researcher, NOKC, Norway
- Owolabi Bjälkander, Ph.D candidate, Karolinska Institute, Sweden
- Vanja Berggren, researcher, Karolinska Institute, Sweden
- Staffan Bergström, professor, Karolinska Institute, Sweden

The aim of this report is to support well-informed decisions in health care that lead to improved quality of services. The evidence should be considered together with other relevant issues, such as clinical experience and patient preference.

Gro Jamtvedt Gunn E. Vist Rigmor C Berg

Department director Unit director Project coordinator

# **Objective**

This systematic review summarizes empirical quantitative research describing the obstetric consequences of FGM/C on girls and women. The overall aim of the systematic review is to support well-informed decisions in health promotion and health care that inform work to reduce the prevalence of FGM/C and improve quality of services related to the consequences of FGM/C.

The main research question for this systematic review was:

• What are the obstetric consequences of FGM/C?

# **Background**

A variety of terms is used to refer to the cutting of external female genital tissues, such as female circumcision, female genital mutilation, female genital cutting, and female genital mutilation/cutting (1). Throughout this report we adopt the official terminology used by the United Nations Children's Fund (UNICEF) and the United Nations Population Fund (UNFPA) "female genital mutilation/cutting" (FGM/C) (1). A glossary of terms is available in appendix 1.

### FGM/C


### Classification

Female genital mutilation/ cutting (FGM/C) is a traditional practice that involves "all procedures involving partial or total removal of the external female genitalia or other injury to the female genital organs for non-medical reasons" ((1) p1). To clarify understanding of the prevalence as well as consequences of the practice, WHO has classified FGM/C into four categories:

- Type I (clitoridectomy)= partial or total removal of the clitoris and/or the prepuce (the external female genital anatomy is depicted in figure 1).
- Type II (excision)= partial or total removal of the clitoris and the labia minora, with or without excision of the labia majora.
- Type III (infibulation)= narrowing of the vaginal orifice with creation of a covering seal by cutting and appositioning the labia minora and/or the labia majora, with or without excision of the clitoris. This is considered the most invasive type of FGM/C.
- Type IV (other)= all other harmful procedures to the female genitalia for non-medical purposes, for example pricking, piercing, incising, scraping, and cauterizing. No genital tissue is excised (1).

Defibulation, opening of the covering seal, is often necessary prior to childbirth. Reinfibulation refers to the recreation of an infibulation after defibulation. While WHO guidelines recommend permanent defibulation, reinfibulation is considered a type of FGM/C (1).

Figure 1: Female external genitalia



### Prevalence and reasons

It is widely recognized that FGM/C violates a series of human rights principles – including the Universal Declaration of Human Rights, the Convention on the Elimination of all Forms of Discrimination against Women, the Convention on the Rights of the Child (1). Nevertheless, the practice is found among diverse ethnic groups in about 28 countries in Africa as well as some countries in the Middle East and Asia (2;3). It is estimated that three million girls are at risk of undergoing the practice every year (4). No national prevalence data exist for countries outside of the African continent, but survey data suggest that in Africa, there are 91.5 million girls and women aged 10 years and above who have been subjected to FGM/C (3). National figures show a prevalence of FGM/C of more than 70% in Burkina Faso, Djibouti, Eritrea, Ethiopia, Mauritania, Northern Sudan, and Sierra Leone, and more than 90% in Egypt, Guinea, and Mali. In Somalia, available sources put FGM/C prevalence at 95-98% (3;4). However, because of the magnitude of FGM/C among certain ethnic groups there is great variation in prevalence between and within countries (3). On a country level, in Africa the prevalence of FGM/C is estimated to range from 0.6% to 98% of the female population (1).

Due to increased migration, FGM/C transcends geography and is also found among immigrant communities in a number of Western countries, such as Australia, Canada, France, Norway, Sweden, Switzerland, and the United States (2). Research indicates that the majority of girls living in Western countries who are subjected to FGM/C do not undergo the procedure in these countries. Rather, they are sent to their country of origin, usually in Africa, in order to undergo the practice (5-7).

A range of reasons, which vary across countries, regions and cultural groups, exist for FGM/C, but the practice is generally carried out as a matter of social convention. It is closely linked with ethnic identity, with FGM/C serving as an ethnic marker throughout the lifespan (8). The practice is also rooted in tradition as well as religiosocial beliefs such as the conviction that FGM/C is a religious requirement, that it is necessary to control women's sexuality and preserve family honour (9), and that it is a prerequisite for marriage or an economic necessity in cases where women are largely dependent on men (10).

In a previous systematic review, we summarized factors perpetuating and hindering the continuance of FGM/C, as expressed by members from FGM/C practicing communities residing in a Western country (11;12). Understanding the motivations underpinning FGM/C is necessary such that messages and activities can be tailored to their audiences accordingly, thus enhancing the chances of abandonment of the practice. The systematic review, which included 21 studies, revealed six key factors that underpin FGM/C: cultural tradition, sexual morals, marriageability, religion, health benefits, and male sexual enjoyment. There were four key factors perceived to hinder FGM/C: health consequences, it is not a religious requirement, it is illegal in Western countries, and the host society discourse rejects FGM/C. The results showed that, among members of communities practicing FGM/C who reside in a Western country, FGM/C appears to be a tradition in transition and its continuation motivated by a complex mix of interlinked factors.

As social conventions go, the practice of FGM/C is not static but is changing in a number of ways. The practice is declining in several countries. For example, representative survey data from Egypt show that while 95% of 45-49 year olds have been subjected to FGM/C, only 79% of women aged 15-19 have been genitally cut (13). Another general trend is a lowering of the average age at which girls are subjected to the procedure. There is some speculation that this is to elude scrutiny, the reasoning being that the younger the girl, the easier it is to avoid detection (2). Lastly, there is a trend towards medicalization of FGM/C. Parents are increasingly utilizing healthcare providers to perform FGM/C for their daughters, rather than traditional circumcisers (13). Although FGM/C performed by medical personnel in health clinics may minimize short term complications, it tends to obscure its human rights aspect and there are no data to suggest that medicalization reduces long term complications (1). Rather, some research has shown that medicalization in some countries has led to institutionalization and increased severity of the procedure (14). The medical profession, led by WHO and the World Medical Association, has condemned medicalization of FGM/C (15).

### Consequences

The practice is typically performed on pre-pubescent girls, often without anaesthetics (2), thus, it is reasonable to assume that it is a traumatic event that may cause

short-term as well as long-term harm. WHO writes that, on the physiological level, FGM/C causes permanent, irreparable changes in the external female genitalia and that there are no known health benefits to FGM/C (1). According to WHO estimates from 2008 (1), across the world, between 100-140 million girls/women are presently living with FGM/C.

In a previous systematic review, we summarized empirical quantitative data describing the social, psychological, and sexual consequences of FGM/C (16;17). Only studies that compared women with FGM/C to women without FGM/C were included. Unfortunately, we were unable to draw any conclusions concerning social consequences because only two studies, both of low study quality, included some measure of social consequences following FGM/C. With respect to psychological consequences, results from the four included studies suggested that women with FGM/C may be more likely than women without FGM/C to experience psychological disturbances (i.e. have a psychiatric diagnosis, suffer from anxiety, somatisation, phobia, and low self-esteem). The effect estimates for sexual consequences, derived from 15 comparative studies, showed that women with FGM/C were more likely than women without FGM/C to experience pain during intercourse, reduced sexual satisfaction, and reduced sexual desire.

As today, the literature "A systematic review of the health complications of female genital mutilation, including sequelae in childbirth" (18) provides the most comprehensive summary of physical complications from FGM/C. This review identified and summarized primary data on health complications after FGM/C with particular emphasis on sequelae in childbirth and psychosexual outcomes. It included a range of study designs and identified various complications, the most common being severe pain, bleeding, difficulty in passing urine and faeces and infections. Around the same time, Obermeyer completed a related review of women's health complications and sexual consequences following FGM/C, which concluded that "the powerful discourse that depicts these practices as inevitably causing death and serious ill health, and as unequivocally destroying sexual pleasure, is not sufficiently supported by the evidence" ((19) p79). The review was updated in 2005 (20), with largely similar conclusions but also the acknowledgement that there were statistically higher risks documented for some but not all types of health conditions. Drawbacks of both sets of reviews are that the literature searches are out-dated, they are not systematic, some outcomes are missing, and risks of various health consequences are not quantified.

### **Obstetrics**

The term obstetrics comes from the Latin word obstare, which means "to stand by". It is the medical specialty area dealing with the care of women's reproductive tracts and their children during pregnancy, childbirth, and the first six weeks after delivery

(21). Pregnancy is a life-affirming state which many women aspire to at some point in their lives. Yet the process carries with it risks of complications and even death. Obstetric complications include disruptions and disorders of pregnancy, labor and delivery, and complications during the early neonatal period. Complications can have short- and long-term effects on the mother and child (21). Each year, approximately eight million women around the world suffer from pregnancy-related complications (22) and over 300,000 die in childbirth (23). In 2008, more than half of all maternal deaths were in six developing countries: India, Nigeria, Pakistan, Afghanistan, Ethiopia, and the Democratic Republic of Congo (23). For example, in West Africa, estimates indicate that the ratio of maternal death is 38 times higher than in more developed regions (24). Rates of maternal morbidity and mortality are hampered by obstacles to measurement, however, especially in developing countries, and they are likely to be underestimated given the high percentage of women in some areas who give birth at home (24;25). UNICEF writes that a large percentage of obstetric complications could be avoided if skilled health personnel and essential supplies, equipment and facilities were available (26). In fact, research has identified a close relationship between levels of maternal mortality and the percentage of births with a skilled birth attendant (25). Unfortunately, malfunctioning public health services in developing countries nonetheless mean that a considerable number of women who deliver within health services are in fact not attended by qualified health personnel (24). In eastern and southern Africa, half of all births occur without the support of a skilled birth attendant (26).

The relevant question for the present systematic review is whether women who have been subjected to FGM/C are more likely than women without FGM/C to experience obstetric complications. A reasonable follow-up question is by which mechanisms FGM/C may lead to adverse obstetric outcomes. In the WHO literature review, it is concluded that "the serious obstetric consequences of FGM, when it is performed prior to the index pregnancy, are mainly due to the scarring resulting from FGM" ((18) p12). In fact, across a number of studies, the most plausible pathway of effect suggested is inelastic scar tissue (27-33). As explained by WHO (18), FGM/C is generally performed on girls under the age of ten, and healing from any type of cutting inevitably involves varying amounts of scar formation. Further, scar tissue consists of mature collagen. The highest concentration of collagen is found in tissue subjected to recurrent incision and healing (33). Such scar tissue is less elastic and has decreased tensile strength, compared to undamaged tissue. It follows that a likely mechanism through which FGM/C may increase the risk of obstetric complications is the increase in scarring of perineal and vulval tissues found in women with FGM/C. Such scarring increases the possibility of tearing and hemorrhage during labor, even when appropriate episiotomy is performed, note Orji and Babalola (30). Obstetrician Hakim (27) writes that female genital tissue that has been cut is subjected to greater tears/lacerations during parturition and may interfere with the progress of labor. Additionally, researchers have suggested that damage to the vagina, internally and externally through obstructions such as stenosis and retention cysts following FGM/C, may compromise a normal vaginal delivery, including prolongation of labor (28;31). According to a study (63), women with FGM/C are also more likely to suffer genital- and urinary-tract infections, which could have repercussions for obstetric outcomes. Similarly, women with FGM/C may be more susceptible to reproductive tract infections, which could affect labor (28). The degree to which women with FGM/C are more likely than non-cut women to suffer cysts, stenosis, infections, and similar will be examined in one of our subsequent systematic reviews.

## **Method**

This systematic review of the obstetric consequences of FGM/C was conducted in accordance with the NOKC Handbook for Summarizing Evidence (34) and the Cochrane Handbook for Systematic Reviews of Interventions (35).

### Literature search

The main literature search strategy was searches in databases. We systematically searched for relevant literature in the following 15 international databases:

- African Index Medicus
- British Nursing Index and Archive
- CINAHL
- The Cochrane Library:
  - Cochrane Central Register of Controlled Trials
  - Cochrane Database of Systematic Reviews
  - Database of Abstracts of Reviews of Effects
  - Health Technology Assessment Database
- EMBASE
- MEDLINE
- PILOTS
- POPLINE
- PsycINFO
- Social Services Abstracts
- Sociological Abstracts
- WHOLIS

The database search strategy was designed by Sari Ormstad, information retrieval specialist at the NOKC, in cooperation with the project group and commissioners. Sari Ormstad executed the search in January 2012. We planned to search also Anthropology Plus, but starting 2012, NOKC no longer had access to this database. The search strategy incorporated both text words (in title and abstract) and subject headings (e.g. MeSH terms in MEDLINE) relating to FGM/C and the four classifications of FGM/C, including mutilation, circumcision, excision. We applied no methodology search filters in order to maximize the sensitivity of searches. We did not restrict the

searches to any specific languages or publication dates. The complete search strategy is found in appendix 2.

We supplemented the electronic database searches with searches in sources for grey literature (OpenGrey, OpenSigle, OAIster), and browsed websites of six international organizations that are engaged in projects regarding FGM/C:

- Population Council: http://www.popcouncil.org/
- Population Reference Bureau (PRB): http://www.prb.org/
- The Centre for Development and Population Activities (CEDPA): http://www.cedpa.org/
- The United Nations Children's Fund (UNICEF): http://www.unicef.org/
- The United Nations Population Fund (UNFPA): http://www.unfpa.org/public/
- The World Health Organization (WHO): http://www.who.int/en/

We also searched reference lists of relevant reviews and all included studies. Finally, we communicated with experts engaged in FGM/C related work and asked for studies about the health consequences of FGM/C.

### **Inclusion criteria**

### **Study design** (in order of priority):

- 1. systematic reviews
- 2. cohort studies
- 3. case-control studies
- 4. cross-sectional studies
- 5. case series
- 6. case reports

We used study design features (as defined in the Cochrane glossary, http://www.cochrane.org/glossary) not study design labels to designate the studies. Methodological study quality was not a basis for inclusion/exclusion.

**Population:** Girls and women who have been subjected to any type of

FGM/C, as classified by WHO (1). We enforced no limitations on age, race/ethnicity, nationality or other partici-

pant characteristics.

**Event/Intervention:** FGM/C classified as type I to type IV according to the

WHO modified typology (1).

**Comparison:** No FGM/C or a different type of FGM/C. We note that

both studies with and without a comparison group were eligible for inclusion. When the study reported a comparison group, the study had to compare either 1) a type of FGM/C vs no FGM/C, or 2) one type of FGM/C vs another

type, e.g., type I vs type III, as defined by WHO (1).

**Outcome**: We included all types of physical consequences / complica-

tions following FGM/C, both short- and long term consequences experienced by girls/women. In this report, we summarize the obstetric consequences of FGM/C. These included but were not limited to: prolonged labor, tears, caesarean section, episiotomy, instrumental delivery, postpartum hemorrhage. All physical outcomes were included, but outcomes not considered obstetric are presented in

separate reports.

**Language:** We included all publication languages. When considered

likely to meet the inclusion criteria, studies in languages not mastered by the review team were translated to English using Google translator. Professional translation was not necessary for any of the studies included in this report.

Unpublished reports, abstracts, brief and preliminary reports were considered for inclusion on the same basis as published reports. We also note that the outcomes had to be self-reported by the girls/women having experienced these or documented by health personnel and study investigators. When physical outcomes pertained to children, we accepted reports by the girl's parents.

#### **Exclusion criteria**

**Study design:** Qualitative studies and all studies without a quantitative measure

of a physical consequence of FGM/C.

**Population**: We excluded consequences of a woman's FGM/C on other indi-

viduals, such as her sexual partners or babies during birth. We also excluded studies about FGM/C on populations where modifications of genital tissue were performed for medically indicated

or purely cosmetic reasons.

**Intervention:** All genital modifications not captured by the WHO stated FGM/C

definition (1).

**Outcome:** Psychological and social outcomes and any other outcomes that

cannot be considered a physical outcome.

### **Selection of studies**

Two reviewers (Berg and Underland) independently read all titles/and or abstracts resulting from the literature searches. We compared our judgments and obtained

full text copies of the studies that we deemed relevant. The same pairs of reviewers, working independently, classified the studies read in full text as relevant (met all inclusion criteria) and therefore to be included, or not relevant and therefore to be excluded. Next, we compared our judgments and included studies that we agreed met all inclusion criteria. We used pre-designed inclusion forms for each of the two screening levels. These forms contained questions regarding type of study, types of participants, type of FGM/C, and outcomes measured. Differences in opinion in the screening process were few and were resolved through a re-examination of the record and subsequent discussion. It was not necessary to contact the author(s) of any studies to aid the selection process. A list of studies formally considered in full text but excluded is found in appendix 3, and reasons for exclusion are provided.

### Data extraction and analysis

### Assessment of methodological study quality

With respect to assessment of methodological quality of included studies, two reviewers first independently assessed the quality of studies, using appropriate checklists for each included study design (see below). The two reviewers then discussed and agreed upon a final decision of high, moderate or low methodological quality for each study. There were few differences in judgments, and these were resolved by a re-examination of the publication and subsequent discussion. If consensus had not been reached, we would have consulted a third person.

We did not assess the methodological quality of case reports. Case reports are descriptive studies that report observations on a single or a few individuals and are considered among the study designs with lowest validity for effect questions. Thus, a methodological quality assessment would not have added valuable information. For case series, cross-sectional descriptive studies, case-control, and cohort studies, we used the respective NOKC checklists. Given our focus on consequences of exposure to FGM/C, the NOKC assessment tool for cross-sectional studies was used for analytic cross-sectional comparative studies (where two or more groups of women were compared with respect to consequences of FGM/C) but modified by the addition of five questions from the NOKC quality assessment tool for cohort studies in order to capture whether 1) the compared groups (women with FGM/C and women without FGM/C or women with different types of FGM/C) were selected from the same population; 2) the groups were comparable with respect to important backgrounds factors; 3) exposure and outcome were measured in the same way in the two groups; 4) the person who assessed the outcome was blind to whether participants were exposed or not; and 5) known, potentially important confounders had been considered in the study design and/or analyses, resulting in an adapted checklist with 12 questions (this modified checklist was successfully used by us previously, in (16)). The

paired reviewers' assessment of each checklist question of each study is listed in appendix 4.

#### **Data extraction**

Extraction of data from the included sources was completed first independently by two authors (Berg and Underland) using a pre-designed data recording form. The two authors next compared their results and when differences in data extracted occurred this was resolved by re-examination of the publication and subsequent discussion. The following core data were extracted from all included studies:

- Title, authors, and other publication details
- Study design
- Location/mode of recruitment
- Sample characteristics (current age, country of residency)
- FGM/C characteristics (type of cutting, age of cutting, type of practitioner, method of 'measurement' of FGM/C)
- Methods of outcome measurement (clinical or self-report)
- Health consequences

### Data analysis

We extracted dichotomous and continuous data for all outcomes (health consequence/complication) meeting the inclusion criteria. When outcome data were missing in the publication, we contacted the corresponding author(s) via e-mail and requested that they send us the data. We grouped the data according to outcomes across the studies, and present the results of these in text and tables. We prioritized presenting results from those studies with highest internal validity (studies which compared groups of women). In line with the prioritization to present results from studies which compared the prevalence of complications at delivery for women with and without FGM/C (alternatively, for women with one type of FGM/C and women with another type), results from studies with the lowest internal validity are presented in appendix 5.

With respect to data analysis, when possible, we estimated effect on dichotomous variables by the relative risk (RR) and 95% confidence interval (95%CI). We estimated effect on continuous variables by mean difference (MD, or standardized mean difference when possible) and 95%CI. No case-control studies were included. If they had been, for studies where dichotomous variables were presented, we would estimate effect by the odds ratio (OR) and 95%CI, because a case-control design involves the selection of research subjects on the basis of the outcome measurement rather than on the basis of the exposure. With respect to descriptive cross-sectional

studies, case series and case reports — which express the number of women with FGM/C who experience an obstetric outcome — reported proportion of women experiencing an eligible outcome is presented in tables.

When studies were sufficiently similar, we pooled those that could be grouped together and used the statistical technique of meta-analysis to estimate risk, with RevMan v5.1. (Cochrane Collaboration meta-analysis software). To be pooled, the same outcome/consequence had to be assessed in similar populations across similar studies. Standard analysis procedures were used; i.e. Mantel-Haenszel random effects meta-analysis was conducted for dichotomous outcomes and inverse-variance random effects meta-analysis for continuous outcomes. We also examined between-study heterogeneity, with the Chi-square (Chi²) and I-square (I²) tests. A high value shows that most of the variability across studies is due to heterogeneity rather than to chance.

When possible (i.e. there was a sufficient number of similar studies), we planned to perform sensitivity analyses for:

- performer (health care provider and traditional circumciser)
- age (at which FGM/C was done, at onset of complications, or time between procedure and onset)
- type of FGM/C (according to WHO modified typology (1))
- other pertinent factors, such as type of study.

We were able to perform sensitivity analyses for type of FGM/C and type of study.

We applied the instrument Grading of Recommendations Assessment, Development and Evaluation (GRADE) with GRADE-Profiler version 3.6 to assess the extent to which we could have confidence in the effect estimates (36). It is a transparent and systematic approach to grading the strength of evidence that can minimize bias and aid interpretation. Examples of organizations that have endorsed or that are using GRADE include WHO, National Institute for Clinical Excellence (UK), Agency for Healthcare Research and Quality (USA), Cochrane Collaboration, and British Medical Journal. We applied the eight GRADE criteria:

- methodological quality of study
- consistency (were results consistent across studies?)
- directness (did the evidence directly answer the health care question?)
- precision (were the results precise enough?)
- publication bias
- strength of evidence of association
- evidence of a dose-response gradient

• all plausibe confounders would have reduced the effect.

For more details about the GRADE system we refer to publications by the GRADE Working Group (gradeworkinggroup.org). We used the standard definitions in grading the quality of the evidence (37):

- High= We are very confident that the true effect lies close to that of the estimate of effect.
- Moderate= We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
- Low= Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
- Very low= We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

When it comes to establishing a causal relationship between exposure to an intervention (or procedure such as FGM/C) and an outcome, evidence based on observational studies will usually be appreciably weaker than evidence from experimental studies. In this systematic review, because all included studies were necessarily observational (non-randomized), the evaluation of evidence started from a position of low quality, as per GRADE instructions. For resource reasons we assessed the quality of the evidence through GRADE only for outcomes which were eligible for metanalysis.

### **Results**

### **Description of included literature**

### Results of the search

The electronic search resulted in 4,989 individual records and the manual search in 120 potentially relevant records (figure 2). After removal of duplicates, Berg and Underland screened the records by reviewing all titles and abstracts. We eliminated non-relevant records based on titles and where available, abstracts.

After excluding 4,665 records, we were left with 444 potentially relevant records. Unfortunately, 13 records could not be obtained in full text, despite extensive retrieval efforts through national and international libraries, research contacts, and attempts at contacting the authors (38-49). Thus, we read the full text for 431 publications. We excluded 246 publications, these are listed with reasons for exclusion in appendix 3, and included 44 primary studies for the present report.




Figure 2: Flow diagram for selection of literature

### **Description of included studies**

The majority of the 44 included studies were published in peer-reviewed journals (89%), four included studies were reports (50-53), and there was one conference abstract (54) included. Thirty of the studies (68%) were published after 2000, and with the exception of three case reports from 1927 (55), 1937 (56), and 1969 (57), the remaining third of the studies were published in the 1980s and 1990s (table 1 and 2).

There were 28 cross-sectional studies in which two or more groups were compared (comparative studies). These studies are presented in table 1. Additionally, we identified and included 16 non-comparative studies (table 2). Briefly, across all 44 studies, the great majority of the studies (75%) were judged to be of low methodological quality. Collectively, the studies involved a total of almost 3 million participants (2,978 458, range= 1 – 2.18 million). The median sample size was 492 (average= 67,692). Women with FGM/C made up 2.4% of the sample (n= 70,495). Most of the studies were conducted in Africa (29 studies, 66%). The most frequently reported outcomes were cesarean section, episiotomy, and obstetric tears. The majority of the studies (61%) had clinically measured obstetric outcomes, but 15 studies (34%) relied on women's self-report and two studies did not explain how the outcomes were ascertained (54;58).

Table 1: Included comparative studies (n=28)

Author, year	Study quality	Population, Country	Outcomes (self report or clinical verification)		
Adinma 1997 (59)	Low	N=256, Nigeria	Episiotomy (self-report)		
Berardi 1985 (60)	Low	N=852, France	Tears; Cesarean section; Episiotomy (clinical)		
Bohoussou 1986 (58)	Low	N=4935, Ivory Coast	Prolonged labor; Tears; Cesarean section; Episiotomy; Instrumental delivery (not stated)		
Browning 2010 (61)	High	N=492, Ethiopia	Prolonged labor (clinical)		
Chibber 2011 (62)	Low	N=4800, not stated	Prolonged labor; Cesarean section; Hemorrhage; Infection: Other (clinical)		
De Silva 1989 (63)	Low	N=2157, Saudi Arabia	Prolonged labor; Tears; Cesarean section; Episiotomy; Instrumental delivery; Hemorrhage; Other (clinical)		
Diop 1998 (51)	Low	N=5390, Mali	Tears; Episiotomy; Hemorrhage; Other (clinical)		
Elnashar 2007 (64)	Low	N=264, Egypt	Tears; Cesarean section; Episiotomy (self-report)		
Eritrea DHS 2002 (52)	Low	N=7765, Eritrea	Problems during delivery (self-report)		
Eritrea DHS 1995 (53)	Low	N=4775, Eritrea	Problems during delivery (self-report)		
Essén 2005 (65)	Moderate	N=2554, Sweden	Prolonged labor (clinical)		
Hakim 2001 (27)	Low	N=1481, Ethiopia	Prolonged labor; Tears; Episiotomy; Hemorrhage; Fever; Other (clinical)		
Johnson 2005 (66)	Low	N=5416, USA	Tears; Cesarean section; Instrumental delivery; Hemorrhage; Other (clinical)		

Jones 1999 a (28)	Low	N=1920, Burkina Faso	Other (self-report)		
Jones 1999 b (28)	Moderate	N=5337, Mali	Other (clinical)		
Larsen 2002 (29)	Low	N=1836, Nigeria	Prolonged labor; Tears; Cesarean section; Episiotomy (self-report)		
Lupo 1999 (54)	Low	N=114, USA	Tears; Infection (not stated)		
Millogo-Traore 2007 (67)	Low	N=454, Burkina Faso	Prolonged labor; Tears; Episiotomy; Instrumental delivery (clinical)		
Ndiaye 2010 (68)	Low	N=354, Burkina Faso	Tears; Cesarean section; Episiotomy; Hemorrhage; Other (clinical)		
Oduro 2006 (69)	High	N=5071, Ghana	Cesarean section (clinical)		
Orji 2006 (30)	Low	N=500, Nigeria	Cesarean section; Episiotomy (self-report)		
Slanger 2002 (70)	Moderate	N=1107, Nigeria	Tears; Cesarean section; Episiotomy; Instrumental delivery; Hemorrhage; Fever; Other (self-report)		
Small 2008 (71)	Low	N=2 179322, multiple	Cesarean section; Instrumental delivery; Other (clinical)		
Vangen 2002 (31)	Low	N=703925, Norway	Prolonged labor; Tears; Cesarean section; Hemorrhage (clinical)		
WHO study group 2006 (32)	High	N=28393, multiple	Tears; Cesarean section; Episiotomy; Hemorrhage (clinical)		
Wuest 2009 (33)	Low	N=232, Switzerland	Prolonged labor; Tears; Cesarean section; Episiotomy; Instrumental delivery; Hemorrhage (clinical)		
Yount 2007 (72)	Moderate	N=3167, Kenya	Cesarean section (self-report)		
Yount 2006 (73)	Low	N=1700, Egypt	Miscarriage (self-report)		
1 1 1000	D	F 1 40001 1 1	' NA 12 /2'		

Legend: Jones 1999 a=study in Burkina Faso, Jones 1999 b= study in Mali (i.e., two studies reported in same publication).

We included seven cross-sectional studies in which the prevalence of obstetric complications on women with FGM/C was presented, five case series, and four case reports (table 2).

Table 2: Included cross-sectional, case series and case report studies (n=16)

Author, year	Study design	Study quality	Population, Country	Outcomes (self report or clinical verification)
Abor 2006 (74)	Cross-sectional	Low	N=34, Ghana	Cesarean section; Episiotomy; Instrumental delivery (self-report)
Akotionga 2001 (75)	Case series	High	N=49, Burkina Faso	Difficult delivery (clinical)
Al-Hussaini 2003 (76)	Cross-sectional	Moderate	N=254, Egypt	Tears; Cesarean section; Episiotomy (clinical)
Awuah 2008 (77)	Case series	Low	N=70, Ghana	Prolonged labor; Tears; Episiotomy; Hemorrhage; Fistula (self-report)
Bayoudh 1995 (78)	Cross-sectional	Low	N=300, Somalia	Episiotomy (self-report)
Bonessio 2001 (79)	Case series	Low	N=9, Italy	Prolonged labor; Cesarean section; Other (clinical)
CAR DHS 1995 (50)	Cross-sectional	High	N=2555, CAR	Obstetric complications (self-report)

Chalmers 2000 (80)	Cross-sectional	Low	N=432, Canada	Cesarean section; Instrumental delivery (self-report)
Dörflinger 2000 (81)	Case series	Low	N=39, Sudan	Prolonged labor; Tears; Hemorrhage (clinical)
Litorp 2008 (82)	Cross-sectional	Low	N=40, Sweden	Obstetric difficulties (self-report)
McCaffrey 1995 (83)	Cross-sectional	Low	N=50, England	Tears; Cesarean section; Instrumental delivery; Other (clinical)
McSwiney 1992 (84)	Case report	NA	N=1, England	Tears (clinical)
Osifo 2009 (85)	Case series	High	N=51, Nigeria	Tears (clinical)
Philp 1927 (55)	Case report	NA	N=1, Kenya	Death in childbirth (clinical)
Preston 1937 (56)	Case report	NA	N=1, Kenya	Birth per rectum (clinical)
Pritchard 1969 (57)	Case report	NA	N=3, England	Dystocia (clinical)

Legend: CAR= Central African Republic; DHS= Demographic and Health Survey; NA= Not applicable (we did not assess the methodological quality of the four case reports).

### Study design and sample recruitment

We identified no systematic reviews, cohort studies or case-control studies for inclusion in this report on obstetric complications. According to the study descriptions, 28 (64%) of the 44 included studies employed a cross-sectional comparative study design in which two or more groups of women were compared. For some obstetric outcomes, a few of these comparative studies reported results only for the FGM/C group – in these cases we place the results in appendix 5. Seven of the studies classified as cross-sectional comparative were registry studies (54;61;65;66;69;71;86). The researchers selected a sample frame and extracted data from hospital records, ranging in sample size from 50 to over 2 million women. For most of the registry studies (54;65;66;71;86), the 'exposed' group was not selected from the same population as the 'non-exposed' group, thus offering less confidence in the effect estimates. There were seven single-group cross-sectional studies (50;74;76;78;80;82;83), five case series (75;77;79;81;85), and four case reports (55-57;84).

All studies were based on a non-random sample, with the exception of five studies. Four of these were Demographic and Health Surveys (DHS) (50;52;53;72), which are nationally-representative household surveys that provide results for a range of population and health data. The study by Yount and Carrera (73) was based on a representative survey of 3,125 households in Minya, Egypt.

The five representative studies mentioned above were all based on household sampling. The great majority (37 studies, 84%) of the remaining non-random studies were clinical-/hospital-based. These studies recruited women attending a general-or a specialist hospital, family planning center, antenatal clinic, gynecological and obstetric clinic, or (maternity) welfare center. One study was community-based (80). One study did not state how and where the sample was recruited (74).

### Population in the comparative studies

Overall, the 28 included comparative studies involved almost 3 million women (2, 974 569; range 114 - 2,18 million) (table 3). Twenty-three of the studies compared cut- and non-cut women, three studies compared women with various types of FGM/C (52;53;73), and two studies allowed a mix of comparisons (29;32). Most of the 28 included comparative studies took place in a country in Africa: Burkina Faso, Egypt, Ethiopia, Eritrea, Ghana, Ivory Coast, Kenya, Mali, Nigeria (note that Jones (28) included one study sample from Burkina Faso and one from Mali). Eight studies were carried out outside the African continent. Six of these eight studies included immigrant women residing in Europe or North America (31;33;54;60;65;66), one study included women residing in Saudi Arabia (63), and one combined registry data from six different western countries (71). In two of the eight non-African based studies, the entire sample of women originated from a country in Africa where FGM/C is commonly practiced (33;63). However, two studies compared cut women who originated from Africa with non-cut women who had diverse origins (60;65). Three studies compared Somali-born, immigrant women with women who were born in the country in which the study took place (31;66;71), and in Lupo (54) it was simply stated that Somali-born women were compared to non-Somali women. In these latter four studies (31;54;66;71), it was assumed that the absolute majority of the Somali-born women had FGM/C, presumably type III, since about 95-98% of the women in Somalia are subjected to FGM/C type III. The location of residence and origin of the women included in Chibber, El-Saleh and Harmi's study (62) was not specified. Across the studies, the women's ages ranged from early childhood to around 60, with a mean age of 26. Six studies did not state the age of the women.

With respect to FGM/C characteristics of the cut women included in the comparative studies, seven studies did not describe the extent of genital alteration, but most of the studies provided some information about type of FGM/C (table 3). Five registry studies (31;54;65;66;71) appeared to include only women with FGM/C type III. In each of the remaining 16 studies that explained which type of FGM/C the women had been subjected to, the female study participants had a mix of genital alterations. Across the studies, however, the most common type of cutting was type III, which was the type of FGM/C for about 41% of the women across the comparative studies. About 31% of the women were described as having FGM/C type II and 22% as type I. Across the five studies that reported FGM/C type IV (29;33;52;70;73), a total of about 2,880 women were classified as having this type of FGM/C. In two studies it was not explained how women's FGM/C status was ascertained (27;54), in three studies FGM/C type III was assumed (31;66;71), but in the majority of the studies (18 studies, 64%) the women were examined gynaecologically, generally both to confirm whether or not they had been genitally cut and to which type of FGM/C the women had been subjected. Physical examinations were not undertaken to verify the cutting statements in the remaining five studies but relied on women's self-report (52;53;64;72;73). In the majority of cases, the women self-reported that they had

been subjected to FGM/C in early childhood, typically before the age of 10 (mean age ca 7.0). In general, similar to data regarding age of cutting, information regarding who performed the FGM/C procedure was scarce. In the studies that did provide this information, the cutting was typically done by a traditional circumciser.

Table 3: Description of the population in included comparative studies (n=28)

N	Country/ Origin	Age	FGM/C characteristics
N=256 (124 cut, 132 non-cut)	Nigeria	16-40	Type: 22% TI, 78% TII (gyn exam) Age cut/by: 97% in childhood / not stated
N=852	France /	Not	Type: 100% TII (gyn exam)
(71 cut, 781 non-cut)	69% Senegal	stated	Age cut/by: not stated
N=4935	Ivory Coast	Not	Type: 29% TI, 73% TII (gyn exam)
(1099 cut, 3836 non-cut)		stated	Age cut/by: not stated
N=492	Ethiopia	Mean	Type: 100% TI and TII (gyn exam)
(255 cut, 237 non-cut)		28.5	Age cut/by by: not stated
N=4800 (1842 cut, 2958 non-cut)	not stated	15-46	Type: "type I to III most common" (gyn exam) Age cut/by: not stated
N=2157	Saudi Arabia/	≥15	Type: 9% TI, 34% TII, 32%TIII (gyn exam)
(167 cut, 1990 non-cut)	Sudan		Age cut/by: not stated
N=5390	Mali	Mean	Type: 21% TI, 73% TII, 6%TIII (gyn exam)
(4359 cut, 431 non-cut)		27.0	Age cut/by: not stated
N=264 (200 cut, 64 non-cut)	Egypt	Not stated	Type: "circumcised" (self-report) Age cut/by: not stated
N=7765 (310 TI-II, 3028 TIII, 3572 TIV)	Eritrea	15-49	Type: 4% TI-II, 39%TIII, 46% TIV (self-report) Age cut/by: 62% ≤1 yr / 84% tc
N=4775 (2937 TI, 210 TII, 1624 TIII)	Eritrea	15-49	Type: 62% TI, 4% TII, 34%TIII (self-report) Age cut/by: 60% ≤5 yrs / 91% tc
N=2554 (68 cut, 2486 non-cut)	Sweden/ Ethiopia, Somalia	Not stated	Type: most TIII (gyn exam) Age cut/by: not stated
N=1481	Ethiopia	Mean	Type: 12% TI, 85% TII, 3%TIII (not stated)
(1225 cut, 256 non-cut)		25.9	Age cut/by: not stated
N=5416	USA/	Most 20-	Type: most likely type III (assumed, unverified). Age cut/by: not stated
(579 cut, 4837 non-cut)	Somalia	34	
N=1920	Burkina Faso	Mean	Type: 56% TI, 39% TII, 5%TIII (gyn exam)
(1787 cut, 133 non-cut)		26.6	Age cut/by: median 9.5 yrs / not stated
N=5337	Mali	Mean	Type: 21% TI, 74% TII, 5%TIII (gyn exam)
(5017 cut, 320 non-cut)		25.0	Age cut/by: not stated
N=1836 (1009 cut, 590 non-cut)	Nigeria	15-49	Type: 71% TI, 25% TII, 3%TIII, 1% TIV (gyn exam). Age cut/by: not stated
N=114	USA/	Not	Type: "female circumcision" (not stated) Age cut/by: not stated
(38 cut, 76 non-cut)	Somalia	stated	
N=454	Burkina Faso	Median	Type: 28% TI, 69% TII, 3% TIII (gyn exam)
(227 cut, 227 non-cut)		25	Age cut/by: not stated
	N=256 (124 cut, 132 non-cut) N=852 (71 cut, 781 non-cut) N=4935 (1099 cut, 3836 non-cut) N=492 (255 cut, 237 non-cut) N=4800 (1842 cut, 2958 non-cut) N=2157 (167 cut, 1990 non-cut) N=5390 (4359 cut, 431 non-cut) N=7765 (310 TI-II, 3028 TIII, 3572 TIV) N=4775 (2937 TI, 210 TII, 1624 TIII) N=2554 (68 cut, 2486 non-cut) N=1481 (1225 cut, 256 non-cut) N=1481 (1225 cut, 256 non-cut) N=1920 (1787 cut, 133 non-cut) N=5337 (5017 cut, 320 non-cut) N=1836 (1009 cut, 590 non-cut) N=114 (38 cut, 76 non-cut) N=454	N         Country/Origin           N=256 (124 cut, 132 non-cut)         Nigeria           N=852 (71 cut, 781 non-cut)         France / 69% Senegal           N=4935 (1099 cut, 3836 non-cut)         Ivory Coast           N=490 (1842 cut, 2958 non-cut)         Inot stated           N=2157 (167 cut, 1990 non-cut)         Saudi Arabia/ Sudan           N=5390 (4359 cut, 431 non-cut)         Egypt           N=7765 (310 TI-II, 3028 TIII, 3572 TIV)         Eritrea           N=4775 (2937 TI, 210 TII, 1624 TIII)         Eritrea           N=2554 (68 cut, 2486 non-cut)         Sweden/ Ethiopia, Somalia           N=1481 (1225 cut, 256 non-cut)         USA/ Somalia           N=5416 (579 cut, 4837 non-cut)         USA/ Somalia           N=1920 (1787 cut, 133 non-cut)         Burkina Faso           N=5337 (5017 cut, 320 non-cut)         Nigeria           N=1836 (1009 cut, 590 non-cut)         Nigeria           N=1454         Burkina Faso	N=256 (124 cut, 132 non-cut)         Nigeria         16-40           N=852 (71 cut, 781 non-cut)         France / 69% Senegal         Not stated           N=4935 (1099 cut, 3836 non-cut)         Ivory Coast         Not stated           N=492 (255 cut, 237 non-cut)         Ethiopia         Mean 28.5           N=4800 (1842 cut, 2958 non-cut)         not stated         15-46           N=2157 (167 cut, 1990 non-cut)         Saudi Arabia/ Sudan         ≥15           N=5390 (4359 cut, 431 non-cut)         Egypt         Not stated           N=7765 (310 TI-II, 3028 TIII, 3572 TIV)         Eritrea         15-49           N=4775 (2937 TI, 210 TII, 1624 TIII)         Eritrea         15-49           N=2554 (68 cut, 2486 non-cut)         Sweden/ Ethiopia, Somalia         Not stated           N=1481 (1225 cut, 256 non-cut)         USA/ Somalia         Mean 25.9           N=5416 (579 cut, 4837 non-cut)         USA/ Somalia         Mean 25.9           N=1920 (1787 cut, 133 non-cut)         Burkina Faso         Mean 25.0           N=5337 (5017 cut, 320 non-cut)         Mali Mean 25.0         15-49           N=1836 (1009 cut, 590 non-cut)         Nigeria         15-49           N=1454         Burkina Faso         Median

Ndiaye 2010	N=354 (210 cut, 144 non-cut)	Burkina Faso	Mean 24.0	Type: 47% TI, 47% TII, 6% TIII (gyn exam) Age cut/by: not stated
Oduro 2006	N=5071 (1466 cut, 3605 non-cut)	Ghana	Mean 25.8	Type: "type II is the commonest form" (gyn exam). Age cut/by: not stated
Orji 2006	N=500 (423 cut, 77 non-cut)	Nigeria	Mean 27.5	Type: 87% TI, 13% TII (gyn exam) Age cut/by: 95% cut in childhood / 80% tc, 14% hcp
Slanger 2002	N=1107 (621 cut, 486 non-cut)	Nigeria	Mean 33.7	Type: 72% TI, 24% TII, 4% TIII+IV (gyn exam). Age cut/by: 95% cut in childhood / 80% tc, 14% hcp
Small 2008	N=2179322 (10431 cut, 2168891 non- cut)	6 western countries/ Somalia <sup>a</sup>	Most 20- 34	Type: most likely type III (assumed, unverified). Age cut/by: not stated
Vangen 2002	N=703 925 (1733 cut, 702192 non-cut)	Norway/ Somalia	Not stated	Type: most likely type III (assumed, unverified). Age cut/by: not stated
WHO study group 2006	N=28 393 (21222 cut, 7171 non-cut)	6 countries in Africa <sup>b</sup>	Mean 26.3	Type: 32% TI, 37% TII, 31% TIII (gyn exam) Age cut/by: not stated
Wuest 2009	N=232 (122 cut, 110 non-cut)	Switzerland/ 34% Somalia	Mean 28.0	Type: 17% TI, 24% TII, 48% TIII, 11% TIV (gyn exam). Age cut/by: not stated
Yount 2007	N=3167 (1071 cut, 2096 non-cut)	Kenya	15-49 Type: "had undergone FGC" (self-rep Age cut/by: not stated	
Yount 2006	N=1700 (72 TI, 1232 TII, 396 TIV)	Egypt	17-55 Type: 4% TI, 73% TII, 23% TIV (self-ro Age cut/by: mode 9-10 yrs / 93% tc, 4	

Legend: TI= FGM/C type I; TII= FGM/C type II; TIII= FGM/C type III; TIV= FGM/C type IV; gyn exam= cutting status verified through gynecological examination; self-report= cutting status based on self-report; hcp= health care provider; tc: traditional circumciser. a= Australia, Belgium, Canada, Finland, Norway, Sweden; b= Burkina Faso, Ghana, Kenya, Nigeria, Sudan, Senegal.

### Population in the non-comparative studies

Regarding the 16 non-comparative studies, there were seven cross-sectional studies, five case series, and four case reports (table 4). In total, 3,889 women were included in these studies and the study samples ranged from 1 to 2,555. Ten of the non-comparative studies took place in a country in Africa, five in a country in Europe, and one in Canada. Across the 16 studies, there was a range of ages and a mix of genital alterations, ascertained by gynecological examination in ten of them and self-reported in six studies. Generally, the women self-reported that they had been subjected to FGM/C in early childhood. In the seven non-comparative studies that reported on who performed the FGM/C procedure, this was almost exclusively done by a traditional circumciser.

Table 4: Description of the population in included non-comparative studies (n=16)

(11-10)				
Author, year	N	Country/ Origin	Age	FGM/C characteristics
Abor 2006	N=34	Ghana	21-50	Type: "have undergone FGM" (self-report) Age cut/by: 47% 0-10 yrs, 29% 11-15 yrs / 100% tc

Akotionga 2001	N=49	Burkina Faso	5-32	Type: not stated (gyn exam) Age cut/by: 67% 3-7 yrs, up to age 19 / 100% tc
Al-Hussaini 2003	N=254	Egypt	16-37	Type: 51% TI, 49% TII (gyn exam) Age cut/by: 47% 0-10 yrs, 29% 11-15 yrs / 100% tc
Awuah 2008	N=70	Ghana	Not stated	Type: "circumcised" (self-report) Age cut/by: not stated
Bayoudh 1995	N=300	Somalia	20-60	Type: 12% TI, 8% TII, 80%TIII (self-report) Age cut/by: most ≤10 yrs (0-13) / 83% tc
Bonessio 2001	N=9	Italy/ 89% Somalia	21-45	Type: 100%TIII (gyn exam) Age cut/by: not stated
CAR DHS 1995	N=2555	CAR	15-49	Type: "circumcision" (self-report) Age cut/by: 55% 0-10 yrs / not stated
Chalmers 2000	N=432	Canada/ 100% Somalia	Mean 34.0	Type: 0.2% TI, 0.5% TII, 96%TIII (self-report) Age cut/by: mean 5.7 yrs / 58% tc, 10% hcp
Dörflinger 2000	N=39	Sudan	8-41	Type: 3% TII, 97%TIII (gyn exam) Age cut/by: median 8 yrs (0-12) / not stated
Litorp 2008	N=40	Sweden/ 65% Somalia, 20% Eritrea	Mean 31.8	Type: most type I or II (self-report) Age cut/by: mean 6.1 yrs (0-12) / 38% tc
McCaffrey 1995	N=50	England/ mostly Somalia	17-34	Type: 100%TIII (gyn exam) Age cut/by: mean 6.7 yrs / not stated
McSwiney 1992	N=1	England/ Somalia	22	Type: TIII (gyn exam) Age cut/by: not stated
Osifo 2009	N=51	Nigeria	Mean 5.0	Type: 41% TI, 59% TII (gyn exam) Age cut/by: not stated / 94% tc, 6% hcp
Philp 1927	N=1	Kenya	25	Type: "slicing off of the external parts and removal of vaginal mucous membrane" (gyn exam)  Age cut/by: not stated
Preston 1937	N=1	Kenya	18	Type: "circumcised" (gyn exam) Age cut/by: 4 yrs / not stated
Pritchard 1969	N=3	England/ Sudan	Not stated	Type: 100%TIII (gyn exam) Age cut/by: not stated

Legend: TI= FGM/C type I; TII= FGM/C type II; TIII= FGM/C type III; TIV= FGM/C type IV; gyn exam= cutting status verified through gynecological examination; self-report= cutting status based on self-report; hcp= health care provider.

### Methodological quality assessment

We arrived upon a final decision of high study quality for three (11%) of the 28 cross-sectional studies in which two or more groups were compared (comparative studies), using the NOKC modified checklist for cross-sectional studies (appendix 4). Four of the comparative studies were of moderate quality (14%), and the remaining 21 studies were judged to be of low methodological study quality (75%). It was a strength that in all studies, except five (31;54;65;66;71), the authors explained that the non-exposed group (non-FGM/C) was selected from the same population as the exposed group (FGM/C), and that most had used standardized data collection methods and appropriate statistical methods. Conversely, most of the studies failed to explain

whether and how the participants who agreed to participate were different from those who declined to participate. All of the studies, except two (61;70), failed to show that the groups were comparable with respect to important background factors, and all of the studies, except one (68), failed to describe whether the person who assessed the outcome was blind to whether participants were exposed (genitally cut) or not.

With respect to the single-group cross-sectional studies, we found that one of the seven studies had high study quality (appendix 4). One of the cross-sectional studies was of moderate quality, and the remaining five studies were judged to be of low study quality. Two of the case series had high methodological study quality, and the remaining three had low study quality (appendix 4).

We reiterate that when it comes to establishing a causal relationship between exposure to an intervention (or procedure such as FGM/C) and an outcome, evidence based on observational studies will usually be appreciably weaker than evidence from experimental studies. In this systematic review, all included studies were necessarily observational (non-randomized) and, as this section describes, the majority of the studies had methodological shortcomings.

# **Obstetric consequences of FGM/C**

There were eight main outcomes reported across the included studies. We present the data for each outcome in the following order:

- Prolonged labor
- Obstetric tears/lacerations
- Cesarean section
- Episiotomy
- Instrumental delivery
- Obstetric hemorrhage
- Dystocia/ difficult delivery
- Other obstetric and antenatal complications

Table 5 points out the number and types of studies located for each obstetric outcome.

Table 5: Outcomes reported in comparative and non-comparative studies

Outcome	Nº of studies	Comparative studies	Non-comparative studies	
Prolonged labor	13	10 studies: Bohoussou 1986, Browning 2010, Chibber 2011, De Silva 1989, Essén 2005, Hakim 2001, Larsen 2002, Millogo-Traore 2007, Vangen 2002, Wuest 2009	3 studies: Awuah 2008, Bonessio 2001, Dörflinger 2000	
Obstetric tears	21	15 studies: Berardi 1985, Bohoussou 1986, De Silva 1989, Diop 1998, Elnashar 2007, Hakim 2001, Johnson 2005, Larsen 2002, Lupo 1999, Millogo-Traore 2007, Ndiaye 2010, Slanger 2002, Vangen 2002, WHO study group 2006, Wuest 2009	6 studies: Al-Hussaini 2003, Awuah 2008, Dörflinger 2000, McCaffrey 1998, McSwiney 1992, Osifo 2009	
Cesarean section	21	16 studies: Berardi 1985, Bohoussou 1986, Chibber 2011, De Silva 1989, Elnashar 2007, Johnson 2005, Larsen 2002, Ndiaye 2010, Oduro 2006, Orji 2006, Slanger 2002, Small 2008, Vangen 2002, WHO study group 2006, Wuest 2009, Yount 2007	5 studies: Abor 2006, Al-Hussaini 2003, Bonessio 2001, Chalmers 2000, McCaffrey 1995	
Episiotomy	18	14 studies: Adinma 1997, Berardi 1985, Bohoussou 1986, De Silva 1989, Diop 1998, Elnashar 2007, Hakim 2001, Larsen 2002, Millogo-Traore 2007, Ndiaye 2010, Orji 2006, Slanger 2002, WHO study group 2006, Wuest 2009	4 studies: Abor 2006, Al-Hussaini 2003, Awuah 2008, Bayoudh 1995	
Instrumental delivery	11	8 studies: Bohoussou 1986, De Silva 1989, Johnson 2005, Millogo-Traore 2007, Slanger 2002, Small 2008, Vangen 2002, Wuest 2009	3 studies: Abor 2006, Chalmers 2000, McCaffrey 1995	
Obstetric hemorrhage	13	10 studies: Chibber 2011, De Silva 1989, Diop 1998, Hakim 2001, Johnson 2005, Ndiaye 2010, Slanger 2002, Vangen 2002, WHO study group 2006, Wuest 2009	3 studies: Abor 2006, Chalmers 2000, McCaffrey 1995	
Difficult labor	11	9 studies: Chibber 2011, Diop 1998, Eritrea DHS 2002, Eritrea DHS 1995, Johnson 2005, Jones 1999 a, Jones 1999 b, Ndiaye 2010, Slanger 2002	2 studies: Akotionga 2001, Pritchard 1969	
Other complications				
- Fever	4	3 studies: Hakim 2001, Johnson 2005, Slanger 2002	1 study: Bonessio 2001	
- Labor induction	3	3 studies: Johnson 2005, Small 2008, Vangen 2002	0 studies	
- Death	2	1 study: WHO study group 2006	1 study: Philp 1927	
- Other	11	5 studies: Chibber 2011, Hakim 2001, Lupo 1999, Slanger 2002, Vangen 2002	6 studies: Awuah 2008, Bonessio 2001, CAR DHS 1995, Litorp 2008, McCaffrey 1995, Preston 1937	

As described in the methods, results from studies which compare groups of women are most valid for evaluating the risk of cut women relative to non-cut women (or alternatively cut women) experiencing obstetric complications. Therefore, in this chapter we present results from the 28 comparative studies. Results presented in the 16 cross-sectional, case series and case report studies can be found in appendix 5.

# **Prolonged labor**

Labor is a series of strong, repeated muscle contractions which push the baby out of the uterus and into the birth canal. The duration of labor varies from woman to woman, but is usually shorter in women who have given birth before than women who are giving birth for the first time. Typically, labor is considered prolonged when the baby is not born after approximately 20 hours of regular contractions, but some

health experts define prolonged labor as occurring after 18 to 24 hours of regular contractions (21).

Ten comparative studies (27;29;31;33;58;61-63;65;67) reported on prolonged labor. One comparative study (58), only provided prolonged labor data for the FGM/C group (see appendix 5). One study (29) stated whether the women were primiparous/nulliparous or multiparous, but we present the results for all women, since first- and later pregnancies are not specified in any of the other studies reporting on prolonged labor. Six of the studies presented prolonged labor as a dichotomous outcome and four as a continuous outcome. The dichotomous results for prolonged labor are presented in table 6.


Table 6: Study outcomes (dichotomous) and effect estimates for prolonged la-

DOI					
Author, year	Study quality	Outcome <sup>a</sup>	FGM/C group	Non-FGM/C group	Results RR (95%CI)
Chibber 2011	Low	Prolonged labor	257/1842 (14.0%)	129/2958 (4.4%)	3.20 (2.61, 3.92)*
De Silva 1989	Low	Prolonged stage 1 Prolonged stage 2	19/167 (11.4%) 23/167 (13.8%)	238/1990 (12.0%) 86/1990 (4.3%)	0.70 (0.45, 1.08) 3.19 (2.07, 4.91)*
Essén 2005	Moderate	Prolonged stage 2	Data not received		OR=0.3 (0.2, 0.5) b
Larsen 2002	Low	Prolonged labor <sup>c</sup>	62/1929 (3.2%) TI 8/572 (1.4%) TII	22/1553 (1.4%)	2.27 (1.40, 3.67)* 0.99 (0.44, 2.20)
Millogo-Traore 2007	Low	Prolonged labor	7/81 (8.6%)	6/62 (9.7%)	0.89 (0.32, 2.52)
Vangen 2002	Low	Prolonged stage 2	95/1733 (5.5%)	32864/702192 (4.7%)	1.17 (0.96, 1.42)

Legend: RR= relative risk with 95% confidence interval (CI). TI= FGM/C type I; TII= FGM/C type II; a= The definition of prolonged labor for the included studies is found in appendix 5, table 6.1; b= Bivariate odds ratio stated in publication; c= Larsen reported results also separately for first and second pregnancy, but we present only results for all pregnancies; \*= statistically significant.

We carried out meta-analyses, pooling available data from six studies for the obstetric complication prolonged labor. Sensitivity analyses were conducted for study type. Figure 3 presents the meta-analyses results for prolonged labor, comparing cut and non-cut women.





The pooled results showed that there was a statistically significant difference between the two groups of women regarding prolonged labor (RR= 1.69, CI= 1.03, 2.77). Women with FGM/C were 1.7 times at greater risk of prolonged labor compared to women without FGM/C. In these studies, among women with FGM/C there were 8 per 100 woman (8%) who experienced prolonged labor, while 5 per 100 (5%) non-cut women experienced prolonged labor. The absolute risk difference was 3 more cases of prolonged labor among women with FGM/C per 100 woman (CI= o more to 8 more). Considerable heterogeneity indicated by I<sup>2</sup> and Chi<sup>2</sup> (I<sup>2</sup> = 92%, Chi<sup>2</sup>= 52.5, p< 0.00001) showed inconsistency across studies. The results of the sensitivity analyses indicated that the heterogeneity was not due to the registry study, which compared Somali-born women to ethnic Norwegian women. But we note that the pooled effect size for Africa-based studies (figure 3, 1.14.1) was greater than the effect size for the registry study (figure 3, 1.14.2), which offers less confidence in the effect estimate. Using GRADE, we judged the quality of the evidence for this outcome as very low (table 24). The Summary of Findings (GRADE) tables are presented at the end of the results chapter and the GRADE Evidence profile tables are in appendix 6.

Four studies presented prolonged labor as a continuous outcome (table 7). Essential data were missing to calculate mean difference and/or the outcomes were not sufficiently similar to warrant meta-analysis. As is evident in the table, the duration of labor for cut vs non-cut women varied across the studies with no observable pattern.

Table 7: Study outcomes (continuous) and effect estimates for prolonged labor

Author, year	Study quality	Outcome	FGM/C group	Non-FGM/C group	Results Mean diff (95%CI)
Browning 2010	High	Days in labor	3.1 (1.7) days	2.8 (1.5) days	0.30 (0.02, 0.58)*
Essén 2005	Moderate	Duration of labor stage 2	35 min <sup>a</sup>	53 min	-
Hakim 2001	Low	Duration of labor stage 1 Duration of labor stage 2 Duration of labor stage 3	11.8 (4.7) hrs (708 min) 41.5 (13.3) min 11.0 (4.0) min	11.6 (2.2) hrs (696 min) 40.1 (3.2) min 11.1 (4.5) min	0.20 (-0.54, 0.94) 1.40 (-0.08, 2.88) -0.10 (-1.40, 1.20)
Wuest 2009	Low	Duration of labor stage 1 Duration of labor stage 2	220 min <sup>a</sup> 39 min	300min 45 min	-

Legend: Mean diff=mean difference; a= Essén 2005 and Wuest 2009 reported duration of labor as median minutes (not mean); \*= statistically significant.

# FGM/C type I vs type II

Larsen (29) presented results for women with FGM/C type I and women with FGM/C type II separately (see above, table 6). The relative risk with 95% CI for this comparison was RR= 2.30 (CI= 1.11, 4.77). That is, in this study, women with FGM/C type I had a significantly higher risk of prolonged labor than women with FGM/C type II.

# What we know about prolonged labor

- Women who have been genitally cut seem to be more likely than non-cut women to experience prolonged labor; this is based on very low quality of evidence.
- We do not know if various FGM/C types differentially affect the risk of prolonged labor.

# **Obstetric tears/lacerations**

Childbirth may lead to overstretching of the vagina which in turn may cause tearing of tissue in the vagina, perineum and/or anus. Perineal lacerations during vaginal childbirth are usually classified into four categories according to the severity of trauma (21):

- 1st degree tear: laceration only of the fourchette and superficial perineal skin or vaginal mucosa
- 2nd degree tear: laceration extends beyond fourchette, perineal skin and vaginal mucosa to perineal muscles and fascia (but not to the anal sphincter)
- 3rd degree tear: laceration of fourchette, perineal skin, vaginal mucosa, muscles, and anal sphincter
- 4th degree tear: laceration of fourchette, perineal skin, vaginal mucosa, muscles, anal sphincter, and rectal mucosa.

Fifteen comparative studies reported on some type of obstetric tear/laceration (27;29;31-33;51;54;58;60;63;64;66-68;70). Results from the comparative studies which reported on the occurrence of obstetric tears in cut women vs non-cut women are shown in table 8.

Table 8: Study outcomes (dichotomous) and effect estimates for obstetric tears/lacerations

Author, year	Study quality	Outcome	FGM/C group	Non-FGM/C group	Results RR (95%CI)
Berardi 1985	Low	Perineal injury	13/62 (20.7%)	22/698 (3.2%)	6.65 (3.53, 12.55)*
Bohoussou 1986	Low	Perineal tears	63/1097 (5.7%)	138/3836 (3.6%)	1.60 (1.19, 2.13)*
De Silva 1989	Low	Second degree tear Urethral tear	11/167(6.6%) 6/167 (3.6%)	27/1894 (1.4%) 1/1894 (0.1%)	4.62 (2.33, 9.15)* 68.05 (8.24, 561.88)*
Diop 1998	Low	Tears	Data not received		
Elnashar 2007	Low	Perineal tear	15/169 (8.9%)	2/47 (4.2%)	2.09 (0.49, 8.80)
Hakim 2001	Low	Perineal tears degree 1 Perineal tears degree 2 Perineal tears degree 3	102/489 (20.9%) 56/489 (11.5%) 13/489 (2.7%)	15/50 (30.0%) 4/50 (8.0%) 1/50 (2.0%)	0.70 (0.44, 1.10) 1.43 (0.54, 3.78) 1.33 (0.18, 9.95)
Johnson 2005 <sup>a</sup>	Low	1st/2nd degree tear 3rd/4th degree tear	194/579 (33.5%) 57/579 (9.8%)	1336/4837 (27.6%) 201/4837 (4.2%)	1.21 (1.07, 1.37)* 2.37 (1.79, 3.14)*
Larsen 2002 b	Low	Tear	35/1929 (1.8%) TI 20/572 (3.5%) TII	25/1553 (1.6%)	1.33 (0.68, 1.87) 2.17 (1.22, 3.88)*
Lupo 1999	Low	Perineal laceration	4/17(23.5%)	7/34 (11.8%)	1.14 (0.39, 3.37)
Millogo-Traore 2007	Low	Perineal tears d1-2	23/227 (10.1%)	13/227 (5.7%)	1.77 (0.92, 3.41)
Ndiaye 2010	Low	Perineal tear	14/187 (7.4%)	1/143 (0.7%)	10.71 (1.42, 80.47)*
Slanger 2002	Moderate	Perineal tear	25/621 (4.0%)	17/486 (3.5%)	1.15 (0.63, 2.11)
Vangen 2002	Low	Perineal injury d2-4	56/1733 (3.2%)	22299/702192 (3.2%)	1.02 (0.79, 1.32)
WHO study group 2006	High	Tear (any) <sup>c</sup>	422/4386 (9.6%) TI 596/4962 (12.0%) TII 49/642 (7.6%) TIII	544/4604 (11.8%)	0.81 (0.72, 0.92)* 1.02 (0.91, 1.13) 0.65 (0.49, 0.86)*
Wuest 2009	Low	1st degree tear 2nd degree tear 3rd degre tear	6/122 (4.9%) 6/122 (4.9%) 9/122 (7.4%)	28/110 (25.5%) 22/110 (20.0%) 1/110 (0.9%)	0.19 (0.08, 0.45)* 1.25 (0.10, 0.58)* 8.11 (1.04, 63.03)*

Legend: RR= relative risk with 95% confidence interval (CI). TI= FGM/C type I; TII= FGM/C type II; TIII= FGM/C type III; TIII= FGM/C type II

We conducted meta-analysis of the outcome obstetric tear; it is presented by degree of tear and study type (figure 4).

Figure 4: Forest plot, obstetric tears/lacerations (cut vs non-cut)

Figure 4: Forest p					eration		
	cut		non-			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I M-H, Random, 95% CI
1.1.1 Perineal tears degr	ee 1-2						
De Silva 1989	11	167	27	1894	6.2%	4.62 [2.33, 9.15]	
Hakim 2001	158	489	19	50	8.7%	0.85 [0.58, 1.24]	<del></del>
Millogo-Traore 2007	23	227	13	227	6.4%	1.77 [0.92, 3.41]	<del>  •</del>
Wuest 2009	12	122	50	110	7.0%	0.22 [0.12, 0.38]	<del></del> _
Subtotal (95% CI)		1005		2281	28.3%	1.09 [0.35, 3.42]	
Total events	204		109				
Heterogeneity: Tau <sup>2</sup> = 1.2	7; Chi <sup>2</sup> = 5	0.87, df	= 3 (P <	0.00001);	$I^2 = 94\%$		
Test for overall effect: Z =	0.15 (P =	0.88)					
1.1.2 Perineal tears degr	ee 3-4						
Hakim 2001	13	489	1	50	1.5%	1.33 [0.18, 9.95]	
Wuest 2009	9	122	1	110	1.5%	8.11 [1.04, 63.03]	
Subtotal (95% CI)	9	611	Į.	160	3.0%	3.25 [0.54, 19.72]	
Total events	22	• • • • • • • • • • • • • • • • • • • •	2	100	0.070	0.20 [0.04, 10.12]	
Heterogeneity: Tau <sup>2</sup> = 0.6		50 df -	_	21\.  2 _ 1	270/		
Test for overall effect: Z =			- 1 (F = 0	.21), 1	31 /0		
rest for overall effect. Z =	1.20 (1 –	0.20)					
1.1.3 Perineal tear/injury							
Berardi 1985	13	62	22	698	6.6%	6.65 [3.53, 12.55]	_ <del></del>
Bohoussou 1986	63	1097	138	3836	9.3%	1.60 [1.19, 2.13]	-
Diop 1998	0	0	0	0		Not estimable	
Elnashar 2007	15	169	2	47	2.6%	2.09 [0.49, 8.80]	-
Larsen 2002	55	2501	25	1553	7.9%	1.37 [0.86, 2.18]	+-
Ndiaye 2010	14	187	1	143	1.5%	10.71 [1.42, 80.47]	
Slanger 2002	25	621	17	486	6.8%	1.15 [0.63, 2.11]	<del></del>
WHO study group 2006	1067	9990	544	4604	10.3%	0.90 [0.82, 1.00]	•
Subtotal (95% CI)		14627		11367	45.0%	1.84 [1.10, 3.05]	•
Total events	1252		749				
Heterogeneity: Tau <sup>2</sup> = 0.3	$3; Chi^2 = 5$	6.44, df	= 6 (P <	0.00001);	$I^2 = 89\%$		
Test for overall effect: Z =	2.34 (P =	0.02)					
1.1.4 Perineal tears (regi	stry studi	es)					
Johnson 2005	251	579	1537	4837	10.3%	1.36 [1.23, 1.51]	-
Lupo 1999	4	17	7	34	3.8%	1.14 [0.39, 3.37]	
Vangen 2002	56	1733	22299	702192	9.5%	1.02 [0.79, 1.32]	+
Subtotal (95% CI)		2329		707063	23.7%	1.21 [0.95, 1.55]	<b>*</b>
Total events	311		23843				
Heterogeneity: Tau <sup>2</sup> = 0.03	3; Chi² = 4	.65, df =	= 2 (P = 0	.10); I <sup>2</sup> = \$	57%		
Test for overall effect: Z =	1.52 (P =	0.13)					
Total (95% CI)		18572		720871	100.0%	1.39 [1.07, 1.82]	•
Total events	1789		24703				
Heterogeneity: Tau <sup>2</sup> = 0.18	8; Chi² = 1	32.90, c		< 0.0000	1); I <sup>2</sup> = 89 <sup>6</sup>	%	
Test for overall effect: Z =			`		• *		0.1 0.2 0.5 1 2 5 10
Test for subgroup differen	,	,	f = 3 (P =	= 0.37), I <sup>2</sup>	= 4.6%		Favours cut Favours non-cut
			•				

As shown in the forest plot, there was a statistically significant difference between cut and non-cut women (RR= 1.39, CI= 1.07, 1.82). Women with FGM/C were 1.4 times at greater risk of tears/lacerations compared to women without FGM/C. In these studies, among women with FGM/C there were 5 per 100 woman (5%) who experienced lacerations, while 3 per 100 (3%) non-cut women experienced lacerations. The absolute risk difference was 1 more case of lacerations among women with FGM/C per 100 woman (CI= 0 more to 3 more). The results show that there was

large, unexplained heterogeneity across studies ( $I^2=89\%$ ,  $Chi^2=132.9$ , p< 0.00001). The pooled effect size for Africa-based studies (figure 4, 1.1.3) was greater than the effect size for the registry studies (figure 4, 1.1.4), which compared Somali-born women to women born in the USA or Norway. The difference between these two sets of studies was not statistically significant, but there is greater confidence in the estimate for the Africa-based studies since the exposed groups were selected from the same population as the non-exposed groups. The quality of the evidence for this outcome is very low (table 24). The GRADE Evidence profile tables are in appendix 6.

# FGM/C type I vs type II

Two studies (29;32) presented results regarding obstetric tears/lacerations for women with FGM/C type I and women with FGM/C type II separately (table 9).

Table 9: Study outcomes (dichotomous) and effect estimates for obstetric tears,

FGM/C type I vs type II

<u> </u>	-J P		*		
Author, year	Study quality	Outcome	FGM/C type I	FGM/C type II	Results RR (95%CI)
Larsen 2002	Low	Tear <sup>a</sup>	35/1929 (1.8%)	20/572 (3.5%)	0.52 (0.30, 0.89)*
WHO study group 2006	High	Tear (any) <sup>b</sup>	422/4386 (9.6%)	596/4962 (6.3%)	0.80 (0.71, 0.90)*

Legend: RR= relative risk with 95% confidence interval (CI). a= Larsen 2002 reported results also separately for first and second pregnancy, but we present only results for all pregnancies; b= Data provided by study authors; \*= statistically significant

We conducted meta-analysis of obstetric tears/lacerations, comparing women with FGM/C type I to women with FGM/C type II (figure 5).

Figure 5: Forest plot, obstetric tears/lacerations (type I vs type II)

	type	I	type	II		Risk Ratio		Risl	k Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	IV	I-H, Ran	dom, 95	% CI	
Larsen 2002	35	1929	20	572	30.7%	0.52 [0.30, 0.89]		_	-		
WHO study group 2006	422	4386	596	4962	69.3%	0.80 [0.71, 0.90]					
Total (95% CI)		6315		5534	100.0%	0.70 [0.47, 1.04]		•			
Total events	457		616								
Heterogeneity: Tau <sup>2</sup> = 0.09	5; Chi <sup>2</sup> = 2	2.36, df	= 1 (P = 0	0.12); l²	2 = 58%		0.1 0.2	0.5	1 2	<del> </del> 5	10
Test for overall effect: Z =	1.77 (P =	0.08)					0.1 0.2	type	l type II	J	10

The pooled relative risk with 95% CI for the comparison of obstetric tears/lacerations between women with FGM/C type I and II was RR= 0.70 (CI= 0.47, 1.04), showing that there was no statistically significant difference between the two groups of women. There was moderate heterogeneity across the two studies (I<sup>2</sup>= 58%, Chi<sup>2</sup>= 2.7, p= 0.12). The quality of the evidence for this outcome is very low (table 25). The GRADE Evidence profile tables are in appendix 6.

#### What we know about obstetric tears/lacerations

- Women who have been genitally cut seem to be more likely than non-cut women to experience obstetric tears; this is based on very low quality of evidence.
- The risk of obstetric tears does not seem to be significantly different between women with FGM/C type I and women with FGM/C type II; this is based on very low quality of evidence. However, the direction of effect across studies seems to favor FGM/C type I over type II.

#### **Cesarean section**

Usually, women deliver their baby through the birth canal, i.e. they have a vaginal birth. But there are cases when a cesarean section is necessary for the safety of the mother and/or the baby. In the general case, cesarean sections are performed because of problems that arise during labor (emergency/unplanned cesarean), but a cesarean section can also be elective (planned). Whether unplanned or planned, a cesarean section is the delivery of a baby through a cut (incision) in the mother's belly and uterus, rather than through the birth canal (21).

Among the included studies in this systematic review, a total of 16 studies reported the prevalence of cesarean section for women with FGM/C compared to women who were not genitally cut (29-33;58;60;62-64;66;68-72). Results regarding cesarean section from these comparative studies are shown in table 10. We note that Small and colleagues' study (71) included registry data from six countries, and the researchers compared labor events between Somali-born women and receiving country-born women. Because of considerable variation between countries in these outcomes, we treated each country as one dataset/study, denoted by country in tables and figures where this study is included.

Table 10: Study outcomes (dichotomous) and effect estimates for cesarean section

Author, year	Study quality	Outcome	FGM/C group	Non-FGM/C group	Results RR (95%CI)
Berardi 1985	Low	Cesarean section	9/71 (12.7%)	86/781 (11.0%)	1.15 (0.61, 2.19)
Bohoussou 1986	Low	Cesarean section	376/1097 (34.3%)	1212/3836 (31.6%)	1.08 (0.99, 1.19)
Chibber 2011	Low	Cesarean section	884/1842 (48.0%)	532/2958 (18.0%)	2.67 (2.44, 2.92)*
De Silva 1989	Low	Cesarean section	7/167 (4.2%)	96/1990 (4.8%)	0.87 (0.41, 1.84)
Elnashar 2007	Low	Cesarean section	10/169 (5.9%)	3/47 (6.4%)	0.93 (0.27, 3.23)
Johnson 2005 a	Low	Cesarean delivery	138/579 (23.8%)	1019/4837 (21.1%)	1.13 (0.97, 1.32)
Larsen 2002 b	Low	Cesarean section	16/385 (4.2%) TI 5/123 (4.1%) TII	28/393 (7.1%)	0.58 (0.32, 1.06) 0.57 (0.23, 1.45)
Ndiaye 2010	Low	Cesarean section	23/210 (11.0%)	1/144 (0.7%)	15.77 (2.15, 115.48)*

Oduro 2006	High	Cesarean section	120/1466 (8.2%)	241/3605 (6.7%)	1.22 (0.99, 1.51)
Small 2008 b	Low	Cesarean section			
-Australia			284/1124 (25.3%)	74189/353907 (21.0%)	1.21 (1.09, 1.33)*
-Belgium			61/207 (29.5 %)	59373/328983 (18.0%)	1.63 (1.32, 2.02)*
-Canada			519/2527 (20.5%)	74103/370606 (20.0%)	1.03 (0.95, 1.11)
-Finland			142/832 (17.1%)	26717/158470 (16.8%)	1.01 (0.87, 1.18)
-Norway			367/2288 (16.1%)	44567/310923 (14.3%)	1.12 (1.02, 1.23)*
-Sweden			500/3450 (14.5%)	69476/447464 (15.5%)	0.93 (0.86, 1.01)
Slanger 2002	Moderate	Cesarean section	32/621 (5.2%)	42/486 (8.6%)	0.60 (0.38, 0.93)*
Vangen 2002	Low	Cesarean section	330/1733 (19.0%)	87210/702192 (12.4%)	1.53 (1.39, 1.69)*
WHO study group 2006	High	Cesarean section	463/6856 (6.8%) TI 493/7771 (6.3%) TII 294/6595 (4.5%) TIII	510/7171 (7.1%)	0.95 (0.84, 1.07) 0.89 (0.79, 1.01) 0.63 (0.55, 0.72)*
Wuest 2009	Low	Emergency c- section	18/122 (14.8%)	3/110 (2.7%)	5.41 (1.64, 17.87)*
		Elective c-section	9/122 (7.4%)	8/110 (7.3%)	1.01 (0.41, 2.54)
Yount 2007	Moderate	Cesarean section	32/1071 (3.0%)	48/2096 (2.3%)	1.30 (0.84, 2.03)

Legend: RR= relative risk with 95% confidence interval (CI). TI= FGM/C type I; TII= FGM/C type II; TIII= FGM/C type III; a= Johnson 2005 reported results also separately for nulliparous and multiparous women and white and black US-born women, but we present only results for all pregnancies and all US-born women; b= Larsen 2002 and Small 2008 reported results also separately for first and second pregnancy, but we present only results for all pregnancies; \*= statistically significant.

We carried out meta-analyses, pooling available data from 15 studies for cesarean section. Sensitivity analyses were conducted for type of study. Figure 6 presents the meta-analyses results for cesarean section, comparing cut and non-cut women.

Figure 6: Forest plot, cesarean section (cut vs non-cut)

	cut	:	non	-cut		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	<b>Events</b>	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
1.2.1 Cesarean section							
Berardi 1985	9	71	86	781	3.5%	1.15 [0.61, 2.19]	<del></del>
Bohoussou 1986	376	1097	1212	3836	6.5%	1.08 [0.99, 1.19]	<del>-</del>
Chibber 2011	884	1842	532	2958	6.5%	2.67 [2.44, 2.92]	
De Silva 1989	7	167	96	1990	3.0%	0.87 [0.41, 1.84]	
Elnashar 2007	10	169	3	47	1.5%	0.93 [0.27, 3.23]	
Larsen 2002	21	508	28	393	4.0%	0.58 [0.33, 1.01]	
Ndiaye 2010	23	210	1	144	0.7%	15.77 [2.15, 115.48]	<del></del>
Oduro 2006	120	1466	241	3605	6.0%	1.22 [0.99, 1.51]	<del> -</del>
Slanger 2002	32	621	42	486	4.6%	0.60 [0.38, 0.93]	
WHO study group 2006	1250	21222	510	7171	6.5%	0.83 [0.75, 0.91]	<b>-</b>
Wuest 2009	18	122	3	110	1.6%	5.41 [1.64, 17.87]	
Yount 2007	32	1071	48	2096	4.6%	1.30 [0.84, 2.03]	1
Subtotal (95% CI)		28566		23617	48.9%	1.23 [0.84, 1.79]	•
Total events	2782		2802				
Heterogeneity: Tau <sup>2</sup> = 0.3	34; Chi <sup>2</sup> = 3	868.07, d	df = 11 (P	< 0.00001	); I <sup>2</sup> = 97%	Ď	
Test for overall effect: Z =	= 1.06 (P =	0.29)					
1.2.2 Cesarean section (	(registry s	tudies)					
Johnson 2005	138	579	1019	4837	6.3%	1.13 [0.97, 1.32]	<del> -</del>
Small 2008 (Australia)	284	1124	74189	353907	6.5%	1.21 [1.09, 1.33]	-
Small 2008 (Belgium)	61	207	59373	328983	6.0%	1.63 [1.32, 2.02]	<del>-</del>
Small 2008 (Canada)	519	2527	74103	370606	6.5%	1.03 [0.95, 1.11]	<u>†</u>
Small 2008 (Finland)	142	832	26717	158470	6.3%	1.01 [0.87, 1.18]	+
Small 2008 (Norway)	367	2288	44567	310923	6.5%	1.12 [1.02, 1.23]	<del>-</del>
Small 2008 (Sweden)	500	3450	69476	447464	6.5%	0.93 [0.86, 1.01]	7
Vangen 2002	330	1733	87210	702192	6.5%	1.53 [1.39, 1.69]	<del></del>
Subtotal (95% CI)		12740		2677382	51.1%	1.17 [1.03, 1.33]	<b>◆</b>
Total events	2341		436654				
Heterogeneity: Tau <sup>2</sup> = 0.0			= 7 (P <	0.00001);	<sup>2</sup> = 91%		
Test for overall effect: Z =	= 2.36 (P =	0.02)					
Total (95% CI)		41306		2700999	100.0%	1.18 [0.99, 1.40]	<b>•</b>
Total events	5123		439456				
Heterogeneity: Tau <sup>2</sup> = 0.1	2; Chi <sup>2</sup> = 4	181.38, 0	df = 19 (P	< 0.00001	); I <sup>2</sup> = 96%	,	
Test for overall effect: Z =			•				0.1 0.2 0.5 1 2 5 1 Favours cut Favours non-cut
Test for subgroup differer	•	,	df = 1 (P =	= 0.81), I <sup>2</sup> =	: 0%		ravouis cut ravouis non-cut

As evident from the forest plot, we did not find a statistically significant difference between cut and non-cut women with respect to cesarean section (RR= 1.18, CI= 0.99, 1.40). Considerable, unexplained heterogeneity indicated by  $I^2$  and  $Chi^2$  ( $I^2$ = 96%,  $Chi^2$ = 481.4, p< 0.00001) showed inconsistency across studies. Similar to the pooled result for the outcome obstetric tears, we note that the Africa-based studies provide greater confidence in the estimate than the registry studies since the groups were selected from the same population. We judged the quality of the evidence for this outcome as very low (table 24).

# FGM/C type I vs II

As shown in table 11, three studies presented results concerning cesarean section for women with FGM/C type I and women with FGM/C type II separately (29;30;32).

Table 11: Study outcomes (dichotomous) and effect estimates for cesarean sec-

tion, FGM/C type I vs type II

Author, year	Study quality	Outcome	FGM/C type I	FGM/C type II	Results RR (95%CI)
Larsen 2002	Low	Cesarean section	16/385 (4.2%)	5/123 (4.1%)	1.02 (0.38, 2.73)
Orji 2006	Low	Cesarean section	10/225 (4.4%)	1/35 (2.9%)	1.56 (0.21, 11.78)
WHO study group 2006	High	Cesarean section	463/6856 (6.8%)	493/7771 (6.3%)	1.06 (0.94, 1.20)

We conducted meta-analysis of cesarean section, comparing women with FGM/C type I to women with FGM/C type II (figure 7).

Figure 7: Forest plot, cesarean section (type I vs type II)

	type	I	type	II		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Larsen 2002	16	385	5	123	1.5%	1.02 [0.38, 2.73]	
Orji 2006	10	225	1	35	0.4%	1.56 [0.21, 11.78]	<u> </u>
WHO study group 2006	463	6856	493	7771	98.1%	1.06 [0.94, 1.20]	
Total (95% CI)		7466		7929	100.0%	1.07 [0.94, 1.20]	<b>*</b>
Total events	489		499				
Heterogeneity: Tau <sup>2</sup> = 0.0	0; Chi <sup>2</sup> = 0	).14, df	= 2 (P = 0	0.93); l <sup>2</sup>	$^{2} = 0\%$	ŀ	0.1 0.2 0.5 1 2 5 10
Test for overall effect: Z =	1.02 (P =	0.31)				(	Favours type I Favours type II

The pooled estimate showed that there was not a statistically significant difference between the two groups of women (RR= 1.07, CI= 0.94, 1.20). The quality of the evidence for this outcome is very low (table 25).

### What we know about cesarean section

- The risk of cesarean section does not seem to be significantly different between women with FGM/C and women without FGM/C; this is based on very low quality of evidence.
- The risk of cesarean section does not seem to be significantly different between women with FGM/C type I and women with FGM/C type II; this is based on very low quality of evidence.

### **Episiotomy**

Vaginal childbirth stretches the vagina. In some cases, during delivery, the birth attendant will make a surgical incision of the vulva in order to avoid tearing of the vaginal opening and rectum. This surgical cut is referred to as episiotomy. It can be midline or at an angle from the posterior end of the vulva, and is sutured closed after delivery (21).

In total, 14 comparative studies reported on episiotomy (27;29;30;32;33;51;58-60;63;64;67;68;70). One study (58) only provided episiotomy data for the FGM/C group (see appendix 5). Table 12 shows the results for episiotomy at study level between cut and non-cut women.


Table 12: Study outcomes (dichotomous) and effect estimates for episiotomy

Author, year	Study quality	Outcome	FGM/C group	Non-FGM/C group	Results RR (95%CI)
Adinma 1997	Low Episiotomy 1st deliver Episiotomy all deliveri		47/124 (37.9%) 25/124 (20.2%)	46/132 (34.9%) 13/132 (9.8%)	1.09 (0.79,1.50) 2.05 (1.10, 3.82)*
Berardi 1985	Low	Episiotomy	16/62 (25.8%)	178/698 (25.5%)	1.01 (0.65, 1.57)
De Silva 1989	Low	Episiotomy 1st delivery Episiotomy 2+ delivery	43/43 (100%) 49/124 (39.5%)	325/361 (90.0%) 557/1533 (36.3%)	1.10 (1.05, 1.15)* 1.09 (0.87, 1.37)
Diop 1998	Low	Episiotomy	Data not received		
Elnashar 2007	Low	Episiotomy 1st delivery	150/169 (88.8%)	33/47 (70.2%)	1.26 (1.04, 1.53)*
Hakim 2001	Low	Episiotomy	527/1225 (43.0%)	63/256 (24.6%)	1.75 (1.40, 2.19)*
Larsen 2002	Low	Episiotomy 1st delivery  Episiotomy 2nd delivery  Episiotomy any delivery	90/368 (24.5%) TI 31/106 (29.2%) TII 20/385 (5.2%) TI 11/123 (8.9%) TII 133/1929 (6.9%) TI	152/447 (34.0%) 36/393 (9.2%) 216/1553 (13.9%)	0.72 (0.58, 0.90)* 0.86 (0.62, 1.19) 0.57 (0.33, 0.96)* 0.98 (0.51, 1.86) 0.50 (0.40, 0.61)*
Millogo-Traore 2007	Low	Episiotomy	56/572 (9.8%) TII 95/227 (41.9%)	56/227 (24.7%)	0.70 (0.53, 0.93)* 1.70 (1.29, 2.23)*
Ndiaye 2010	Low	Episiotomy	68/187 (36.4%)	10/143 (7.0%)	5.20 (2.78, 9.74)*
Slanger 2002	Moderate	Episiotomy 1st delivery	162/621 (26.1%)	180/486 (37.0%)	0.70 (0.59, 0.84)*
WHO study group 2006	High	Episiotomy any delivery	1810/5774 (31.3%) TI 2152/6518 (33.0%) TII 5579/6172 (90.4%) TIII	1992/6052 (32.9)	0.95 (0.90, 1.00) 1.00 (0.95, 1.05) 2.75 (2.65, 2.85)*
Wuest 2009	Low	Episiotomy	24/122 (19.7%)	16/110 (14.5%)	1.35 (0.76, 2.41)

Legend: RR= relative risk with 95% confidence interval (CI). TI= FGM/C type I; TII= FGM/C type II; TIII= FGM/C type III; a= Data provided by study authors, \*= statistically significant.

Eleven studies were sufficiently similar to warrant pooling of effect sizes of episiotomy in meta-analysis (figure 8). It is presented by first delivery and second or later /any delivery.





As shown in the forest plot, there was not a statistically significant difference between the two groups concerning episiotomy (RR= 1.19, CI= 0.98, 1.44). The results show that there was large, unexplained heterogeneity across studies ( $I^2$ = 96%,  $Chi^2$ = 322.4, p< 0.00001). Using GRADE, we judged the quality of the evidence for this outcome as very low (table 24).

### FGM/C type I vs II

Table 13 shows the results of the three studies that presented results concerning episiotomy for women with FGM/C type I and women with FGM/C type II separately (29;30;32).

Table 13: Study outcomes (dichotomous) and effect estimates for episiotomy,

FGM/C type I vs FGM/C type II

ram/c type r vs	Tam/C type I vs Fam/C type II										
Author, year	Study quality	Outcome	FGM/C type I	FGM/C type II	Results RR (95%CI)						
Larsen 2002	Low	Episiotomy 1st delivery Episiotomy 2nd delivery	90/368 (24.5%) 20/385 (5.2%)	31/106 (29.2%) 11/123 (8.9%)	0.84 (0.59, 1.18) 0.58 (0.29, 1.18)						

		Episiotomy any delivery	133/1929 (6.9%) <sup>a</sup>	56/572 (9.8%)	0.70 (0.52, 0.95)*
Orji 2006	Low	Episiotomy	62/225 (27.6%)	1/35 (2.9%)	9.64 (1.38, 67.34)*
WHO study group 2006	High	Episiotomy any delivery b	1810/5774 (31.3%)	2152/6518 (33.0%)	0.95 (0.90, 1.00)

Legend: RR= relative risk with 95% confidence interval (CI); a= Created from two categories by collapsing across categories; b= Data provided by study authors; \*= statistically significant.

The meta-analysis of episiotomy comparing women with FGM/C type I to women with FGM/C type II is shown in figure 9.

Figure 9: Forest plot, episiotomy (type I vs type II)

	type	I	type	II		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Larsen 2002	133	1929	56	572	42.3%	0.70 [0.52, 0.95]	-
Orji 2006	62	225	1	35	4.3%	9.64 [1.38, 67.34]	<del></del>
WHO study group 2006	1810	5774	2152	6518	53.4%	0.95 [0.90, 1.00]	•
Total (95% CI)		7928		7125	100.0%	0.92 [0.61, 1.40]	•
Total events	2005		2209				
Heterogeneity: Tau <sup>2</sup> = 0.0	8; Chi <sup>2</sup> = 9	).28, df	= 2 (P = 0	0.010);	$I^2 = 78\%$	<u> </u>	1 0.2 0.5 1 2 5 10
Test for overall effect: Z =	0.37 (P =	0.71)				U.	Favours type   Favours type

The pooled estimate shows that there was not a statistically significant difference between the two groups of women (RR= 0.923, CI= 0.61, 1.40) and there was considerable heterogeneity (I<sup>2</sup>= 78%, Chi<sup>2</sup>= 9.3, p= 0.01). Using GRADE, we judged the quality of the evidence for this outcome as very low (table 25).

### What we know about episiotomy

- The risk of episiotomy does not seem to be significantly different between women with FGM/C and women without FGM/C; this is based on very low quality of evidence.
- The risk of episiotomy does not seem to be significantly different between women with FGM/C type I and women with FGM/C type II; this is based on very low quality of evidence.

### **Instrumental delivery**

In order to assist with delivery of the baby during vaginal birth, typically in cases of fetal or maternal distress during the second stage of labor, it is sometimes necessary to use special devices. Broadly speaking, these devices are either forceps or vacuum. Both devices are introduced into the vagina of a laboring woman, applied onto the head of the baby, and used to assist the delivery (21).

We identified and included eight comparative studies which reported on instrumental delivery (31;33;58;63;66;67;70;71). These studies and their results are presented in table 14.

Table 14: Study outcomes (dichotomous) and effect estimates for instrumental delivery

Author, year	Study quality	Outcome	FGM/C group	Non-FGM/C group	Results RR (95%CI)
Bohoussou 1986	Low	Instrumental extraction	61/1097 (5.6%)	119/3836 (3.1%)	1.79 (1.33, 2.42)*
De Silva 1989	Low	Forceps/ventouse	12/167 (7.2%)	109/1990 (5.5%)	1.31 (0.74, 2.33)
Johnson 2005 a	Low	Operative vaginal delivery	46/579 (7.9%)	331/4837 (6.8%)	1.16 (0.86, 1.56)
Millogo-Traore 2007	Low	Instrumental delivery	4/227 (1.8%)	1/227 (0.4%)	4.00 (0.45, 35.51)
Slanger 2002	Moderate	Instrumental delivery	3/621 (0.5%)	1/486 (0.2%)	2.35 (0.24, 22.50)
Small 2008 -Australia -Belgium -Canada -Finland -Norway -Sweden	Low	Operative vaginal birth	76/1124 (6.8%) 24/207 (11.6%) 7/109 (6.4%) 29/832 (3.5%) 156/2289 (6.8%) 154/3450 (6.7%)	32761/353907 (9.3%) 38707/328983 (11.8%) 1926/16229 (11.9%) 9422/159470 (6.0%) 23304/310923 (7.5%) 33310/447465 (7.4%)	0.73 (0.59, 0.91)* 0.99 (0.68, 1.44) 0.54 (0.26, 1.11) 0.59 (0.41, 0.84)* 0.91 (0.78, 1.06) 0.60 (0.51, 0.70)*
Vangen 2002	Low	Operative delivery	154/1733 (8.9%)	52315/702192 (7.5%)	1.19 (1.03, 1.39)*
Wuest 2009	Low	Forceps Ventouse	3/122 (2.5%) 11/122 (9.0%)	0/110 (0%) 10/110 (9.1%)	6.32 (0.33, 120, 94) 0.99 (0.44, 2.24)

Legend: RR= relative risk with 95% confidence interval (CI). a= Johnson 2005 reported results also separately for nulliparous and multiparous women and white and black US-born women, but we present only results for all pregnancies and all US-born women; \*= statistically significant.

We carried out meta-analysis, pooling available data from eight studies for the obstetric outcome instrumental delivery. Sensitivity analyses were conducted for study type. Figure 10 presents the results.

Figure 10: Forest plot, instrumental delivery (cut vs non-cut)

	cut		non	-cut		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	<b>Events</b>	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI
1.5.1 Instrumental deliv	very						
Bohoussou 1986	61	1097	119	3836	9.7%	1.79 [1.33, 2.42]	-
De Silva 1989	12	167	109	1990	6.6%	1.31 [0.74, 2.33]	+-
Millogo-Traore 2007	4	227	1	227	1.0%	4.00 [0.45, 35.51]	<del>-   · · ·  </del>
Slanger 2002	3	621	1	486	0.9%	2.35 [0.24, 22.50]	-
Wuest 2009	14	122	10	110	4.9%	1.26 [0.58, 2.72]	<del></del>
Subtotal (95% CI)		2234		6649	23.1%	1.65 [1.29, 2.12]	•
Total events	94		240				
Heterogeneity: Tau <sup>2</sup> = 0.	.00; Chi <sup>2</sup> =	2.09, df	= 4 (P =	0.72); l <sup>2</sup> =	0%		
Test for overall effect: Z	= 3.95 (P ·	< 0.0001	1)				
1.5.2 Instrumental deliv	very (regis	stry stud	dies)				
Johnson 2005	46	579	331	4837	9.7%	1.16 [0.86, 1.56]	+-
Small 2008 (Australia)	76	1124	32761	353907	10.6%	0.73 [0.59, 0.91]	
Small 2008 (Belgium)	24	207	38707	328983	8.8%	0.99 [0.68, 1.44]	+
Small 2008 (Canada)	7	109	1926	16229	5.3%	0.54 [0.26, 1.11]	<del></del>
Small 2008 (Finland)	29	832	9422	159470	9.0%	0.59 [0.41, 0.84]	
Small 2008 (Norway)	156	2289	23304	310923	11.2%	0.91 [0.78, 1.06]	<del></del> +
Small 2008 (Sweden)	154	3450	33310	447465	11.1%	0.60 [0.51, 0.70]	<b>+</b>
Vangen 2002	154	1733	52315	702192	11.2%	1.19 [1.03, 1.39]	<del>-</del>
Subtotal (95% CI)		10323		2324006	76.9%	0.83 [0.66, 1.04]	<b>◆</b>
Total events	646		192076				
Heterogeneity: Tau <sup>2</sup> = 0.	.08; Chi <sup>2</sup> =	53.08, 0	df = 7 (P <	< 0.00001);	$I^2 = 87\%$		
Test for overall effect: Z	= 1.63 (P =	= 0.10)					
Total (95% CI)		12557		2330655	100.0%	0.96 [0.77, 1.20]	•
Total events	740		192316				
Heterogeneity: Tau <sup>2</sup> = 0.	.11; Chi <sup>2</sup> =	80.32, 0	df = 12 (P	< 0.00001	); I <sup>2</sup> = 85%	, 0	0.1 0.2 0.5 1 2 5 10
Test for overall effect: Z	= 0.36 (P =	= 0.72)					0.1 0.2 0.5 1 2 5 10 Favours cut Favours non-cut
Test for subgroup differe	ences: Chi²	= 16.17	, df = 1 (l	P < 0.0001	), $I^2 = 93.8$	3%	r avours cut Favours Horr-cut

As shown in the forest plot, there was a significant difference between the Africabased studies and the registry studies (test for subgroup differences, Chi<sup>2</sup>= 16.2, p= 0.0001). Pooled results from studies where the cut and non-cut women were selected from the same population suggested that women with FGM/C are more likely than women with no FGM/C to require instrumental delivery (figure 10, 1.5.1, RR= 1.65, CI= 1.29, 2.12). Women with FGM/C were 1.6 times at greater risk of instrumental delivery compared to women without FGM/C. In these studies, among women with FGM/C there were 6 per 100 woman (6%) who needed instrumental delivery, while 4 per 100 (4%) non-cut women required instrumental delivery. The absolute risk difference was 2 more cases of instrumental delivery among women with FGM/C per 100 woman (CI= 1 more to 4 more). The quality of the evidence for this outcome is very low (table 24). The GRADE Evidence profile tables are in appendix 6. The registry studies, comparing Somali-born women (likely FGM/C type III) and western-born women without FGM/C showed no statistically significant difference between the two groups of women with respect to instrumental delivery (figure 10, 1.5.2, RR= 0.83, CI= 0.66, 1.04). There was large heterogeneity across the registry studies (I<sup>2</sup>= 87%, Chi<sup>2</sup>= 53.1, p< 0.00001).

# What we know about instrumental delivery

- Women with FGM/C seem to be more likely than non-cut women to experience instrumental delivery; this is based on very low quality of evidence.
- The risk of instrumental delivery does not seem to be significantly different between Somali-born women and western-born women; this is based on low quality of evidence.
- There were no studies that compared women with different types of FGM/C with respect to instrumental delivery, thus, we do not know if various FGM/C types differentially affect the risk of instrumental delivery.

# **Obstetric hemorrhage**

While obstetrical hemorrhage refers to heavy bleeding during pregnancy, labor, or immediately after birth, here we focus on such bleeding occurring only during labor and the post-partum period (reported in included studies). Main causes of bleeding during labor include uterine rupture and separation of the placenta from the wall of the uterus before birth. Postpartum hemorrhage is usually defined as the loss of greater than 500 ml of blood in relation to vaginal delivery (21).

We identified and included ten comparative studies that reported on obstetric hemorrhage (27;31-33;51;62;63;66;68;70). Nine of the studies measured obstetric hemorrhage as a dichotomous outcome and one as a continuous outcome. The dichotomous results for obstetric hemorrhage are presented in table 15.

Table 15: Study outcomes (dichotomous) and effect estimates for obstetric

hemorrhage

	7 -				·
Author, year	Study quality	Outcome	FGM/C group	Non-FGM/C group	Results RR (95%CI)
Chibber 2011	Low	Postpartum hemorrhage	254/1842 (13.8%)	142/2958 (4.8%)	2.87 (2.36, 3.50)*
De Silva 1989	Low	Postpartum hemorrhage ≥500ml	9/167 (5.4%)	31/1990 (1.6%)	3.46 (1.68, 7.14)*
Diop 1998	Low	Hemorrhage	Data not received		
Hakim 2001	Low	Bleeding	54/489 (11.0%)	5/50 (10.0%)	1.10 (0.46, 2.63)
Johnson 2005a	Low	Postpartum hemorrhage	30/579 (5.2%)	147/4837 (3.0%)	1.70 (1.16, 2.50)*
Ndiaye 2010	Low	Obstetric hemorrhage	57/187 (30.5%)	4/143 (2.8%)	10.90 (4.05, 29.33)*
Slanger 2002	Moderate	Obstetric hemorrhage	18/621 (2.9%)	5/486 (1.0%)	2.82 (1.05, 7.53)*
Vangen 2002	Low	Postpartum hemorrhage ≥500ml	76/1733 (4.4%)	30668/702192 (4.4%)	1.00 (0.81, 1.25)
WHO study group 2006	High	Postpartum blood loss ≥500 ml	583/6856 (8.5%)TI 530/7771 (6.8%)TII 432/6595 (6.6%) TIII	425/7171 (5.9%)	1.43 (1.27, 1.62)* 1.15 (1.02, 1.30)* 1.11 (0.97, 1.26)

Legend: RR= relative risk with 95% confidence interval (CI); TI= FGM/C type I; TII= FGM/C type II; TIII= FGM/C type III; a= Johnson 2005 reported results also separately for nulliparous and multiparous women and white and black US-born women, but we present only results for all pregnancies and all US-born women; \*= statistically significant.

We conducted meta-analysis of the outcome obstetric hemorrhage; it is presented by hemorrhage classification stated in the studies and type of study (figure 11).

Figure 11: Forest plot, obstetric hemorrhage (cut vs non-cut)

	cut		non-	cut		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I M-H, Random, 95% CI
1.8.1 Postpartum hemor	rhage >50	00 ml					
De Silva 1989	9	167	31	1990	10.8%	3.46 [1.68, 7.14]	
WHO study group 2006	1545	21222	425	7171	16.5%	1.23 [1.11, 1.36]	•
Subtotal (95% CI)		21389		9161	27.4%	1.93 [0.71, 5.30]	
Total events	1554		456				
Heterogeneity: Tau <sup>2</sup> = 0.4			= 1 (P = 0	.006); I <sup>2</sup> =	: 87%		
Test for overall effect: Z =	: 1.28 (P =	0.20)					
1.8.2 Obstetric hemorrh	age						
Chibber 2011	254	1842	142	2958	16.1%	2.87 [2.36, 3.50]	-
Diop 1998	0	0	0	0		Not estimable	
Hakim 2001	54	489	5	50	9.4%	1.10 [0.46, 2.63]	<del>-  •</del>
Ndiaye 2010	57	187	4	143	8.3%	10.90 [4.05, 29.33]	
Slanger 2002	18	621	5	486	8.4%	2.82 [1.05, 7.53]	
Subtotal (95% CI)		3139		3637	42.2%	3.03 [1.49, 6.18]	
Total events	383		156				
Heterogeneity: Tau <sup>2</sup> = 0.3			= 3 (P =	0.008); l <sup>2</sup>	= 75%		
Test for overall effect: Z =	: 3.05 (P =	0.002)					
1.8.3 Obstetric hemorrh	age (regis	try stuc	lies)				
Johnson 2005	30	579	147	4837	14.5%	1.70 [1.16, 2.50]	<del></del>
Vangen 2002	76	1733	30668	702192	15.9%	1.00 [0.81, 1.25]	+_
Subtotal (95% CI)		2312		707029	30.5%	1.28 [0.76, 2.14]	
Total events	106		30815				
Heterogeneity: Tau <sup>2</sup> = 0.1			= 1 (P = 0	.02); I <sup>2</sup> =	82%		
Test for overall effect: Z =	0.93 (P =	0.35)					
Total (95% CI)		26840		719827	100.0%	2.04 [1.36, 3.05]	•
Total events	2043		31427				
Heterogeneity: Tau <sup>2</sup> = 0.2	25; Chi² = 9	1.09, df	= 7 (P <	0.00001);	$I^2 = 92\%$		0.1 0.2 0.5 1 2 5 10
Test for overall effect: Z =	3.46 (P =	0.0005)					Favours cut Favours non-cut
Test for subgroup differer	nces: Chi² :	= 3.75, c	f = 2 (P =	= 0.15), l <sup>2</sup>	= 46.6%		. around out i around non out

As shown in the forest plot, there was a significantly higher risk of obstetric hemorrhage among women with FGM/C compared to women without FGM/C (RR= 2.04, CI= 1.36, 3.05). Women with FGM/C were 2 times at greater risk of obstetric hemorrhage compared to women without FGM/C. In these studies, among women with FGM/C there were 9 per 100 woman who experienced hemorrhage, while 4 per 100 non-cut women experienced hemorrhage. The absolute risk difference was 5 more cases of obstetric hemorrhage among women with FGM/C per 100 woman (CI= 2 more to 9 more). The  $I^2$  and  $Chi^2$  results showed that there was large, unexplained heterogeneity across studies ( $I^2$ = 92%,  $Chi^2$ = 91.1, p<0.00001). The quality of the evidence for this outcome is very low (table 24). The GRADE Evidence profile tables are in appendix 6.

Wuest and colleagues (33) used a continuous measure for maternal blood loss during labor, measured as ml blood loss, which ranged from 100 to 3500 ml among the patients (table 16). Cut women experienced a median of 50 ml blood loss more than non-cut women during labor.

Table 16: Study outcomes (continuous) and effect estimate for maternal blood loss

Author, year	Study quality	Outcome	FGM/C group	Non-FGM/C group	Result Median diff (p-value)
Wuest 2009	Low	Maternal blood loss	400ml (range 200-1000)	350ml (range 100-3500)	-50 (p= 0.81)

# Comparison of different types of FGM/C

The WHO study (32) presented results for various FGM/C groups separately with regards to postpartum blood loss  $\geq$  500 ml (see table 15 above), allowing an evaluation of the relative risk of this outcome for various types of FGM/C:

- Type I vs Type II (583/6856 vs 530/7771): RR= 1.25 (CI= 1.11, 1.40)
- Type I vs Type III (583/6856 vs 432/6595): RR= 1.30 (CI= 1.15, 1.46)
- Type II vs Type III (530/7771 vs 432/6595): RR= 1.04 (CI= 0.92, 1.18)

The results show that there was a significant difference between women with FGM/C type I and women with FGM/C type II, and between women with FGM/C type II and women with FGM/C type III with regards to postpartum hemorrhage. In both cases, women with FGM/C type I had a greater risk of experiencing postpartum hemorrhage.

# What we know about obstetric hemorrhage

- Women with FGM/C seem to be more likely than non-cut women to experience obstetric hemorrhage; this is based on very low quality of evidence.
- We do not know if various FGM/C types differentially affect the risk of obstetric hemorrhage.

### **Difficult delivery**

Nine comparative studies reported outcomes categorized as difficult delivery (28;51-53;62;66;68;70). While the terminology used in the studies varied (difficult delivery, obstructed labor, difficulties/problems during delivery, dystocia) all seemed to refer to obstructed labor, which means difficult childbirth. Dystocia usually means failure to progress in labor. A difficult delivery may arise due to several reasons, such as incoordinate uterine activity and abnormal fetal presentation (21).

The seven comparative studies that examined difficult delivery among women with FGM/C and women without FGM/C are shown in table 17.

Table 17: Study outcomes (dichotomous) and effect estimates for difficult deliv-

ery

Author, year	Study quality	Outcome	FGM/C group	Non-FGM/C group	Results RR (95%CI)
Chibber 2011	Low	Obstructed labor	110/1842 (6.0%)	56/2958 (1.9%)	3.15 (2.30, 4.33)*
Diop 1998	Low	Difficult delivery	Data not received		
Johnson 2005	Low	Labor dystocia	45/579 (7.8%)	291/4819 (6.0%)	1.29 (0.95, 1.74)
Jones 1999 a	Low	Difficulties with delivery	Data not located		OR=1.00 TI (ref) <sup>a</sup> OR=1.30 (1.04, 1.62) TII OR=2.28 (1.33, 3.94) TIII OR=0.32 (0.19, 0.54) nonFGM/C
Jones 1999 b	Moderate	Observable difficulties with delivery	Data not located		OR=1.00 TI (ref) <sup>a</sup> OR=1.79 (1.10, 2.89) TII OR=1.77 (0.87, 3.61) TIII OR=0.17 (0.06, 0.52) nonFGM/C
Ndiaye 2010	Low	Obstructed labor/dystocia	91/210 (43.3%)	9/144 (6.3%)	6.93 (3.62, 13.30)*
Slanger 2002	Moderate	Obstructed labor	21/621 (3.4%)	10/486 (2.1%)	1.64 (0.78, 3.46)

Legend: RR= relative risk with 95% confidence interval (CI); TI= FGM/C type I; TII= FGM/C type II; TIII= FGM/C type III; a= Odds ratio reported in publication; \*= statistically significant.

We conducted meta-analyses of the outcome difficult delivery, with sensitivity analyses for study type (figure 12).

Figure 12: Forest plot, difficult delivery (cut vs non-cut)

	cut		non-c	ut		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I M-H, Random, 95% CI
1.9.1 Obstructed labor	or						
Chibber 2011	110	1842	56	2958	27.4%	3.15 [2.30, 4.33]	-
Ndiaye 2010	91	210	9	144	23.2%	6.93 [3.62, 13.30]	-
Slanger 2002 Subtotal (95% CI)	21	621 <b>2673</b>	10	486 <b>3588</b>	21.9% <b>72.5%</b>	1.64 [0.78, 3.46] <b>3.35 [1.71, 6.55</b> ]	•
Total events Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	Z = 3.52 (I	P = 0.00	•	= 0.01	); I <sup>2</sup> = 77%		
1.9.2 Labor dystocia	(registry s	study)					
Johnson 2005 Subtotal (95% CI)	45	579 <b>579</b>	291	4819 <b>4819</b>	27.5% <b>27.5%</b>	1.29 [0.95, 1.74] <b>1.29 [0.95, 1.74</b> ]	<b>-</b> ♦
Total events	45		291				
Heterogeneity: Not ap Test for overall effect:	•	P = 0.10	0)				
Total (95% CI)		3252		8407	100.0%	2.57 [1.27, 5.20]	•
Total events	267		366				
Heterogeneity: Tau <sup>2</sup> = Test for overall effect:			•	P < 0.0	0001); l² =	90%	0.01 0.1 1 10 10 Favours cut Favours non-cu
Test for subgroup diffe	erences: C	$hi^2 = 6.4$	46, df = 1	(P = 0.	01), $I^2 = 84$	1.5%	. 470410 040 1 470410 11011 00

As shown in the forest plot, there was a significant difference between the Africa-based studies and the registry study (test for subgroup differences, Chi²= 6.5, p=

o.01). Pooled results from studies where the cut and non-cut women were selected from the same population suggested that women with FGM/C are more likely than women with no FGM/C to experience difficult labor (figure 12, 1.9.1, RR= 3.35, CI= 1.71, 6.55). Women with FGM/C were 3.3 times at greater risk of difficult delivery compared to women without FGM/C. In these studies, among women with FGM/C there were 7 per 100 woman who experienced difficult delivery, while 2 per 100 non-cut women experienced difficult delivery. The absolute risk difference was 5 more cases of difficult delivery among women with FGM/C per 100 woman (CI= 1 more to 12 more). Using GRADE, we judged the quality of the evidence for this outcome as very low (table 24). The GRADE Evidence profile tables are in appendix 6. The registry studies, comparing Somali-born women (likely FGM/C type III) and US-born women showed no statistically significant difference between the two groups of women regarding labor dystocia (figure 12, 1.9.2, RR= 1.29, CI= 0.95, 1.74).

# Comparison of different types of FGM/C

Two studies compared difficult delivery among women with various types of FGM/C (52;53). The results of these two studies are found in table 18.

Table 18: Study outcomes (dichotomous) and effect estimates for difficult deliv-


ery, comparing various types of FGM/C

Author, year	Study quality	Outcome	FGM/C type	FGM/C type	Results RR (95%CI)
Eritrea DHS 2002	Low	Problems during delivery	13/203 (6.4%) TI-II	468/2158 (21.7%) TIII	0.30 (0.17, 0.50)*
			13/203 (6.4%) TI-II	61/2434 (2.5%) TIV	2.56 (1.43, 4.57)*
			468/2158 (21.7%) TIII	61/2434 (2.5%) TIV	8.65 (6.67, 11.23)*
Eritrea DHS 1995	Low	Problems during delivery	101/2240 (4.5%) TI	75/190 (39.5%) TII	0.11 (0.09, 0.15)*
			101/2240 (4.5%) TI	479/1444 (33.2%) TIII	0.14 (0.11, 0.17)*
			75/190 (39.5%) TII	479/1444 (33.2%) TIII	1.19 (0.98, 1.44)

Legend: RR= relative risk with 95% confidence interval (CI). TI= FGM/C type I; TII= FGM/C type II; TIII= FGM/C type III; TIV= FGM/C type IV; TI-II= FGM/C type I and II; \*= statistically significant.

The two studies were sufficiently similar for us to conduct meta-analyses of problems during delivery comparing women with FGM/C type I-II to women with FGM/C type III. The results are shown in figure 13.





The pooled estimate demonstrates that there was a statistically significant difference between the two groups of women, favoring FGM/C type I-II over FGM/C type III (RR= 0.24, CI= 0.21, 0.28). Women with FGM/C type I-II had a smaller risk of problems during delivery compared to women with FGM/C type III. In these studies, among women with FGM/C type III there were 26 per 100 woman who experienced problems during delivery, while 6 per 100 woman with FGM/C type I-II experienced problems. The absolute risk difference was 20 fewer cases of problems during delivery among women with FGM/C type I-II per 100 woman (CI= 19 fewer to 21 fewer). Using GRADE, we judged the quality of the evidence for this outcome as very low (table 26). The GRADE Evidence profile tables are in appendix 6.

# What we know about difficult delivery

- Women who have been genitally cut seem to be more likely than non-cut women to experience a difficult delivery; this is based on very low quality of evidence.
- Women with FGM/C type I-II seem to be less likely to experience problems during delivery compared to women with FGM/C type III; this is based on very low quality of evidence.

# Other obstetrical and antenatal complications

In addition to the seven main complications described above, a few studies reported on other obstetrical and antenatal complications.

#### Fever

Fever during labor can have infectious or non-infectious etiology, such as receiving epidural anesthesia, and can lead to a variety of maternal and neonatal sequelae (21). Three of our included comparative studies reported on fever in the laboring woman (27;66;70). The results from these three studies are shown in table 19.

Table 19: Study outcomes (dichotomous) and effect estimates for fever related to childbirth

Author, year	Study quality	Outcome	FGM/C group	Non-FGM/C group	Results RR (95%CI)
Hakim 2001	Low	Febrile illness	39/489 (8.0%)	1/50 (2.0%)	3.99 (0.56, 28.41)
Johnson 2005 a	Low	Febrile illness	49/579 (8.4%)	193/4837 (4.0%)	2.12 (1.57, 2.87)*
Slanger 2002	Moderate	Fever	3/621 (0.5%)	3/486 (0.6%)	0.78 (0.16, 3.86)

Legend: RR= relative risk with 95% confidence interval (CI). a= Johnson 2005 reported results also separately for nulliparous and multiparous women and white and black US-born women, but we present only results for all pregnancies and all US-born women, \*= statistically significant.

We conducted meta-analyses for maternal fever, pooling available data from three studies comparing women with FGM/C to women without FGM/C (figure 14).

Figure 14: Forest plot, fever (cut vs non-cut)

	cut		non-c	ut		Risk Ratio	Risk	Ratio
Study or Subgroup	<b>Events</b>	Total	<b>Events</b>	Total	Weight	M-H, Random, 95% C	I M-H, Ran	dom, 95% CI
1.11.1 Fever								
Hakim 2001	39	489	1	50	2.2%	3.99 [0.56, 28.41]		<u> </u>
Slanger 2002	3	621	3	486	3.4%	0.78 [0.16, 3.86]	-	+
Subtotal (95% CI)		1110		536	5.6%	1.61 [0.31, 8.41]		
Total events	42		4					
Heterogeneity: Tau <sup>2</sup> =	0.61; Chi <sup>2</sup>	= 1.74	, df = 1 (P	= 0.19	); I <sup>2</sup> = 42%			
Test for overall effect:	Z = 0.56 (1	P = 0.58	8)					
1.11.2 Febrile illness	(registry	study)						
Johnson 2005	49	579	193	4837	94.4%	2.12 [1.57, 2.87]		-
Subtotal (95% CI)		579		4837	94.4%	2.12 [1.57, 2.87]		◆
Total events	49		193					
Heterogeneity: Not ap	plicable							
Test for overall effect:	Z = 4.89 (1	o.00	0001)					
Total (95% CI)		1689		5373	100.0%	2.08 [1.55, 2.79]		•
Total events	91		197					
Heterogeneity: Tau <sup>2</sup> =	0.00; Chi <sup>2</sup>	= 1.88	df = 2 (P	= 0.39	); I <sup>2</sup> = 0%		1 1 1 1	<del>                                     </del>
Test for overall effect:					-		0.1 0.2 0.5	1 2 5 1 Favours non-cu
Test for subgroup diffe	erences: C	hi² = 0.	11. df = 1	(P = 0.	75). I <sup>2</sup> = 0%	, D	ravouis cut	. ravouis non-cu

As shown in the forest plot, there was a statistically significant difference between cut and non-cut women (RR= 2.08, CI= 1.55, 2.79). The registry study that compared Somali-born women to US-born women contributed disproportionate weight to the pooled result (figure 14, 1.11.2), and there is less confidence in its estimate since the groups were not selected from the same population. The quality of the evidence for this outcome is very low (table 24).

### What we know about maternal fever

We conclude that the data from three comparative studies are insufficient to establish whether there is a significant difference in the risk of maternal fever between women with FGM/C and women with no FGM/C.

### Induction of labor

Occasionally, artificially or prematurely stimulating childbirth in a woman is necessary for the health of the woman and/or the baby. Labor induction is necessary in cases such as when labor does not start within a specific amount of time after the membranes have ruptured (21). We included three comparative studies that reported on labor induction. All were registry studies of Somali-born women compared to western-born women (31;66;71). The three studies and their results are presented in table 20.

Table 20: Study outcomes (dichotomous) and effect estimates for labor induction

Author, year	Study quality	Outcome	FGM/C type III group	Non-FGM/C group	Results RR (95%CI)
Johnson 2005 a	Low	Labor induction	111/579 (19.2%)	932/4819 (19.3%)	0.99 (0.83, 1.18)
Small 2008	Low	Induction of labor			
-Australia			315/988 (31.9%)	90386/335638 (26.9%)	1.18 (1.08, 1.30)*
-Belgium			43/208 (20.7%)	96439/323583 (29.8%)	0.69 (0.53, 0.91)*
-Finland			127/786 (16.2%)	23173/146159 (15.8%)	1.02 (0.87, 1.20)
-Norway			346/2001 (17.3%)	34820/271047 (12.8%)	1.35 (1.22, 1.48)*
-Sweden			527/3156 (16.7%)	44680/410795 (10.9%)	1.54 (1.42, 1.66)*
Vangen 2002	Low	Induction of labor	334/1733 (19.3%)	92459 /702192 (13.2%)	4.59 (4.17, 5.06)*

Legend: RR= relative risk with 95% confidence interval (CI). a= Johnson 2005 reported results also separately for white and black US-born women, but we present only results for all US-born women, \*= statistically significant.

The three registry studies were sufficiently similar to warrant pooling of effect sizes in meta-analyses. Figure 15 presents the meta-analyses results for induction of labor, comparing Somali-born women (likely FGM/C type III) to western-born women (non-cut).

Figure 15: Forest plot, induction of labor (cut vs non-cut)

	cut		non-	-cut		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Johnson 2005	111	579	932	4819	13.3%	0.99 [0.83, 1.18]	+
Small 2008 (Australia)	315	988	90386	335638	15.5%	1.18 [1.08, 1.30]	•
Small 2008 (Belgium)	43	208	96439	323583	10.7%	0.69 [0.53, 0.91]	
Small 2008 (Finland)	127	786	23173	146159	13.8%	1.02 [0.87, 1.20]	+
Small 2008 (Norway)	346	2001	34820	271047	15.4%	1.35 [1.22, 1.48]	
Small 2008 (Sweden)	527	3156	44680	410795	15.8%	1.54 [1.42, 1.66]	
Vangen 2002	334	1733	92459	702192	15.4%	1.46 [1.33, 1.61]	•
Total (95% CI)		9451		2194233	100.0%	1.17 [1.01, 1.36]	<b>♦</b>
Total events	1803		382889				
Heterogeneity: Tau <sup>2</sup> = 0.	03; Chi <sup>2</sup> =	67.07,	df = 6 (P	< 0.00001	); I <sup>2</sup> = 91%	)	
Test for overall effect: Z	= 2.15 (P	= 0.03)	•				0.1 0.2 0.5 1 2 5 1 Favours cut Favours non-cut

The pooled result shows there was a statistically significant difference between Somali-born women, who likely had FGM/C type III, and western-born, non-cut women with regards to labor induction. The difference favored western-born, non-cut women (RR= 1.17, CI= 1.01, 1.36). Using GRADE, we judged the quality of the evidence of this outcome as very low (table 23). Considerable heterogeneity indicated by I² and Chi² (I²= 91%, Chi² =67.1, p= 0.00001) showed that there was large heterogeneity across the registry data.

#### What we know about induction of labor

We can conclude that a) the results from registry studies suggest that Somali-born women have a greater risk of labor induction than receiving country-born women, and b) we do not know whether women with FGM/C are more likely than non-cut women to experience labor induction, due to the lack of data from studies where the cut and non-cut women were selected from the same population. This is based on very low quality of evidence (table 24).

### Death

One comparative study reported on maternal death. The WHO multi-centre study (32) reported that 54 (0.19%) of the women in their study died before being discharged from the hospital (table 21). Despite being a large study, there was a small number of events and the results are therefore uncertain. Table 21 shows the relative risks of maternal death for various comparisons.

Table 21: Study outcome (dichotomous) and effect estimates for maternal death

Author, year	Study quality	FGM/C type I	FGM/C type II	FGM/C type III	No FGM/C	Results RR (95%CI)
WHO study group 2006	High	15/6856 (0.22%)	23/7771 (0.30%)	7/6595 (0.11%)	9/7171 (0.13%)	0.74 (0.39, 1.42) TI vs TII 2.06 (0.84, 5.05) TI vs TIII 2.79 (1.20, 6.49) TII vs TIII* 1.69 (0.83, 3.45) cut vs not

Legend: RR= relative risk with 95% confidence interval (CI). TI= FGM/C type I. TII= FGM/C type II. TIII= FGM/C type III; \*= statistically significant.

In the article (32), the authors state the following relative risks, adjusted for potential confounding factors such as illness at admission: FGM/C type I RR= 1.29 (CI= 0.36, 4.60), FGM/C type II RR= 4.18 (CI= 1.24, 14.08), FGM/C type III RR= 1.56 (CI= 0.25, 9.92) (versus non-cut).

Additionally, a case report from 1927 (55) reported on the death of a woman and her child in childbirth. We mention it here along with the WHO study (32) because it is one of the few studies we identified which described death as a likely complication of FGM/C. The author, Dr Philp, concluded "The result of circumcision narrowed the patient's vagina and drew the patient's bladder down on the left side. This led to the urethra not being retracted at labour, and when the pressure of the child's head came against a cicatrized opening, the thinned walls of the bladder and rectum gave way. If my conclusions are correct, this woman died as another victim of the abominable practice of female circumcision among the Akikuyu" ((55) p128). In sum, with respect to maternal death, there were insufficient data to conclude regarding differences between cut and non-cut women.

### Other obstetrical and antenatal complications

A total of six comparative studies reported various obstetric complications not described earlier (27;31;54;62;70;73). Each of these outcomes was only reported in one study. The outcomes were: antenatal kidney infection, antenatal hepatitis-C infection, urinary incontinence, faecal/flatus incontinence, urinary tract infection (UTI) in pregnancy, convulsion/seizure, secondary arrest of labor. These outcomes comparing cut vs non-cut women are listed in table 22. They show that there was a statistically higher risk among cut women, compared to non-cut women, to experience the following: antenatal kidney infection, antenatal hepatitis-C infection, secondary arrest of labor. Conversely, there was no significant difference between the cut and non-cut women with respect to: urinary incontinence, faecal/flatus incontinence, UTI in pregnancy, convulsion/seizure.

Table 22: Study outcomes (dichotomous) and effect estimates for other obstet-

rical and antenatal complications

Author, year	Study quality	Outcome	FGM/C group	Non-FGM/C group	Results RR (95%CI)
Chibber 2011	Low	Antenatal kidney infection	405/1842 (22.0%)	243/2958 (8.2%)	2.68 (2.31, 3.10)*
Chibber 2011	Low	Antenatal hepatitis-C	722/1842 (39.2%)	26/2958 (1.4%)	44.59 (30.29, 65.66)*
Hakim 2001	Low	Urinary incontinence	4/489 (1.0%)	0/50(0%) a	0.51 (0.06, 4.29)
Hakim 2001	Low	Faecal/flatus incontinence	2/489 (0.4%)	0/50 (0%) <sup>a</sup>	0.31 (0.03, 2.89)
Lupo 1999	Low	UTI in pregnancy	2/38 (5.3%)	19/76 (25.0%)	0.21 (0.05, 0.86)
Slanger 2002	Moderate	Convulsion/seizure	4/621 (0.6%)	0/486 (0%)1	3.91 (0.46, 33.38)
Vangen 2002	Low	Secondary arrest of labor	204/1733 (11.8%)	60358/702192 (8.6%)	1.37 (1.20, 1.56)*

Legend: RR= relative risk with 95% confidence interval (CI); UTI= Urinary tract infection; a= in the calculation of RR, 1 event was added to both groups to avoid 0 events; \*= statistically significant.

We also identified one comparative study which reported on miscarriage. It compared the prevalence of pregnancy loss for women with various types of FGM/C. Yount and Carrera (73) asked women to self-report whether they had experienced pregnancy loss, defined as "ever lost a pregnancy because of miscarriage, stillbirth, abortion" ((73) p190). As shown in table 23, there were no significant differences in pregnancy loss between the groups of women.

Table 23: Study outcome (dichotomous) and effect estimates for pregnancy loss

Author, year	Study quality	Outcome	FGM/C type I	FGM/C type II	FGM/C type IV	Results RR (95%CI)
Yount 2006	Low	Pregnancy loss	28/72 (38.9%)	522/1232 (42.4%)	170/396 (42.9%)	0.92 (0.68, 1.23) TI vs TII 0.91 (0.66, 1.24) TI vs TIV 0.99 (0.87, 1.13) TII vs TIV

Legend: RR= relative risk with 95% confidence interval (CI). TI= FGM/C type I. TII= FGM/C type II. TIV= FGM/C type IV.

In summary, for all of the outcomes reported in only one comparative study, there were insufficient data for us to conclude regarding differences between groups of women.

# Other obstetrical complications reported in non-comparative studies

In this chapter we have presented results from the 28 comparative studies included. Non-comparative studies can give a sense of possible complications following FGM/C and the range of frequency of complications but provide no answers on the strength of association between FGM/C and the proposed complications. Obstetric outcomes reported in the 16 non-comparative studies were the same as those reported in the comparative studies, except that five additional outcomes were presented. Additional obstetric outcomes reported in the cross-sectional, case series and case report studies were labeled: obstetric fistula, infection, obstetric complica-

tions, obstetric difficulties, and not normal vaginal delivery. These outcomes are detailed in appendix 5.

# **Summary of Findings tables**

The following three tables (tables 24-26) present our assessment of the quality of the evidence, organized according to comparison.

Table 24: Summary of Findings table for the comparison cut vs non-cut

# FGM/C compared to non-FGM/C for girls/women – Obstetric outcomes

Patient or population: Girls/women

Settings: Clinics/maternity welfare centers

Intervention: FGM/C
Comparison: non-FGM/C

Companson. non-row	7.0				•
Outcomes	Illustrative o	comparative risks*	Relative	No of	Quality of the Comments
(dichotomous)	(95% CI)		effect	participants	evidence
	Assumed	Corresponding risk	(95% CI)	(studies)	(GRADE)
	risk				
	Non-FGM/C	FGM/C			
Parlam and Jakan		•	DD 4 00	745070	<b>DOO</b>
Prolonged labor	5 per 100	8 per 100	RR 1.69	715079	⊕⊖⊖⊝
		(5 to 13)	(1.03 to	(5 studies <sup>1</sup> )	very low <sup>2,3</sup>
			2.77)		
Obstetric tears/	3 per 100	5 per 100	RR 1.39	739443	$\oplus \ominus \ominus \ominus$
lacerations		(4 to 6)	(1.07 to	(14 studies <sup>4</sup> )	very low <sup>5,6</sup>
			1.82)		
Cesarean section	44 per 100	52 per 100	RR 1.18	1041305	$\oplus \ominus \ominus \ominus$
		(44 to 62)	(0.99 to	(15 studies)	very low <sup>7,8,9</sup>
			1.4)		
Episiotomy	32 per 100	38 per 100	RR 1.19	35467	<b>0</b> 000
		(31 to 46)	(0.98 to	(11 studies <sup>10</sup> )	very low <sup>11,12,13</sup>
		(	1.44)	,	
Instrumental delivery	4 per 100	6 per 100	RR 1.65	8883	<b>0000</b>
(cross-sectional	·	(5 to 8)	(1.29 to	(5 studies)	very low <sup>14</sup>
studies)		,	2.12)	,	•
Obstetric	4 per 100	9 per 100	RR 2.04	746667	<b>0</b> 000
hemorrhage	·	(6 to 13)	(1.36 to	(8 studies <sup>15</sup> )	very low <sup>16,17</sup>
ge		(6.16.10)	3.05)	(0 0100.00 )	,
				2004	
Difficult delivery	2 per 100	7 per 100	RR 3.35	6261	⊕⊖⊖⊝
(cross-sectional		(4 to 14)	(1.71 to	(3 studies)	very low <sup>18,19,20</sup>
studies)			6.55)		_
Maternal fever	1 per 100	1 per 100	RR 1.61	1646	⊕⊖⊝⊝

		(0 to 6)	(0.31 to 8.41)	(3 studies)	very low <sup>21,22</sup>
Induction of labor	38 per 100	<b>45 per 100</b> (39 to 52)	RR 1.17 (1.01 to 1.36)	1009450 (3 studies)	⊕⊖⊝⊝ very low <sup>23</sup>

<sup>\*</sup>The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **RR:** Risk ratio;

GRADE Working Group grades of evidence= **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.

# Table 25: Summary of Findings table for the comparison FGM/C type I vs II

### FGM/C type I compared to FGM/C type II for girls/women - Obstetric outcomes

Patient or population: Girls/women

Settings: Clinics/maternity welfare centers

<sup>&</sup>lt;sup>1</sup> One additional study includes this outcome, but we have not received the data.

<sup>&</sup>lt;sup>2</sup> 5 of 5 studies had low methodological study quality.

<sup>&</sup>lt;sup>3</sup> Considerable heterogeneity indicated by I2 (I2=92%) showed inconsistency across studies.

<sup>&</sup>lt;sup>4</sup> One additional study include this outcome, but we have not received the data.

<sup>&</sup>lt;sup>5</sup> 12 of 14 studies had low methodological study quality.

<sup>&</sup>lt;sup>6</sup> Considerable heterogeneity indicated by I2 (I2=89%) showed inconsistency across studies.

<sup>&</sup>lt;sup>7</sup> 11 of 15 studies had low methodological study quality.

<sup>&</sup>lt;sup>8</sup> Considerable heterogeneity indicated by I2 (I2=97%) showed inconsistency across studies.

<sup>&</sup>lt;sup>9</sup> CI is wide, crosses limitations of precision (CI=0.94, 1.51).

<sup>&</sup>lt;sup>10</sup> One additional study includes this outcome, but we have not received the data.

<sup>&</sup>lt;sup>11</sup> 8 of 11 studies had low methodological study quality.

<sup>&</sup>lt;sup>12</sup> Considerable heterogeneity indicated by I2 (I2=96%) showed inconsistency across studies.

<sup>&</sup>lt;sup>13</sup> CI is wide, crosses limitations of precision (CI=0.98, 1.44).

<sup>&</sup>lt;sup>14</sup> 4 of 5 studies had low methodological study quality.

<sup>&</sup>lt;sup>15</sup> One additional study includes this outcome, but we have not received the data.

<sup>&</sup>lt;sup>16</sup> 6 of 8 studies had low methodological study quality.

<sup>&</sup>lt;sup>17</sup> Considerable heterogeneity indicated by I2 (I2=92%) showed inconsistency across studies.

<sup>&</sup>lt;sup>18</sup> 2 of 3 studies had low methodological study quality.

<sup>&</sup>lt;sup>19</sup> Considerable heterogeneity indicated by I2 (I2=77%) showed inconsistency across studies.

<sup>&</sup>lt;sup>20</sup> CI is wide (CI=1.71, 6.55) and number of events is less than 300.

<sup>&</sup>lt;sup>21</sup> 2 of 3 studies had low methodological study quality.

<sup>&</sup>lt;sup>22</sup> Total number of events is less than 300.

<sup>&</sup>lt;sup>23</sup> Considerable heterogeneity indicated by I2 (I2=91%) showed inconsistency across studies.

Intervention: FGM/C type I
Comparison: FGM/C type II

Outcomes		omparative risks*	Relative	No of	Quality of the	Comments
(dichotomous)	(95% CI)		effect	Participants	evidence	
	Assumed risk	Corresponding risk	(95% CI)	(studies)	(GRADE)	
	FGM/C type	FGM/C type I				
	II					
Obstetric	11 per 100	8 per 100	RR 0.70	11849	<b>0000</b>	
tears/		(5 to 12)	(0.47 to	(2 studies)	very low <sup>1,2</sup>	
lacerations			1.04)			
Cesarean	6 per 100	7 per 100	RR 1.07	15395	<b>0000</b>	
section		(6 to 8)	(0.94 to 1.2)	(3 studies)	very low <sup>3</sup>	
Episiotomy	31 per 100	29 per 100	RR 0.92	15053	<b>0000</b>	
		(19 to 43)	(0.61 to 1.4)	(3 studies)	very low <sup>4,5,6</sup>	

<sup>\*</sup>The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **RR:** Risk ratio;

GRADE Working Group grades of evidence= **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.

Table 26: Summary of Findings table for the comparison FGM/C type I-II vs type III

FGM/C type I-II compared to FGM/C type III in girls/women - Obstetric outcomes

Patient or population: Girls/women

Settings: Community
Intervention: FGM/C
Comparison: non-FGM/C

Outcome	Illustrative comparative risks* (95%	Relative	No of	Quality of	Comments
(dichotomous)	CI)	effect	Participants	the	
	Assumed risk Corresponding risk	(95% CI)	(studies)	evidence (GRADE)	
	FGM/C type III FGM/C type I-II				
Problems during	26 per 100 6 per 100	RR 0.24	6045	$\oplus \ominus \ominus \ominus$	_

<sup>&</sup>lt;sup>1</sup> 1 of 2 studies had low methodological study quality.

<sup>&</sup>lt;sup>2</sup> CI is wide, crosses limitations of precision (CI=0.47, 1.04).

 $<sup>^{\</sup>rm 3}$  2 of 3 studies had low methodological study quality.

<sup>&</sup>lt;sup>4</sup> 2 of 3 studies had low methodological study quality.

<sup>&</sup>lt;sup>5</sup> Considerable heterogeneity indicated by I2 (I2=78%) showed inconsistency across studies.

<sup>&</sup>lt;sup>6</sup> CI is wide, crosses limitations of precision (CI=0.61, 1.40).

delivery	(6 to 7)	(0.21 to	(2 studies)	very low <sup>1</sup>
		0.28)		

\*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI**: Confidence interval; **RR**: Risk ratio;

GRADE Working Group grades of evidence= **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.

<sup>&</sup>lt;sup>1</sup> Number of events is less than 300.

# **Discussion**

This systematic review aimed to summarize empirical data assessing the obstetric sequelae of FGM/C. The estimates for prolonged labor, obstetric tears/lacerations, instrumental delivery, obstetric hemorrhage, and difficult delivery offer evidence in support of a negative association between such obstetric complications and FGM/C. There seems to be a greater risk of problems during delivery for women with FGM/C type III compared to type I-II. However, the low quality of the body of evidence precludes us from drawing conclusions regarding causality. The meta-analysis results further suggest that the risk of cesarean section and episiotomy is not significantly different between women with FGM/C and women without FGM/C. Lastly, the meta-analysis results suggest that the risk of obstetric tears/lacerations, cesarean section, and episiotomy is not significantly different between women with FGM/C type I and those with type II, although the direction of effect across studies favored FGM/C type I over type II with regards to tears/lacerations. There were insufficient data for us to conclude with respect to whether the risk of other obstetric complications is higher among cut women compared to women with no FGM/C and whether various FGM/C types differentially affect the risk of other obstetric complications.

### Discussion of main results

#### Observed associations with FGM/C

The meta-analyses results show that deliveries to women who have undergone FGM/C are more likely to be complicated by prolonged labor, perineal tears/lacerations, instrumental delivery, obstetric hemorrhage, and obstructed labor than deliveries by comparable women who have not had FGM/C. Given the studies included in the meta-analyses included women with various types of FGM/C, genital cutting of any type seems to be associated with obstetric complications (when studied in African countries).

While it is not clear whether the documented association of FGM/C with obstetric complications reflects true causality, aspects of the delivery process for women with FGM/C show cause for concern, particularly the increased risk of obstructed labor and obstetric hemorrhage. Women with FGM/C were 3.3 times more likely to experience obstructed labor and twice as likely to experience obstetric hemorrhage as

non-FGM/C women. The mechanism by which FGM/C may cause problems during delivery is unclear, but, as mentioned above, FGM/C is a physiologically plausible explanation especially for the increased risk of obstetric lacerations and hemorrhage because of the increased inelasticity of scar tissue. Additionally, the presence of inelastic scar tissue may contribute to more obstructions, which may prolong labor. In turn, a longer second stage of labor could underlie the increased risk of perineal lacerations and hemorrhage. Furthermore, lack of episiotomy (results of the metanalysis indicated there was no statistically significant difference between cut and non-cut women in episiotomy) could contribute to the occurrence of obstetric lacerations (21).

As explained by researchers such as Browning, Allsworth, and Wall (61), it is commonly assumed that increased scarring around the introitus from more invasive FGM/C can cause a delay in the second stage of labor, which, in turn, may lead to additional complications. The second stage of labor may impact not just maternal distress but is also considered a determinant phase in the well-being of the fetus in the intrapartum period. If prolonged, there is a risk of anoxic or hypoxic injury to the brain as well as cardiopulmonary functions (27). Given women with FGM/C had statistically significant higher rates of prolonged labor than comparable non-cut women, the health of the fetus may be affected. We did not assess outcomes related to the child, but note that several studies have documented an increased risk of fetal distress in women with FGM/C (27;32;62). Contextually, it must be remembered that while we cannot causally attribute FGM/C to obstetric complications, FGM/C seems implicated in their occurrence, which is in areas with existing high rates of adverse maternal and infant outcomes (23). FGM/C may therefore lead to additional cases of adverse obstetric outcomes. The now sounder understanding of anticipated obstetric improvements with the halting of FGM/C may be used as a strategy for campaigning against the practice.

In addition to being distressful, there are medical costs associated with obstetric complications of FGM/C. In a multistage modeling analysis, the medical costs associated with obstetric complications related to FGM/C were estimated. The researchers calculated that compared to a 15-year-old who does not undergo FGM/C, the average 15-year-old who undergoes FGM/C type III loses nearly one-fourth of a year of life and generates \$5.82 (in international dollars) of associated medical costs over her lifetime; the averages for women who undergo any type of FGM/C were 0.07 years lost and \$1.71 in costs. Overall, the estimated annual cost of treating obstetric complications from FGM/C totaled \$3.7 million for the 53 million women living in the six countries. National costs ranged from 0.1% to 1% of government health spending on women with FGM/C (87). Presumably, there are not only likely obstetric impacts from FGM/C but economic burdens imposed on the health system from providing care for these women.

### No significant associations with FGM/C

The results of the present systematic review show no indication of there being obstetrical benefits to FGM/C. Today's best available evidence documents either a significantly greater risk (prolonged labor, instrumental delivery, obstetric hemorrhage, difficult delivery) or no significant difference in risk (cesarean section, episiotomy) among women with FGM/C relative to women with no FGM/C. We found no statistically significant excess of experiencing cesarean section and episiotomy among women with FGM/C. However, we point out that the direction of effect across studies, particularly for episiotomy, certainly seems to favor women being non-cut.

### Unknown association with FGM/C for some outcomes

Despite including 28 comparative studies, the data were insufficient to show whether or not FGM/C contributes to maternal fever during labor (reported in three studies), labor induction (reported in three studies), and eight other obstetric complications (each reported in one study). The study results for maternal fever and labor induction were heterogeneous. For example, a study from Ethiopia and a study from Nigeria showed opposing results for maternal fever. Regarding maternal mortality, the two studies we identified that reported this outcome are insufficient to give a true sense of the magnitude of the problem. One was a case report from 1927 (55) and one was the WHO study (32) from obstetric centers in six African countries. In the latter study, the difference in maternal inpatient death between cut and non-cut women was only significant for women with FGM/C type II, and there were wide confidence intervals around all of the estimates for maternal death. In this study, which had high methodological study quality and included over 28,000 participants, there were 54 maternal inpatient deaths (0.19%). It is unlikely that the estimate of this outcome would change with additional cross-sectional studies.

### Different degrees of exposure to FGM/C

The opportunity to examine whether various types of FGM/C differentially affect the risk of obstetric consequences was limited. This was because only five comparative studies specifically evaluated risk relative to different degrees of FGM/C exposure, and they largely reported on different outcomes (29;32;52;53;73). However, we could pool results from two or more studies for the outcomes obstetric tears/lacerations, cesarean section, episiotomy, and problems during delivery. The results of these suggested that, similar to the risk between cut and non-cut women, the risks of cesarean section and episiotomy do not seem to be significantly different between women with FGM/C type I and women with FGM/C type II. Nonetheless, the direction of effect across studies favored FGM/C type I over type II with regards to tears/lacerations. Also, women with FGM/C type III seem to be more likely to experience problems during delivery compared to women with FGM/C type I-II, supporting there may be a dose-response relationship between exposure to FGM/C and

experiencing problems during delivery. We recognize that the severity of obstetric complications is likely not just a function of the extent of cutting of genital tissue, but also factors such as complications at the time of the cutting, scar tissue formation, and long-term complications such as cysts, stenosis, infections.

### **Registry studies**

In most of the registry studies, the groups were selected from different sociocultural and ethnic populations, and the rate of- and FGM/C type were not known. This limits the conclusions that can be drawn from these studies regarding the association between FGM/C and adverse obstetric outcomes. Interestingly, the results showed that for all outcomes, except instrumental delivery, the direction of effect was the same for registry studies and Africa-based comparative cross-sectional studies. This strengthens the argument for a true association between FGM/C and obstetric complications. When it comes to instrumental delivery, the meta-analyses results for registry studies comparing Somali-born women and western-born women showed a lower (non-significant) risk among Somali-born women, who likely had FGM/C type III. The difference may be related to Somali women favoring natural childbirth. According to qualitative studies, Somali women living in diaspora express anxiety about childbirth interventions and a general dislike of interference in the birth process. Such studies have also identified language problems and difficulties in communication with caregivers (80;88-90). There are also data suggesting that western practitioners' unfamiliarity with FGM/C, especially infibulations, may contribute to delivery differences between cut and non-cut women giving birth in a western country (89;91;92). Such factors may help explain our finding, from registry studies, that Somali women were at greater risk of labor induction than receiving country-born women.

### Quality of the evidence

Of the 28 included comparative studies, we rated the methodological study quality of three studies as high, four as moderate, and the remaining 21 studies as having low study quality. Using GRADE, the quality of the total body of evidence was assessed as very low, meaning that any estimate of effect is very uncertain. As mentioned in the methods chapter, a cultural practice like FGM/C does not lend itself to a randomized controlled trial, the gold standard for drawing causal inferences between an exposure and an outcome (effect). For obstetric outcomes, also prospective cohort studies will be practically unfeasible, leaving case-control studies as the best study design for evaluating a possible association between FGM/C and obstetric outcomes. In this design, women with obstetric complications (cases) are compared to women from the same population without that complication (controls), and it seeks to find associations between the outcome (e.g. lacerations) and prior exposure to FGM/C (risk factor). To date, however, no case-control studies have been conducted

concerning FGM/C and obstetric complications. Rather, the best evidence on this issue comes from 28 cross-sectional studies that compare FGM/C 'exposed' women and 'unexposed' women (or differently exposed) and that calculate the risk among those exposed compared to those who are not. The issue of study design illustrates the practical barriers to health outcomes research related to FGM/C but at this point it is important to stress the importance of future studies applying the best design possible for examining the consequences of the practice.

Cross-sectional studies are problematic when it comes to sampling bias because the recruitment of sufficiently equivalent and large exposed and unexposed groups of women may be challenging. For practical reasons, studies evaluating obstetric complications are typically done in health clinics and it is possible that women with antepartum complications and those able to afford hospital care are overrepresented in these studies. Researchers also believe that, on a general basis, obstetric complications are likely to be underestimated in low-income countries in Africa, that variations between study sites are related to problems with classification, and that pregnant women's care is poor due to malfunctioning of public health services (24). It is, however, unlikely that such factors are systematically different between cut and noncut women in all included studies, such as to affect the relative risk of obstetric complications between these groups of women. Larsen and colleagues (29) state that clinic based studies on the association between FGM/C and obstetric outcomes in Nigeria may in fact be representative of the general population given more than 90% of the women receive antenatal health care services. With regards to the issue of equivalency, it was a strength that in most studies (85%) the non-exposed group was selected from the same population as the exposed group. However, in four of the included comparative studies (31;54;66;71), the non-exposed group was selected from a different (western) population than the exposed group and in 17 of the studies the researchers did not show whether the groups were comparable with respect to important background factors. It is possible that the obstetric outcome differences between Somali-born women and western-born women are partially attributable to sociocultural and medical factors, including suboptimal perinatal care and intercurrent diseases. However, it is unlikely that the differences documented in risk between cut and non-cut women in the other studies are attributable to sociocultural factors, since these results are based on women selected from the same population. Lastly, cross-sectional studies have to take account of confounding and moderators.

As highlighted by authors of previous reviews on health complications following FGM/C (17;20) another methodological challenge is measurement of 'exposure' to FGM/C. Measuring exposure to FGM/C means determining the extent of genital tissue excised or altered. Here, we applied the WHO classification system for FGM/C (type I through IV) (1) and found that a similar classification system was applied in most of the included studies. Encouragingly, in 18 of the comparative studies (69%), classification and exposure were based on gynaecological examination. Briefly, re-

search shows that both validity and reliability of self-reporting of FGM/C are variable. In general, several studies suggest that most women can correctly say whether or not they have been genitally cut, but are less able to correctly determine the extent of their cutting (59;93-96). Although also gynaecological examination is subject to variation (interindividual and intraindividual), it is currently the best classification method available for measurement of exposure to FGM/C. Thus, we encourage future studies to base classification of FGM/C on gynaecological examination by trained personnel and to compare degrees of exposure, because there may be a doseresponse relationship whereby women with more severe forms of cutting are at greater risk of experiencing complications.

It was also a strength that measurement of the majority of the obstetric outcomes were clinically based. However, there was a lack of a unified approach and standardized definitions to measure common outcomes such as prolonged labor. Although we scrutinized the publications for definitions, these were not always provided. This meant that we heavily relied on the terminology and categories used in the publications, and we could not always be sure that similarly labeled outcomes were identically defined and measured in each study. In a broader perspective, this may not be a serious limitation as the crucial question is whether the risk of obstetric complications in the general case, not only specific to certain outcomes, is greater among cut women than non-cut women. Nonetheless, we stress the importance of researchers using precise definitions and clinical measurement of outcomes such as obstetric lacerations since they are amenable to direct physical measurement and more valid than self-report.

## Strengths and limitations

The results of the systematic review rest on a comprehensive and systematic literature search and a systematic process for identifying relevant studies. Two independent reviewers at NOKC carried out the inclusion selection of studies based on pre-set inclusion criteria, detailed in our published protocol (see

http://www.crd.york.ac.uk/PROSPERO/). A further strength is that we included all empirical research, but prioritized the reporting of comparative studies, i.e., study designs which can say something about the likelihood of health consequences from the exposure (FGM/C) on an outcome (e.g. hemorrhage). The 28 comparative studies with data about the differences in outcomes between groups made it possible to estimate the risk of obstetric complications in women with FGM/C versus women without FGM/C, or an alternative type of FGM/C, and in many cases meta-analyses could be performed.

From this and previous systematic reviews we have carried out on the issue of FGM/C, our impression is that the literature on FGM/C includes numerous un-

published and other hard-to-obtain works. Our search is more than one year old. Despite a comprehensive search strategy, it is possible that we have missed some studies and our systematic review may be subject to publication bias. Missed studies may differ systematically from the ones we identified, the likeliest scenario being that the results of the present systematic review are biased to the positive. We failed to obtain 13 relevant records in full text as well as primary data from three studies which potentially could have been included in meta-analyses (28;51;65). We are exceedingly grateful for the data received from the WHO study group.

Caution is warranted in interpreting the results of this systematic review. Using GRADE, we assessed the quality of the evidence for all outcomes as being too low to warrant conclusions about a causal relationship between FGM/C and obstetric complications. This was largely due to the weaknesses of the observational design of all included studies, but also inconsistencies in results and estimate imprecision. Despite the large sample sizes for several of the pooled analyses, the confidence intervals for many of the effect estimates remained wide. Additional outcome research could narrow the confidence intervals, but for several outcomes only very large studies would alter the direction of effect. Lastly, we acknowledge the limitation of only including outcomes for the woman and not her baby(ies).

## **Conclusion**

The need for synthesized scientific research to specify the health sequelae of FGM/C motivated this systematic review. While the low quality of the body of evidence means that it is unclear whether the documented association of FGM/C with obstetric complications reflects true causality, the evidence base suggests that women who have undergone FGM/C are more likely than women who have not been subjected to FGM/C to experience obstetric complications. Four important findings emerge from this systematic review. First, the strongest associations between FGM/C and obstetric complications were found for obstructed labor and obstetric hemorrhage, but associations were also found for prolonged labor, perineal tears/lacerations, and instrumental delivery. Second, genital cutting of any type seems to be associated with these obstetric complications (when studied in African countries). Third, there seems to exist no significant difference in risk for cesarean section and episiotomy among women with FGM/C relative to women with no FGM/C. Fourth, the data were insufficient to show whether or not FGM/C contributes to maternal fever during labor and labor induction.

The meta-analyses results require cautious interpretation due to the considerable statistical heterogeneity in most of the results. Interpretation of the findings is thus speculative. Yet, while the exact size of the greater risk from FGM/C is unclear, the data clarify the obstetric improvements that may be anticipated with the halting of FGM/C and may be used as arguments for campaigning against the practice.

#### **Need for further research**

The results of the present systematic review show no indication of there being obstetrical benefits to FGM/C. Rather, today's best available evidence generally documents a significantly greater risk, but also no significant difference in risk for a few outcomes, among women with FGM/C relative to women with no FGM/C. It is questionable whether intensified research efforts would change these results. From a women's health standpoint, irrespective of the exact size of the greater risk from FGM/C, the increase in obstetric suffering and morbidity is too high to justify continuing the practice, and even the lowest increase in risk of complications to be avoided.

If further research on the association between FGM/C and obstetric outcomes are considered ethically and financially justified, such studies should be based on the best possible methodological study design, which for this question is case-control studies. Additional cross-sectional studies would possibly narrow the confidence intervals, but it is unlikely that the direction of the estimate of obstetric outcomes would change. Further, any future research should be based on a methodology that ensures representativeness and equivalency between exposed and unexposed groups of women, and that applies standardized definitions and clinical measures for exposure as well as outcomes.

# References

- (1) WHO. Eliminating female genital mutilation: an interagency statement. UNAIDS, UNDP, UNECA, UNESCO, UNFPA, UNHCHR, UNICEF, UNIFEM, WHO. Geneva: World Health Organization; 2008.
- (2) WHO. Female genital mutilation Knew knowledge spurs optimism. Progress in Sexual and Reproductive Health Research 2006;72:1-8.
- (3) UNICEF. Female genital mutilation/female genital cutting: a statistical exploration. New York: United Nations Children's Fund; 2005.
- (4) Yoder S, Kahn S. Numbers of women circumcised in Africa: the production of a total. United States Agency for International Development; 2008. Report No.: 39.
- (5) Elgaali M, Strevens H, Mardh PA. Female genital mutilation -- an exported medical hazard. European Journal of Contraception & Reproductive Health Care 2005;10(2):93-7.
- (6) Kaplan-Marcusan A, Toran-Monserrat P, Moreno-Navarro J, Fabregas MJC, Munoz-Ortiz L. Perception of primary health professionals about female genital mutilation: From healthcare to intercultural competence. BMC Health Services Research 2009;9.
- (7) Poldermans S. A comparative analysis of legislative and preventative tools in the Netherlands, France, the United Kingdom, and Austria. University of Vienna, Austria; 2006.
- (8) UNICEF. Changing a harmful social convention: Female genital mutilation/cutting. New York: United Nations Children's Fund; 2005.
- (9) WHO. Female genital mutilation. Programmes to date: what works and what doesn't? A review. Geneva: World Health Organization; 1999.
- (10) UNFPA. A holistic approach to the abandonment of Female Genital Mutilation/Cutting. New York: United Nations Population Fund; 2007.
- (11) Berg RC, Denison E, Fretheim A. Factors promoting and hindering the practice of female genital mutilation/cutting (FGM/C). Norwegian Knowledge Centre for the Health Services (NOKC), Report nr 23; 2010.

- (12) Berg RC, Denison E. A tradition in transition: Factors perpetuating and hindering the continuance of female genital mutilation/cutting (FGM/C) summarized in a systematic review. Health Care for Women International 2012;DOI: 10.1080/07399332.2012.721417.
- (13) WHO. An update on WHO's work on female genital mutilation (FGM). Progress report. Geneva: World Health Organization; 2011.
- (14) Morris K. Feature: Issues on female genital mutilation/cutting-progress and parallels. Lancet 2006;368(Suppl. 1):S64-S67.
- (15) WHO. Global strategy to stop health-care providers from performing female genital mutilation. Geneva: World Health Organization; 2010.
- (16) Berg RC, Denison E, Fretheim A. Psychological, social and sexual consequences of female genital mutilation/cutting (FGM/C): a systematic review of quantitative studies. Norwegian Knowledge Centre for the Health Services (NOKC), Report nr 13; 2010.
- (17) Berg RC, Denison E. Does female genital mutilation/cutting (FGM/C) affect women's sexual functioning? A systematic review of the sexual consequences of FGM/C. Sexuality Research and Social Policy 2012;9(1):41-56.
- (18) WHO. A systematic review of the health complications of female genital mutilation including sequelae in childbirth. Geneva: World Health Organization; 2000.
- (19) Obermeyer CM. Female genital surgeries: The known, the unknown, and the unknowable. Medical Anthropology Quarterly (New Series) 1999 Mar;13(1):79-106.
- (20) Obermeyer CM. The consequences of female circumcision for health and sexuality: An update on the evidence. Cult Health Sex 2005;7(5):443-61.
- (21) Gibbs RS, Karlan BY, Hanley AF, Nygaard I. Danforth's obstetrics and gynecology. 10th ed. New York: Lippincott, Williams & Wilkins; 2008.
- (22) Lewis G. Beyond the numbers: reviewing maternal deaths and complications to make pregnancy safer. Geneva: World Health Organization; 2004.
- (23) Hogan MC, Foreman KJ, Naghavi M, Ahn SY, Wang M, Makela SM. Maternal mortality for 181 countries, 1980-2008: a systematic analysis of progress towards Millenium Development Goals. Lancet 2010;375:1609-23.
- (24) Prual A, Bouvier-Colle MH, de Bernis L, Breart G. Severe maternal morbidity from direct obstetric causes in West-Africa: incidence and case fatality rates. Bulletin of the World Health Organization 2000;78(5):593-602.
- (25) Ronsmans C, Etard JF, Walraven G, Høj L, Dumont A, de Bernis L, et al. Maternal mortality and access to obstetric services in West Africa. Tropical Medicine and International Health 2003;8(19):940-8.
- (26) UNICEF. Maternal and newborn health. 2009. Available http://www.unicef.org/sowco9/docs/SOWCo9-FullReport-EN.pdf

- (27) Hakim LY. Impact of female genital mutilation on maternal and neonatal outcomes during parturition. East Afr Med J 2001;78(5):255-8.
- (28) Jones H, Diop N, Askew I, Kabore I. Female genital cutting practices in Burkina Faso and Mali and their negative health outcomes. Stud Fam Plann 1999;30(3):219-30.
- (29) Larsen U, Okonofua FE. Female circumcision and obstetric complications. Int J Gynaecol Obstet 2002;77(3):255-65.
- (30) Orji EO, Babalola A. Correlates of female genital mutilation and its impact on safe motherhood. Journal of the Turkish German Gynecology Association Artemis 2006;7(4):319-24.
- (31) Vangen S, Stoltenberg C, Johansen REB, Sundby J, Stray-Pedersen B. Perinatal complications among ethnic Somalis in Norway. Acta Obstet Gynecol Scand 2002;81(4):317-22.
- (32) WHO study group on female genital mutilation and obstetric outcome, Banks E, Meirik O, Farley T, Akande O, Bathija H, et al. Female genital mutilation and obstetric outcome: WHO collaborative prospective study in six African countries. Lancet 2006 Jun 3;367(9525):1835-41.
- (33) Wuest S, Raio L, Wyssmueller D, Mueller MD, Stadlmayr W, Surbek DV, et al. Effects of female genital mutilation on birth outcomes in Switzerland. BJOG: An International Journal of Obstetrics & Gynaecology 2009;116(9):1204-9.
- (34) Nasjonalt kunnskapssenter for helsetjenesten. *Slik oppsummerer vi forskning. Håndbok for Nasjonalt kunnskassenter for helsetjenesten.* 3rd ed. Oslo: Nasjonalt kunnskapssenter for helsetjenesten.; 2011.
- (35) Higgins JPT, Green S. *Cochrane Handbook for Systematic Reviews of Interventions*. Version 5.1.0 ed. The Cochrane Collaboration; 2011.
- (36) Guyatt GH, Oxman AA, Akl E, Kunz R, Vist GE, Brozek J, et al. GRADE guidelines 1. Introduction GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64:383-94.
- (37) Balshem H, Helfand M, Schunemann H, Oxman AA, Kunz R, Brozek J, et al. GRADE guidelines 3: Rating the quality of the evidence introduction. Journal of Clinical Epidemiology 2011;64(401):406.
- (38) Abdel SGI. Circumcision among Sudanese ladies: its health and social implications. Ain Shams University; 1992.
- (39) Ahmed B, Abushama M. A cautionary case of female genital mutilation. Qatar Medical Journal 2007;16(2):70-1.
- (40) Diallo H. Aspects socio-sanitaires de l'excision au Mali. Bamako, Mali: Ecole Nationale de Medecine et de Pharmacie; 1990.
- (41) Doleeb TE. Research: Reproductive health (FGM). Ahfad (unpublished) 1996.
- (42) Inter-African Committee on Traditional Practices Affecting the Health of Women and Children. Survey on female genital mutilation in

- upper and middle Guinea. Discussion of principal findings. (USAID Contract No. HRN-5966-C-00-3038-00); 1998.
- (43) Ismail A. Female genital mutilation: prevalence, practice and effect on female among the Maasai. A case of Ildamat location; Kajiado district. Kenya Medical Training College; 1999.
- (44) Karim M. Circumcision and mutilations male and female: medical aspects. (unpublished) 1991.
- (45) Mawad NM, Hassanein OM. Maternity service in Khartoum civil hospital. Part 1 general review. Sudan Medical Journal 1972;10(4):220-32.
- (46) Muhammad HM. Obstetric fistulae as seen at Dodoma regional hospital, Tanzania. Paper presented at workshop: Maternal health in subsaharan Africa . 1998. Dar es salaam.
- (47) Owumi BE. Forms and age at circumcision: some psychological implications for women's fertility. Women's Behavioural Issues 1994;1(1):10-6.
- (48) Rwiza HT, Msuya DR, Malangwa M, Rwiza SM. Complications of traditional female circumcision as seen at Usangi government hospitals. Presented to M.A.T. meetings. 1980.
- (49) Wani MP, John IS, Khaled MA. Clitoral epidermal inclusion cyst following circumcision. (unpublished) 1997.
- (50) Measure DHS. Central African Republic DHS, 1994-95. Measure DHS; 1995.
- (51) Diop N, Sangaré M, Tandia F, Touré K. Etude de l'efficacité de la formation du personnel socio-sanitaire dans l'educacion des client(e)s sur l'excision et dans le traitemaent de ses complications au Mali. Bamako, Mali: Population Council; 1998.
- (52) Measure DHS. Eritrea DHS, 2002. Measure DHS; 2002.
- (53) Measure DHS. Eritrea DHS, 1995. Measure DHS; 1995.
- (54) Lupo VR, Marcotte KL. Obstetric complications of Somali female circumcision. Obstetrics and Gynecology 1999;93(4), 19S.
- (55) Philp HRA. Vesical fistula complicating labour. Kenya and East Africa Medical Journal 1927;4(1), 126-128. 1927.
- (56) Preston PG. A case of birth per rectum. East African Medical Journal 1937;14, 290-294.
- (57) Pritchard BJ. Soft tissue dystocia in circumcised women. Nursing Mirror & Midwives Journal 1969;128(17):31.
- (58) Bohoussou KM, Anongba S, Djanhan Y, Boni S, Ble B, Sangaret MA. Complications gynecologiques medicales et obstetricales de l'excision rituelle. Afr Med 1986;25, 160-162.

- (59) Adinma JI. Current status of female circumcision among Nigerian Igbos. West Afr J Med 1997;16(4):227-31.
- (60) Berardi JC, Teillet JF, Godard J, Laloux V, Allane P, Franjou MH. Consequences obstetricales de l'excision feminine. Etude chez 71 femmes africaines excisees. J Gynecol Obstet Biol Reprod (Paris) 1985;14(6):743-6.
- (61) Browning A, Allsworth JE, Wall LL. The relationship between female genital cutting and obstetric fistulae. Obstetrics & Gynecology 2010;115(3):578-83.
- (62) Chibber R, El-Saleh E, El Harmi J. Female circumcision: obstetrical and psychological sequelae continues unabated in the 21st century. Journal of Maternal-Fetal & Neonatal Medicine 2011;24(6):833-6.
- (63) De Silva S. Obstetric sequelae of female circumcision. European Journal of Obstetrics, Gynecology, & Reproductive Biology 1989;32(3):233-40.
- (64) Elnashar, A, Abdelhady, R. The impact of female genital cutting on health of newly married women. International Journal of Gynecology & Obstetrics 2007;97(3):238-44.
- (65) Essen B, Sjoberg NO, Gudmundsson S, Ostergren PO, Lindqvist PG. No association between female circumcision and prolonged labour: a case control study of immigrant women giving birth in Sweden. European Journal of Obstetrics, Gynecology, & Reproductive Biology 2005;121(2):182-5.
- (66) Johnson EB, Reed SD, Hitti J, Batra M. Increased risk of adverse pregnancy outcome among Somali immigrants in Washington state. American Journal of Obstetrics and Gynecology 2005;193:475-82.
- (67) Millogo-Traore F, Kaba ST, Thieba B, Akotionga M, Lankoande J. Pronostic maternel et foetal au cours de l'accouchement chez la femme excisee. J Gynecol Obstet Biol Reprod (Paris) 2007;36(4):393-8.
- (68) Ndiaye P, Diongue M, Faye A, Ouedraogo D, Tal DA. Mutilation genitale femminine et complications de l'accouchement dans la province de Gourma (Burkina Faso). Sante Publique (Vandoeuvre-Les-Nancey) 2010;22(5):563-70.
- (69) Oduro A, Ansah P, Hodgson A, Afful T, Baiden F, Adongo P, et al. Trends in the prevalence of female genital mutilation and its effect on delivery outcomes in the Kassena-Aankana district of northern Ghana. Ghana Med J 2006;40(3):87-92.
- (70) Slanger TE, Snow RC, Okonofua FE. The impact of female genital cutting on first delivery in southwest Nigeria. Studies in Family Planning 2002;33(2):173-84.
- (71) Small R, Gagnon A, Gissler M, Zeitlin J, Bennis M, Glazier RH, et al. Somali women and their pregnancy outcomes postmigration: data from six receiving countries. BJOG 2008;115:1630-40.
- (72) Yount KM, Abraham BK. Female genital cutting and HIV/AIDS among Kenyan women. Studies in Family Planning 2007;38(2):73-88.

- (73) Yount KM, Carrera JS. Female genital cutting and reproductive experience in Minya, Egypt. Med Anthropol Q 2006;20(2):182-211.
- (74) Abor PA. Female genital mutilation: Psychological and reproductive health consequences. The case of Kayoro traditional area in Ghana. Gender & Behaviour 2006 Jun;4(1):659-84.
- (75) Akotionga M, Traore O, Lakoande J, Kone B. Sequelles genitales externes de l'excision au centre hospitalier national Yalgado Ouedraogo (CHN-YO): epidemiologie et traitement chirurgical. Gynecologie, Obstetrique & Fertilite 2001;29(4):295-300.
- (76) Al-Hussaini TK. Female genital cutting: types, motives and perineal damage in laboring Egyptian women. Medical Principles & Practice 2003;12(2):123-8.
- (77) Awuah JB. Female genital mutilation: a study in Aboabo, a suburb of Kumasi, Ghana. West African Journal of Nursing 2008 May;19(1):26-32.
- (78) Bayoudh F, Barrak S, Fredj N, Allani R, Hamdi M. Study of a Common Practice in Somalia: Female Circumcision. Medecine Tropicale 1995;55:238-42.
- (79) Bonessio L, Bartucca B, Bertelli S, Morini F, Aleandri V, Spina V. Mutilazioni genitali femminili: pazienti con esiti di FGM ricoverate nel Policlinico "Umberto I" di Roma: periodo 1985-1996. Clin Ter 2001;152(3):171-7.
- (80) Chalmers B, Hashi KO. 432 Somali women's birth experiences in Canada after earlier female genital mutilation. Birth: Issues in Perinatal Care 2000 Dec;27(4):227-34.
- (81) Dorflinger A, Kuhn P, Dreher E. Die zirkumzision der frau (K)Ein rein Afrikanisches problem. Geburtshilfe und Frauenheilkunde 2000;60(11):531-5.
- (82) Litorp H, Franck M, Almroth L. Female genital mutilation among antenatal care and contraceptive advice attendees in Sweden. Acta Obstet Gynecol Scand 2008;87(7):716-22.
- (83) McCaffrey M. Female genital mutilation: consequences for reproductive and sexual health. Sexual & Marital Therapy 1995;10(2):189-200.
- (84) McSwiney MM, Saunders PR. Female circumcision: a risk factor in postpartum haemorrhage. J Postgrad Med 1992;38(3):136-7.
- (85) Osifo DO, Evbuomwan I. Female genital mutilation among Edo people: the complications and pattern of presentation at a pediatric surgery unit, Benin City. Afr J Reprod Health 2009;13(1):17-25.
- (86) Vangen S, Stoltenberg C, Johansen RE, Sundby J, Stray-Pedersen B. Perinatal complications among ethnic Somalis in Norway. Acta Obstet Gynecol Scand 2002;81(4):317-22.

- (87) Bishai D, Bonnenfant YT, Darwish M, Adam T, Bathija H, Johansen E, et al. Estimating the obstetric costs of female genital mutilation in six African countries. Bull World Health Organ 2010;88(4):281-8.
- (88) Essen B, Johnsdotter S, Hovelius B, Gudmundsson S, Sjöberg NO, Friedman J, et al. Qualitative study of pregnancy and childbirth experiences in Somalian women resident in Sweden. British Journal of Obstetrics and Gynaecology 2000;107:1507-12.
- (89) Vangen S, Johansen RE, Sundby J, Traeen B, Stray-Pedersen B. Qualitative study of perinatal care experiences among Somali women and local health care professionals in Norway. European Journal of Obstetrics, Gynecology, & Reproductive Biology 2004;112(1):29-35.
- (90) Davis MM, Bath PA. The maternity information concerns of Somali women in the United Kingdom. Journal of advanced nursing 2001;36(2):237-345.
- (91) Johansen RE. Care for infibulated women giving birth in Norway: an anthropological analysis of health workers' management of a medically and culturally unfamiliar issue. Med Anthropol Q 2006;20(4):516-44.
- (92) Thierfelder C, Tanner M, Bodiang CMK. Female genital mutilation in the context of migration: experience of African women with the Swiss health care system. European Journal of Public Health 2005;15(1):86-90.
- (93) Morison L, Scherf C, Ekpo G, Paine K, West B, Coleman R, et al. The long-term reproductive health consequences of female genital cutting in rural Gambia: a community-based survey. Tropical Medicine & International Health 2001;6(8):643-53.
- (94) Elmusharaf S, Elhadi N, Almroth L. Reliability of self reported form of female genital mutilation and WHO classification: cross sectional study. British Medical Journal (International Edition) 2006; 15;333(7559):124-7.
- (95) Okonofua FE, Larsen U, Oronsaye F, Snow RC, Slanger TE. The association between female genital cutting and correlates of sexual and gynaecological morbidity in Edo State, Nigeria. BJOG: An International Journal of Obstetrics & Gynaecology 2002;109(10):1089-96.
- (96) Snow RC, Slanger TE, Okonofua FE, Oronsaye F, Wacker J. Female genital cutting in southern urban and peri-urban Nigeria: self-reported validity, social determinants and secular decline. Tropical Medicine & International Health 2002;7(1):91-100.
- (97) WHO links female genital mutilation to maternal health problems. Safe motherhood 1994;(15):9.
- (98) New research indicates circumcision does not affect women's STD risk: more investigation needed to determine circumcision's impact on women. Contraceptive Technology Update 2007;2;1-3.
- (99) Egyptian FGM policy fails to prevent girl's death. Reproductive freedom news / from the Center for Reproductive Law & Policy 1996;5(14):8.

- (100) Clinic-based study of female circumcision: Egypt 1996. Newsletter (Macro Systems Institute for Resource Development Demographic and Health Surveys) 1997;8(2):2.
- (101) Abariga SA. Female genital mutilation, attitude and practices-a case study in Rural Ghana. American Journal of Tropical Medicine and Hygiene 2009;81(5 Suppl. 1):129.
- (102) Abubakar I, Iliyasu Z, Kabir M, Uzoho CC, Abdulkadir MB. Knowledge, attitude and practice of female genital cutting among antenatal patients in Aminu Kano Teaching Hospital, Kano. Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria 2004;13(3):254-8.
- (103) Abu-Shamma AD. Female circumcision in Sudan. Lancet 1949;253(6552):544-5.
- (104) Adanu RM, Haefner HK, Reed BD. Vulvar pain in women attending a general medical clinic in Accra, Ghana. J Reprod Med 2005;50(2):130-4.
- (105) Adelusi A, Akande EO, Onifade A. Acquired gynaetresia in Ibadan. Niger Med J 1976;6(2):198-200.
- (106) Adeneye AK, Oke EA, Adeneye AA. Knowledge of the health consequences of female genital mutilation in Bere Community, Oyo State, Nigeria. Healthcare Quarterly 2007;10(1):146.
- (107) Adeokun LA, Oduwole M, Oronsaye F, Gbogboade AO, Aliyu N, Wumi A, et al. Trends in female circumcision between 1933 and 2003 in Osun and Ogun States, Nigeria (a cohort analysis). Afr J Reprod Health 2006;10(2):48-56.
- (108) Adeyinka DA, Oladimeji O, Aimakhu C. Female genital cutting: Its perception and practice in Igbo-Ora community, Nigeria. International Journal of Child Health and Human Development 2009;2(2):143-50.
- (109) Adinma JI, Agbai AO. Practice and perceptions of female genital mutilation among Nigerian Igbo women. Journal of Obstetrics & Gynaecology 1999;19(1):44-8.
- (110) Afifi M, von Bothmer M. Egyptian women's attitudes and beliefs about female genital cutting and its association with childhood maltreatment. Nursing & Health Sciences 2007;9(4):270-6.
- (111) Ahmed B. Management of women who are circumcised especially during pregnancy and childbirth. Journal of Obstetrics & Gynaecology 2000;20(3):280-1.
- (112) Ahmed B, Abushama M. Female genital mutilation and childbirth. Saudi Medical Journal 2005;26(3):376-8.
- (113) Ahnaimugan S, Asuen MI. Acquired gynaetresia in Nigeria. Tropical Doctor 1978;8(4):201-4.
- (114) al-Krenawi A, Wiesel-Lev R. Attitudes toward and perceived psychosocial impact of female circumcision as practiced among the Bedouin-Arabs of the Negev. Fam Process 1999;38(4):431-43.

- (115) Al-Krenawi A, Graham JR. Social Work Practice and Female Genital Mutilation: The Bedouin-Arab Case. Social Development Issues 1999;21(1):29-36.
- (116) Allag F, Abboud P, Mansour G, Zanardi M, Quereux C. Mutilations genitales rituelles feminines. La parole aux femmes. Gynecologie Obstetrique Fertilite 2001;29(11):824-8.
- (117) Ahmed Allam MF, De Irala-Estevez J, Navajas RFC, Del Castillo AS, Hoashi JS, Pankovich MB, et al. Students' knowledge of and attitudes about female circumcision in Egypt. New England Journal of Medicine 1999;341(20):1552-3.
- (118) Allam MF, de Irala-Estevez J, Navajas RF, Del Castillo AS, Hoashi JS, Pankovich MB, et al. Factors associated with the condoning of female genital mutilation among university students. Public Health 2001;115(5):350-5.
- (119) Almroth-Berggren V, Almroth L, Bergstrom S, Hassanein OM, El Hadi N, Lithell U. Reinfibulation among women in a rural area in central Sudan. Health Care Women Int 2001;22(8):711-21.
- (120) Amusan OA, Asekun-Olarinmoye EO. Knowledge, beliefs, and attitudes to female genital mutilation (FGM) in Shao community of Kwara State, Nigeria. Int Q Community Health Educ 2006;27(4):337-49.
- (121) Anderson GV. Problems of native maternity work, with a review of two hundred cases. Kenya and East Africa Medical Journal 1929;6:62-72.
- (122) Applebaum J, Cohen H, Matar M, Abu RY, Kaplan Z. Symptoms of posttraumatic stress disorder after ritual female genital surgery among bedouin in Israel: myth or reality? Primary Care Companion to the Journal of Clinical Psychiatry 2008;10(6):453-6.
- (123) Archibong U. Cutting the Rose -- Female Genital Mutilation: the practice and its prevention. Journal of Gender Studies 1998;7(1):96-7.
- (124) Arthur JW. Female circumcision among the Kikuyu. British Medical Journal 1942;2(498).
- (125) Asali A, Khamaysi N, Aburabia Y, Letzer S, Halihal B, Sadovsky M, et al. Ritual female genital surgery among Bedouin in Israel. Archives of Sexual Behavior 1995;24(5):571-5.
- (126) Azadeh H. Female circumcision genital mutilation and childbirth -- a mother and child tragedy. Br J Theatre Nurs 1997 Oct;7(7):5.
- (127) Baasher TA. Psychosocial aspects of female circumcision. In: Baasher T, Bannerman RHO, Rushwan H, Sharaf I, editors. Traditional practices affecting the health of women and children. Alexandria: WHO; 1982. p. 162-80.
- (128) Badri AE. Female circumcision in the Sudan: change and continuity. Femmes et Reproduction en Afrique 1992;129-50.
- (129) Badri AS. Female circumcision in the Sudan. Ahfad 1984;1:11-21.

- (130) Lo Baido R, Grutta SL, Bressi C, Mauri M, Trombini E. The Female Genital Mutilations (FGM): A clinical and psychopathological study on a group of immigrants in Sicily. Rivista di Psichiatria 2004;39(4):229-37.
- (131) Lo Baido R, La Grutta S, Profeta E, Schiera G. Mutilazioni Genitali Femminili (MGF): Echi nella mente di cicatrici sul corpo. Studio clinico e psicopatologico su un gruppo di donne immigrate in Sicilia. Rivista di Psichiatria 2007;42(3):183-8.
- (132) Baker CA, Gilson GJ, Vill MD, Curet LB. Female circumcision: obstetric issues. Am J Obstet Gynecol 1993;169(6):1616-8.
- (133) Bakr SA. Circumcision and infibulation. Postgraduate Doctor Middle East 1985;624-31.
- (134) Balogun SK. Female Circumcision: Its psychological effects on victims, family and the society. Anthropologist 2001;3(4):261-3.
- (135) Barber G. Female genital mutilation: a review. Practice Nursing 2010 ;21(2):62.
- (136) Beck L, Freundl G. Weibliche genitalbeschneidung. Gynakologe 2008;41(9):719-22.
- (137) Behrendt A, Moritz S. Posttraumatic stress disorder and memory problems after female genital mutilation. Am J Psychiatry 2005;162(5):1000-2.
- (138) Belmaker R. Female genital mutilation: Successful social change exemplified by Israeli Bedouin and Ethiopian Jews. Asian Journal of Psychiatry 2011;4:S1-S2.
- (139) Bender J, Gianotten WL, Huisman WM, Baaij M, Kagie M. Vrouwenbesnijdenis; het verhaal van 3 patienten. Nederlands Tijdschrift Voor Geneeskunde 1999;143(46):2336-8.
- (140) Bikoo M, Davies M. The urological implications of female genital mutilation. Continence UK 2008;2(3):9-14.
- (141) Boddy J. Womb as oasis: The symbolic context of Pharaonic circumcision in rural Northern Sudan. American Ethnologist 1982;9(4):682-98.
- (142) Bonilla E. Kvinnlig omskarelse--tva fallbeskrivningar. Jordemodern 1997;110(4):118-23.
- (143) Brady M. Female genital mutilation: complications and risk of HIV transmission. AIDS Patient Care & STDs 1999;13(12):709-16.
- (144) Briggs LA. Male and female viewpoints on female circumcision in Ekpeye, Rivers State, Nigeria. Afr J Reprod Health 2002;6(3):44-52.

- (145) Brotmacher L. Medical practice among the Somalis. Bulletin of the History of Medicine 1995;29(3):197-229.
- (146) Measure DHS. Burkina Faso DHS, 1999. Measure DHS; 1999.
- (147) Caldwell JC, Caldwell P. The demographic evidence for the incidence and cause of abnormally low fertility in tropical Africa. World Health Statistics Quarterly 1983;36:2-33.
- (148) Campbell M, Abu SZ. Sudan: situational analysis of maternal health in Bara District, North Kordofan. World Health Statistics Quarterly Rapport Trimestriel de Statistiques Sanitaires Mondiales 1995;48(1):60-6.
- (149) Measure DHS. Cameron DHS, 2004. Measure DHS; 2004.
- (150) Cannon DSH, Hartfield VJ. Obstetrics in a developing country. Journal of Obstetrics and Gynaecology of the British Commonweath 1964;71(6):940-50.
- (151) Capraro VJ, Greenberg H. Adhesions of the labia minora A study of 50 patients. Obstetrics & Gynecology 1972;39:65.
- (152) Carton V, Philippe HJ. Consequences medicales, psychologiques et sexuelles des mutilations sexuelles feminines. Arch Pediatr 2008;15(5):820-1.
- (153) Cetinkursun S, Narci A, Sahin O, Ozkaraca E. Epidermoid cyst causing clitorimegaly in a child. International Journal of Gynecology and Obstetrics 2009;105(1):64.
- (154) Cohen HA, Drucker MM, Vainer S, Ashkenasi A, Amir J, Frydman M, et al. Postcircumcision urinary tract infection. Clin Pediatr (Phila) 1992;31(6):322-4.
- (155) Coker AL, Richter DL. Violence against women in Sierra Leone: frequency and correlates of intimate partner violence and forced sexual intercourse. Afr J Reprod Health 1998;2(1):61-72.
- (156) Cook R. Damage to physical health from pharaonic circumcision (infibulations) of female: A review of the medical literature. Traditional practices affecting the health of women and children. WHO; 1979. p. 53-69.
- (157) Damas R, Damas R, Waag J, Aouba. Fistules vesico vaginales obstricales Africaines. Medicine Tropicale 1972;32(4):493-8.
- (158) Dattijo LM, Nyango DD, Osagie OE. Awareness, perception and practice of female genital mutilation among expectant mothers in Jos University Teaching Hospital Jos, north-central Nigeria. Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria 2010;19(3):311-5.
- (159) Davis G, Ellis J, Hibbert M, Perez RP, Zimbelman E. Female circumcision: the prevalence and nature of the ritual in Eritrea. Mil Med 1999;164(1):11-6.

- (160) Daw E. Female circumcision and imfibulation complicating delivery. Practitioner 1970;204(222):559-63.
- (161) Dekou HA, Konan PG, Manzan K, Ouegnin GA, Djedje-Mady A, Dje CY. Le point sur les fistules urogenitales en Cote d'Ivoire a la fin du XXe siecle. Resultats de 70 cas. Ann Urol (Paris) 2002;36(5):334-40.
- (162) De Villeneuve AD. Etude sur une coutume Somalie: les femmes cousues. Journal Social Africanistes 1937;6:15.
- (163) Dirie MA, Lindmark G. Female circumcision in Somalia and women's motives. Acta Obstet Gynecol Scand 1991;70(7-8):581-5.
- (164) Ebomoyi E. Prevalence of Female Circumcision in Two Nigerian Communities. Sex Roles 1987 Aug;17(3 -- 4):139-51.
- (165) Ebong RD. Female circumcision and its health implications: A study of the uruan local government area of Akwa Ibom State, Nigeria. J R Soc Health 1997;117(2):95-9.
- (166) Measure DHS. Egypt DHS, 2008. Measure DHS; 2008.
- (167) Measure DHS. Egypt DHS, 2005. Measure DHS; 2005.
- (168) Measure DHS. Egypt DHS, 2003. Measure DHS; 2003.
- (169) Measure DHS. Egypt DHS, 2000. Measure DHS; 2000.
- (170) Ehigiegba AE, Selo-Ojeme DO, Omorogbe FI. Female circumcision and determinants in southern Nigeria. East African Medical Journal 1998;75(6):374-6.
- (171) Eke N, Nkanginieme KE. Female genital mutilation and obstetric outcome. Lancet 2006;367(9525):1799-800.
- (172) Ekwueme OC, Ezegwui HU, Ezeoke U. Dispelling the myths and beliefs toward female genital cutting of woman: assessing general outpatient services at a tertiary health institution in Enugu state, Nigeria. East African Journal of Public Health 2010;7(1):64-7.
- (173) Elmusharaf K, Shakour S, Fazari A. Attitude of circumcised sudanese women towards mutilating their daughters. Contraception 2009;80(2):225.
- (174) Elnashar A, EL-Dien Ibrahim M, EL-Desoky M, Ali O, M. Female sexual dysfunction in Lower Egypt. BJOG: An International Journal of Obstetrics & Gynaecology 2007;114(2):201-6.
- (175) Epelboin S, Epelboin A. Female circumcision. People 6, 24-31. 1979.
- (176) Ericksen KP. Female circumcision among Egyptian women. Womens Health 1995;1(4):309-28.
- (177) Essen B, Bodker B, Sjoberg NO, Gudmundsson S, Ostergren PO, Langhoff-Roos J. Is there an association between female circumcision and perinatal death? Bull World Health Organ 2002;80(8):629-32.

- (178) Measure DHS. Ethiopia DHS, 2005. Measure DHS; 2005.
- (179) Measure DHS. Ethiopia DHS, 2000. Measure DHS; 2000.
- (180) Fahmy A, El-Mouelhy MT, Ragab AR. Female genital mutilation/cutting and issues of sexuality in Egypt. Reproductive Health Matters 2010;18(36):181-90.
- (181) Feyi-Waboso P, Akinbiyi A. Knowledge of, attitudes about, and practice of female genital cutting in antenatal patients among Igbos in Nigeria. Journal of Gynecologic Surgery 2006;22(3):89-95.
- (182) Fleischer NK. A study of traditional practices and early childhood anaemia in northern Nigeria. Transactions of the Royal Society of Tropical Medicine and Hygiene 1975;69(2):198-200.
- (183) Gage AJ, Van RR. Attitudes toward the discontinuation of female genital cutting among men and women in Guinea. International Journal of Gynaecology & Obstetrics 2006;92(1):92-6.
- (184) Gallo PG. Female circumcision in Somalia: some psychosocial aspects. Genus 1985;41(1-2):133-47.
- (185) Grassivaro GP, Abdisamed M. Female circumcision in Somalia: anthropological traits. Anthropol Anz 1985;43(4):311-26.
- (186) Measure DHS. Ghana DHS, 2003. Measure DHS; 2003.
- (187) Gillian RU. Notes on the Kikuyu custom of female circumcision. Kenya and East Africa Medical Journal 1929;6:199-203.
- (188) Gilson GJ, Toubia N. Female circumcision: Obstetric issues. New England Journal of Medicine 1995;332(3):189.
- (189) Githiora RM. Attitudes and perceptions of female circumcision among African immigrant women in the United States: A cultural and legal dilemma. Rosa Muthoni: U Akron, US: 2011.
- (190) Gordon H, Comerasamy H, Morris NH. Female genital mutilation: Experience in a West London clinic. Journal of Obstetrics & Gynaecology 2007;27(4):416-9.
- (191) Grisaru N, Lezer S, Belmaker RH. Ritual female genital surgery among Ethiopian Jews. Archives of Sexual Behavior 1997;26(2):211-5.
- (192) Gruenbaum E. Sexuality issues in the movement to abolish female genital cutting in Sudan. Med Anthropol Q 2006;20(1):121-38.
- (193) Gurunluoglu R, Dogan T, Numanoglu A. A case of giant keloid in the female genitalia. Plastic and Reconstructive Surgery 1999;104(2):594.
- (194) Hanselmann K, Borsch C, Ikenberg H, Strehlau J, Klug SJ. Weibliche Genitalverstummelung in Deutschland. Geburtshilfe und Frauenheilkunde 2011;71(3):205-8.

- (195) Harris BP, Angwa JOW. Rupture of the uterus in East Africa (a note on its incidence and aetiology of the Kikuyu tribe). Journal of Obstetrics and Gynaecology of the British Empire 1951;58(6):1030-3.
- (196) Harrison KA. Obstetric fistula: one social calamity too many. British Journal of Obstetrics and Gynaecology 1983;90:385-6.
- (197) Hassan A. Sudanese women's struggle to eliminate harmful practices. Planned Parenthood Challenges 1995;(2):17-2.
- (198) Hassanin IM, Saleh R, Bedaiwy AA, Peterson RS, Bedaiwy MA. Prevalence of female genital cutting in Upper Egypt: 6 years after enforcement of prohibition law. Reproductive BioMedicine Online 2008;16 Suppl 1:27-31.
- (199) Henrion R. Les complications obstetricales des mutilations genitales feminines. Revue du Praticien Gynecologie et Obstetrique 2007;(111):24-7.
- (200) Herieka E, Dhar J. Female genital mutilation in the Sudan: survey of the attitude of Khartoum university students towards this practice. Sexually Transmitted Infections 2003;79(3):220-3.
- (201) Hezekiah J, Wafula F. Major health problems of women in a Kenyan village. Health Care Women Int 1989;10(1):15-25.
- (202) Hosken FP. The epidemiology of female genital mutilations. Tropical Doctor 1978;8(3):150-6.
- (203) Hosken F. The Hosken report: Genital and sexual mutilations on females. Lexington, MA: Women's International Network News; 1993.
- (204) Hrdy DB. Cultural practices contributing to the transmission of human immunodeficiency virus in Africa. Rev Infect Dis 1987;9(6):1109-19.
- (205) Huber A. Weibliche Zirkumzision und Infibulation in Athiopien. Acta Trop 1966;23(1):87-91.
- (206) Hulverscheidt MA, Ahlers CJ, Ihring I. Weibliche genitalverstummelung Soziokulturelle hintergrunde, rechtliche rahmenbedingungen, gesundheitliche folgen, moglichkeiten der intervention. Sexuologie 2009;16(1-2):17-32.
- (207) Igwegbe AO, Egbuonu I. The prevalence and practice of female genital mutilation in Nnewi, Nigeria: the impact of female education. Journal of Obstetrics & Gynaecology 2000;20(5):520-2.
- (208) Isa AR, Shuib R, Othman MS. The practice of female circumcision among muslims in Kelantan, Malaysia. Reproductive Health Matters 1999;7(13):137-44.
- (209) Ismail EA. FGM and obstetric complications: Somaliland experience. International Journal of Gynecology and Obstetrics 2009;107:S42.
- (210) Measure DHS. Ivory Coast DHS, 1999. Measure DHS; 1999.

- (211) Jackson E, Akweongo P, Sakeah E, Hodgson A, Asuru R, Phillips J. Inconsistent reporting of female genital cutting status in northern Ghana: explanatory factors and analytical consequences. Studies in Family Planning 2003;34:200-10.
- (212) Jaffer YA, Afifi M, Al Ajmi F, Alouhaishi K. Knowledge, attitudes and practices of secondary-school pupils in Oman: II. Reproductive health. Eastern Mediterranean Health Journal 2006;12(1-2):50-60.
- (213) Jirovsky E. Views of women and men in Bobo-Dioulasso, Burkina Faso, on three forms of female genital modification. Reproductive Health Matters 2010;18(35):84-93.
- (214) Johansen RE. Pain as a counterpoint to culture: toward an analysis of pain associated with infibulation among Somali immigrants in Norway. Med Anthropol Q 2002;16(3):312-40.
- (215) Junaid JA, Thomas SM. Cysts of the vulva and vagina: a comparative study. International Journal of Gynecology and Obstetrics 1981;19:239-43.
- (216) Kangoum AA, Flodin U, Hammar M, Sydsjo G. Prevalence of female genital mutilation among African women resident in the Swedish county of Ostergotland. Acta Obstet Gynecol Scand 2004;83(2):187-90.
- (217) Karmaker B, Kandala N-B, Chung D, Clarke A. Factors associated with female genital mutilation in Burkina Faso and its policy implications. International Journal for Equity in Health 2011;10.
- (218) Kassegne S, Camara L, Compaore S, Barry A. Psychographic factors related to female genital cutting in Guinea. American Journal of Tropical Medicine and Hygiene 2010;83(5 Suppl. 1):10.
- (219) Kastner R. Geburtshilfliche probleme bei beschnittenen frauen. Geburtshilfe und Frauenheilkunde 2005;65(8):806-8.
- (220) Keita D, Blankhart D. Community-based survey on female genital excision in Faranah District, Guinea. Reproductive Health Matters 2001;9(18):135-42.
- (221) Measure DHS. Kenya DHS, 2009. Measure DHS; 2009.
- (222) Measure DHS. Kenya DHS, 2003. Measure DHS; 2003.
- (223) Measure DHS. Kenya DHS, 1998. Measure DHS; 1998.
- (224) Khadivzadeh T, Ahadi M, Seyedialavi G. Female circumcision and women's attitude to it, Minab, Iran, 2002-2003. International Journal of Gynecology and Obstetrics 2009;107:S664.
- (225) Khan N, Qazi SA, Khan N. Congenital hematometrocolpos in a circumcised girl. An anomaly superimposed by cultural mutilating practices. JPMA Journal of the Pakistan Medical Association 1997;47(11):288-9.
- (226) Khanam W, Chogtu L, Mir Z, Shawl F. Adhesion of the labia minora a study of 75 cases. Australiand and New Zealand Journal of Obstetrics and Gynaecology 1977;17:176-7.

- (227) Khisa A, Nyamongo I. What factors contribute to obstetric fistulae formation in rural Kenya? African Journal of Midwifery & Women's Health 2011 Apr;5(2):95-100.
- (228) Kingston AE. The vaginal atresia of Arabia. Journal of Obstetrics and Gynaecology of the British Empire 1957;64:836-9.
- (229) Kiragu K. Female genital mutilation: a reproductive health concern. Population Reports Series J: Family Planning Programs 1995;(41 Suppl):1-4.
- (230) Kun KE. Female genital mutilation: the potential for increased risk of HIV infection. International Journal of Gynaecology & Obstetrics 1997;59(2):153-5.
- (231) Lagarde E, Schim van der Loeff M, Enel C, Holmgren B, Dray-Spira R, Pison G, et al. Mobility and the spread of human immunodeficiency virus into rural areas of West Africa. International Journal of Epidemiology 2003;32(5):744-52.
- (232) Lax RF. Socially Sanctioned Violence against Women: Female Genital Mutilation Is Its Most Brutal Form. Clinical Social Work Journal 2000 Jan;28(4):403-12.
- (233) Levin T. "Unspeakable Atrocities": The psycho-sexual etiology of female genital mutilation. The Journal of Mind and Behavior 1980;1(2):197-210.
- (234) Measure DHS. Liberia DHS, 2007. Measure DHS; 2007.
- (235) Lightfoot-Klein H. Pharaonic circumcision of females in the Sudan. Medicine & Law 1983;2(4):353-60.
- (236) Lightfoot-Klein H. The sexual experience and marital adjustment of genitally circumcised and infibulated females in the Sudan. Journal of Sex Research 1989;26(3):375-92.
- (237) Lightfoot-Klein H. Rites of purification and their effects: Some psychological aspects of female genital circumcision and infibulation (Pharaonic circumcision) in an Afro-Arab Islamic society (Sudan). Journal of Psychology & Human Sexuality 1989;2(2):79-91.
- (238) Lightfoot-Klein H. Disability in female immigrants with ritually inflicted genital mutilation. Women & Therapy 1993;14(3-4):187-94.
- (239) Lister UG. Obstructed labour. Journal of Obstetrics and Gynaecology of the British Empire 1960;67(1):188-98.
- (240) Longo D. Sociocultural practices relating to obstetrics and gynaecology in a community in West Africa. American Journal of Obstetrics and Gynecology 1964;89(4):470-5.
- (241) Lowenstein LF. Attitudes and attitude differences to female genital mutilation in the Sudan: Is there a change on the horizon? Soc Sci Med 1978;12(5A):417-21.

- (242) Lundberg PC, Gerezgiher A. Experiences from pregnancy and childbirth related to female genital mutilation among Eritrean immigrant women in Sweden. Midwifery 2008;24(2):214-25.
- (243) Mahran M. Medical dangers of female circumcision. IPPF Medical Bulletin 1981;15(2):1-3.
- (244) Measure DHS. Mali DHS, 1996. Measure DHS; 1996.
- (245) Cordero MM. Circuncision femenina e infibulacion. Colaboracion involuntaria, por ignorancia, en seis casos de circuncision femenina intrahospitalaria. Su tecnica. Nueva Enfermeria 1980;(10):9-12.
- (246) Marinho E, Bouscarat F. Papules multiples sur cicatrice de circoncision. Annales de Dermatologie et de Venereologie 2009;136(2):199-201.
- (247) Masho SW, Matthews L. Factors determining whether Ethiopian women support continuation of female genital mutilation. International Journal of Gynaecology & Obstetrics 2009;107(3):232-5.
- (248) Mboto CI, Andy IE, Eni OI, Jewell AP. Prevalence, sociodemographic characteristics and risk factors for hepatitis C infection among pregnant women in Calabar municipality, Nigeria. Hepatitis Monthly 2010;10(2):116-20.
- (249) McLintock DG. Phimosis of the prepuce of the clitoris: indication for female circumcision. Journal of the Royal Society of Medicine 1985;78(3):257-8.
- (250) Melhado L. Risks of adverse obstetric and perinatal outcomes increase with severity of female genital mutilation. International Family Planning Perspectives 2006;32(3).
- (251) Menage J. Female genital mutilation: whose problem, whose solution? Psychological damage is immense. British Medical Journal (International Edition) 2006;333(7561):260.
- (252) Meniru GI. Female genital mutilation (female circumcision). British Journal of Obstetrics & Gynaecology 1994;101(9):832.
- (253) Missailidis K, Gebre-Medhin M. Female genital mutilation in eastern Ethiopia. Lancet 2000;356(9224):137-8.
- (254) Mitike G, Deressa W. Prevalence and associated factors of female genital mutilation among Somali refugees in eastern Ethiopia: A cross-sectional study. BMC Public Health 2009;9.
- (255) Mohamud OA. Female circumcision and child mortality in urban Somalia. Genus 1991;47(3-4):203-23.
- (256) Momoh C. Attitudes to female genital mutilation. British Journal of Midwifery 2004;12(10):631-5.
- (257) Momoh C. Female genital mutilation: a global and local concern. Practising Midwife 2010;13(4):12-4.

- (258) Momoh C. Protecting pupils from female genital mutilation. Br J School Nursing 2011;6(3):116-8.
- (259) Monjok E, Essien EJ, Holmes L, Jr. Female genital mutilation: potential for HIV transmission in sub-Saharan Africa and prospect for epidemiologic investigation and intervention. Afr J Reprod Health 2007;11(1):33-42.
- (260) Morgan L. Implications of female genital mutilation. Journal of the Association of Chartered Physiotherapists in Women's Health 2006;(98):41-3.
- (261) Morison L, Scherf C. The association between female genital cutting and correlates of sexual and gynaecological morbidity in Edo State, Nigeria. BJOG 2003;110(12):1137-8.
- (262) Morris R. The culture of female circumcision. Advances in Nursing Science 1996;19(2):43-53.
- (263) Morris RI. Female genital mutilation: perspectives, risks, and complications. Urol Nurs 1999;19(1):13-9.
- (264) Mseddi M, Bouassida S, Turki H. Fiche de pathologie vulvaire: Mutilation genitale feminine. Annales de Dermatologie et de Venereologie 2007;134(5):500-1.
- (265) Mustafa AM. Significant bacteriuria in pregnancy. Ulster Medical Journal 1972;41:161-2.
- (266) Ncayiyana DJ. Astonishing indifference to deaths due to botched ritual circumcision. South African Medical Journal Suid-Afrikaanse Tydskrif Vir Geneeskunde 2003;93(8):545.
- (267) Ng F. Female genital mutilation: its implications for reproductive health: an overview. Br J Family Planning 2000;26(1):47-51.
- (268) Measure DHS. Niger DHS, 2006. Measure DHS; 2006.
- (269) Measure DHS. Niger DHS 1998. Measure DHS; 1998.
- (270) Measure DHS. Nigeria DHS, 2008. Measure DHS; 2008.
- (271) Measure DHS. Nigeria DHS, 2003. Measure DHS; 2003.
- (272) Measure DHS. Nigeria DHS, 1999. Measure DHS; 1999.
- (273) Nkrumah J. Unuttered screams: the psychological efffects of female genital mutilation. Sydney: Transcultural Mental Health Centre; 1999. p. 54-73.
- (274) Nnodum BI. Female genital mutilation and its effects: Implications for counselling. The Nigerian Journal of Guidance & Counselling 2002;8(1):112-32.

- (275) No AI. Halting female genital mutilation in Sudan rests with its leaders. Journal of Medical Ethics: Journal of the Institute of Medical Ethics 2004;30(6):550.
- (276) Nour NM. Female genital cutting: clinical and cultural guidelines. Obstetrical & Gynecological Survey 2004;59(4):272-9.
- (277) Nour NM, Michels KB, Bryant AE. Defibulation to treat female genital cutting: effect on symptoms and sexual function. Obstetrics & Gynecology 2006;108(1):55-60.
- (278) Nour NM. Female genital cutting: a persisting practice. Revue Obstetricale et Gynecologique 2008;1(3):135-9.
- (279) Ntiri DW. Circumcision and health among rural women of Southern Somalia as part of a family life survey. Health Care Women Int 1993;14(3):215-26.
- (280) Obermeyer CM, Reynolds RF. Female genital surgeries, reproductive health and sexuality: A review of the evidence. Reproductive Health Matters 1999;7(13):112-20.
- (281) Obermeyer CM, Reynolds RF. On cutting women's genitals: Female genital surgeries, reproductive health and sexuality: A review of the evidence. Reproductive Health Matters 1999;7(13):112-20.
- (282) Obermeyer CM. The consequences of female circumcision for health and sexuality: an update on the evidence. Cult Health Sex 2005;7(5):443-61.
- (283) Odimegwu CO, Asa S. Women's knowledge, attitude to and practice of female genital mutilation in the Abakaliki area of south-eastern Nigeria. African Population Studies 2001;16(2):1-19.
- (284) Odimegwu CO, Okemgbo CN. Female circumcision and sexual activity: "any relationship". Unilag Sociological Review 2000;1:159-76.
- (285) Odu BK. The attitude of undergraduate females toward genital mutilation in a Nigerian University. Research Journal of Medical Sciences 2008;2(6):295-9.
- (286) Odujinrin OM, Akitoye CO, Oyediran MA. A study on female circumcision in Nigeria. West Afr J Med 1989;8(3):183-92.
- (287) Ogunlola IO, Orji EO, Owolabi AT. Female genital mutilation and the unborn female child in southwest Nigeria. Journal of Obstetrics & Gynaecology 2003;23(2):143-5.
- (288) Olamijulo SK, Joiner KT, Oyedeji GA. Female child circumcision in Ilesha, Nigeria. The present and the future. Clin Pediatr (Phila) 1983;22(8):580-1.
- (289) Onuigbo WIB. Vulval epidermoid cysts in the Igbos of Nigeria. Archives of Dermatology 1976;112:1405-6.
- (290) Osinowo HO, Taiwo AO. Impact of Female Genital Mutilation on sexual functioning, self-esteem and marital instability of women in Ajegunle. IFE Psychologia: An International Journal 2003;11(1):123-30.

- (291) Oyeledun BO, Oyediran MA, Wolter S. Assessment of knowledge, attitude to and practice of female genital mutilation among women in Eti-Osa Local Government Area of Lagos State in Nigeria -- October 1995. Curare 1997;20(2):243-6.
- (292) Paul BK. Maternal mortality in Africa: 1980-87. Soc Sci Med 1993;37(6):745-52.
- (293) Penna C, Fallani MG, Fambrini M, Zipoli E, Marchionni M. Type III female genital mutilation: clinical implications and treatment by carbon dioxide laser surgery. Am J Obstet Gynecol 2002;187(6):1550-4.
- (294) Peterman A, Johnson K. Incontinence and trauma: sexual violence, female genital cutting and proxy measures of gynecological fistula. Soc Sci Med 2009 Mar;68(5):971-9.
- (295) Philp HRA. Artificial atresia in Kikuyu women. Kenya Medical Journal 1925;2(3):86-94.
- (296) Preston PG. Six years' maternity work among the Kakikuyy at the Native Hospital, Fort Hall. East African Medical Journal 1942;19:8-9.
- (297) Preston PG. A review of 100 cases of transplantation of the ureters in the treatment of obstetrical vesico-vaginal fistulae. Journal of Obstetrics and Gynaecology of the British Empire 1951;58(282):290.
- (298) Preston PG. Some observations on Kikuyu marriage and childbirth. East African Medical Journal 1954;31(10):465-70.
- (299) Rasheed SM, Abd-Ellah AH, Yousef FM. Female genital mutilation in Upper Egypt in the new millennium. International Journal of Gynaecology & Obstetrics 2011;114(1):47-50.
- (300) Renaud R, Boury-Heyler C, Sangaret M, Lehman JP, Ekra C, Renaud L, et al. Les consequences gynecologiques obstetricales de l'excision rituelle. Rev Assoc Med Langue Français 1968;4(189):191.
- (301) Reyners M. Health consequences of female genital mutilation. Reviews in Gynaecological Practice 2004;4(4):242-51.
- (302) Roberts M. An analysis of 90 cases of transplantation of the ureters for obstetrical vesicobaginal fistulae. Journal of Obstetrics and Gynaecology of the British Empire 1944;51:519-25.
- (303) Roles NC. Tribal surgery in East Africa during the XIXth century. Part 1: Ritual operations. East African Medical Journal 1966;43(579):594.
- (304) Ronge R. Allgemeine gynakologie: Beschnittene frauen haben erhohtes risiko fur primare infertilitat. Geburtshilfe und Frauenheilkunde 2006;66(2):104.
- (305) Rouzi AA, Aljhadali EA, Amarin ZO, Abduljabbar HS. The use of intrapartum defibulation in women with female genital mutilation. BJOG 2001;108(9):949-51.

- (306) Satti A, Elmusharaf S, Bedri H, Idris T, Hashim MS, Suliman GI, et al. Prevalence and determinants of the practice of genital mutilation of girls in Khartoum, Sudan. Ann Trop Paediatr 2006;26(4):303-10.
- (307) Measure DHS. Senegal DHS, 2011. Measure DHS; 2011.
- (308) Sequeira JH. female circumcision and infibulation. Lancet 1931;218(5645):1054-6.
- (309) Shah G, Susan L, Furcroy J. Female circumcision: history, medical and psychological complications, and initiatives to eradicate this practice. Canadian Journal of Urology 2009;16(2):4576-9.
- (310) Shay TZ, Haidar J, Kogi-Makau W. Magnitude of and driving factors for female genital cutting in schoolgirls in Addis Ababa, Ethiopia: A cross-sectional study. SAJCH South African Journal of Child Health 2010;4(3):78-82.
- (311) Measure DHS. Sierra Leone DHS, 2008. Measure DHS; 2008.
- (312) Silberstein AJ. Circoncision feminine en Cote d'Ivoire. Ann Soc Belg Med Trop 1977;57(3):129-35.
- (313) Stewart H, Morison L, White R. Determinants of coital frequency among married women in Central African Republic: the role of female genital cutting. Journal of Biosocial Science 2002;34(4):525-39.
- (314) Suardi E, Mishkin A, Henderson SW. Female genital mutilation in a young refugee: a case report and review. Journal of Child and Adolescent Trauma 2010;3(3):234-42.
- (315) Measure DHS. Sudan DHS, 1990. Measure DHS; 1990.
- (316) Tanganelli E. Implicazioni ginecologiche e ostetriche della circoncisione femminile in Somalia. Minerva Ginecol 1989;41(9):469-74.
- (317) Measure DHS. Tanzania DHS, 2010. Measure DHS; 2010.
- (318) Measure DHS. Tanzania DHS, 2004. Measure DHS; 2004.
- (319) Measure DHS. Tanzania DHS, 1996. Measure DHS; 1996.
- (320) Tegman I. Obstetrik bland omskurna kvinnor. Jordemodern 1990;103(6):209-5.
- (321) Thabet SM, Thabet AS. Defective sexuality and female circumcision: the cause and the possible management. J Obstet Gynaecol Res 2003;29(1):12-9.
- (322) Thabet SMA. Reality of the G-spot and its relation to female circumcision and vaginal surgery. Journal of Obstetrics & Gynaecology Research 2009;35(5):967-73.

- (323) Thomas J. Female genital mutilation complications lead to lost lives and high costs. International Perspectives on Sexual & Reproductive Health 2010;36(3):161-2.
- (324) Ugboma HA, Akani CI, Babatunde S. Prevalence and medicalization of female genital mutilation. Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria 2004;13(3):250-3.
- (325) Utz-Billing I, Kentenich H. Female genital mutilation: an injury, physical and mental harm. Journal of Psychosomatic Obstetrics & Gynecology 2008;29(4):225-9.
- (326) Vaizey. Female circumcision and medico legal aspects. East African Medical Journal 1955;32(1):28-9.
- (327) Van RJ, Derksen J. Vrouwenbesnijdenis; het verhaal van 3 patienten. Nederlands Tijdschrift Voor Geneeskunde 2000;144(2):95-6.
- (328) Van RR, Gage AJ. The effects of female genital mutilation on the onset of sexual activity and marriage in Guinea. Archives of Sexual Behavior 2009;38(2):178-85.
- (329) Vangen S, Hoffmann R, Flo K, Lorentzen B, Sand S. Omskjaering av kvinner Komplikasjoner og behandling. Tidsskrift for Den Norske Laegeforening 2006;126(4):475-7.
- (330) Verzin J. Sequelae of female circumcision. Tropical Doctor 1975;5:163-9.
- (331) Wagner U. Genitalverstummelung der frau Die harnwege leiden mit. Arztliche Praxis Urologie Nephrologie 2000;(3):30.
- (332) Williams DP, Acosta W, McPherson HA Jr. Female genital mutilation in the United States: implications for women's health. American Journal of Health Studies 1999;15(1):47-52.
- (333) Wilson DC, Sutherland I. Female circumcision and the age of the menarche. British Medical Journal 1955;1(4926):1375.
- (334) Worsley A. Infibulation and female circumcision: a study of a little-known custom. Journal of Obstetrics & Gynaecology of the British Empire 1938;45:686-91.
- (335) Measure DHS. Yemen DHS, 1992. Measure DHS; 1992.
- (336) Yoder PS, Abderrahim N, Zhuzhuni A. Female genital cutting in the Demographic and Health Surveys: a critical and comparative analysis. Calverton, Maryland, USA: ORC Macro; 2004.
- (337) Yoong W, Kolhe S, Karoshi M, Ullah M, Nauta M. The obstetric performance of United Kingdom asylum seekers from Somalia: a case-control study and literature review. International Journal of Fertility & Womens Medicine 2005;50(4):175-9.

- (338) Young EH. Female circumcision in Sudan. The Anti-slavery Reporter and Aborigine's Friend Series IV 1949;5(1):13-5.
- (339) Yount KM, Balk DL. A Demographic Paradox: Causes and Consequences of Female Genital Cutting in Northeastern Africa. Advances in Gender Research 2004;8(1529-2126, 1529-2126):199-249.

# **Appendix**

## **Appendix 1: Glossary**

The explanation for obstetric terms is taken from Danforth's Obstetrics and Gynecology (21). The explanation of methodological and statistical terms is copied from the glossary of the Cochrane handbook.

**TERM** EXPLANATION

**Anoxic** Absence of oxygen.

**Case-control study** A study that compares people with a specific disease or out-

come of interest (cases) to people from the same population without that disease or outcome (controls), and which seeks to find associations between the outcome and prior exposure to particular risk factors. This design is particularly useful where the outcome is rare and past exposure can be reliably measured. Case-control studies are usually retrospective, but not

always.

**Case report** A study reporting observations on a single individual.

(Also called anecdote, case history, or case study).

**Case series** A study reporting observations on a series of individuals,

usually all receiving the same intervention, with no

control group.

**Cervix** The lower, narrow portion of the uterus where it joins with the

top end of the vagina.

**Cesarean section** A surgical procedure, during which the fetus is delivered

through an incision in the lower abdomen and the uterine

wall.

**Chi<sup>2</sup>** A statistic used to express heterogeneity. A small p-value is

often used to indicate evidence of heterogeneity. As it applies to Cochrane reviews, the test is of somewhat limited value. This is because most meta-analyses in Cochrane reviews have very few studies in them. When there are few studies, the test is not very good at detecting heterogeneity if it is present (it has 'low power'). For this reason, a p-value of less than 0.10 is often used to indicate heterogeneity rather than the conventional cutpoint of p=0.05.

CI

Confidence interval. A measure of the uncertainty around the main finding of a statistical analysis. Estimates of unknown quantities, such as the odds ratio comparing an experimental intervention with a control, are usually presented as a point estimate and a 95% confidence interval. This means that if someone were to keep repeating a study in other samples from the same population, 95% of the confidence intervals from those studies would contain the true value of the unknown quantity. Alternatives to 95%, such as 90% and 99% confidence intervals, are sometimes used. Wider intervals indicate lower precision; narrow intervals, greater precision.

**Cohort study** 

An observational study in which a defined group of people (the cohort) is followed over time. The outcomes of people in subsets of this cohort are compared, to examine people who were exposed or not exposed (or exposed at different levels) to a particular intervention or other factor of interest. A prospective cohort study assembles participants and follows them into the future. A retrospective (or historical) cohort study identifies subjects from past records and follows them from the time of those records to the present. Because subjects are not allocated by the investigator to different interventions or other exposures, adjusted analysis is usually required to minimize the influence of other factors (confounders).

**Cross-sectional study** 

A study measuring the distribution of some characteristic(s) in a population at a particular point in time.

Diaspora

Far from ancestral homelands.

**Episiotomy** 

Surgical incision of the vulva (area behind the vagina, above the rectum). Used during delivery to avoid tearing or laceration of the vaginal opening and rectum.

Fascia

A layer of fibrous tissue.

**Forceps** 

Vacuum device used to assist the delivery of a baby when the second stage of labor has not progressed adequately.

FGM/C

Female genital mutilation/cutting.

**Forceps** 

Instrument used to help remove baby from the birth canal

during delivery.

**Fourchette** The band of membranes at the posterior angle of the vagina

that connects the posterior ends of the labia minora.

Hypoxic Inadequate oxygen supply.

**T**2 A measure used to quantify heterogeneity. It describes the

> percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance). A value greater than 50% may be considered to represent substantial

heterogeneity.

**Instrumental** 

delivery

The use of special devices, forceps or vacuum, to facilitate vag-

inal delivery.

Intrapartum During childbirth.

**Introitus** Entrance to a cavity or space or canal, for example vaginal

introitus.

Hard or tough collagen (tissue). Mature collagen

**Meta-analysis** The use of statistical techniques in a systematic review to in-

tegrate (pool) the results of included studies.

Moist tissue that lines certain parts of the inside of the body, Mucosa

for example the mouth and vagina.

**Multiparous** Having experienced one or more parturitions (births).

Nulliparous/

primiparous

Having experienced zero parturitions (births).

**Observational** 

study

A study in which the investigators do not seek to intervene, and simply observe the course of events. Changes or differences in one characteristic (e.g. whether or not people received the intervention of interest) are studied in relation to changes or differences in other characteristic(s) (e.g. whether or not they died), without action by the investigator. There is a greater risk of selection bias than in experimental studies (Al-

so called nonexperimental study).

**Obstetrics** Branch of medicine that involves care of a woman during

pregnancy, labor, childbirth and after the baby is born.

tear/laceration

**Obstetric/ perineal** A superficial tearing of the tissue in the vagina, perineum and/or anus that occurs during a vaginal delivery. Lacerations are classified as one of four types (degree 1-4), based on the

severity.

OR

Odds ratio. The ratio of the odds of an event in one group to the odds of an event in another group. In studies of treatment effect, the odds in the treatment group are usually divided by the odds in the control group. An odds ratio of one indicates no difference between comparison groups. For undesirable outcomes an OR that is less than one indicates that the intervention was effective in reducing the risk of that outcome. When the risk is small, odds ratios are very similar to risk ratios.

**Postpartum** 

The period immediately following childbirth.

Postpartum hemorrhage

Bleeding greater than 500ml at time of delivery.

Random effects model

In meta-analysis: A statistical model in which both withinstudy sampling error (variance) and between studies variation are included in the assessment of the uncertainty (confidence interval) of the results of a meta-analysis. When there is heterogeneity among the results of the included studies beyond chance, random-effects models will give wider confidence intervals than fixed-effect models.

RR

Relative risk or Risk ratio. The ratio of risks in two groups. In intervention studies, it is the ratio of the risk in the intervention group to the risk in the control group. A risk ratio of one indicates no difference between comparison groups. For undesirable outcomes, a risk ratio that is less than one indicates that the intervention was effective in reducing the risk of that outcome.

**UNFPA** 

**United Nations Population Fund** 

**UNICEF** 

United Nations Children's Fund

Vacuum extractor

Device used to provide traction on fetal head during delivery.

Ventouse

Vacuum device used to assist the delivery of a baby when the

second stage of labor has not progressed adequately.

## **Appendix 2: Search for literature**

#### **African Index Medicus**

Database: African Index Medicus

Date: 22.12.2011

Number of records: 14

Search:

102

"CIRCUMCISION" [Descriptor] or "CIRCUMCISION, FEMALE" [Descriptor] or "INFIBULATION" [Descriptor]

## **British Nursing Index and Archive**

Database: Ovid British Nursing Index and Archive 1985 to January 2012

Date: 20.01.2012

Number of records: 177

Search:

1. Circumcision/

- 2. ((female\$ or wom#n or girl\$1) adj3 (mutilation\$ or circumcis\$ or cutting\$)).tw.
- 3. "fgm/c".tw.
- 4. ((removal\$ or alteration\$ or excision\$) adj6 female genital\$).tw.
- 5. pharaonic circumcision\$.tw.
- 6. sunna.tw.
- 7. (clitoridectom\$ or clitorectom\$).tw.
- 8. (infibulat\$ or reinfibulat\$ or deinfibulat\$).tw.
- 9. or/1-8

#### **CINAHL**

Database: EBSCO Host CINAHL 1981-Present

Date: 16.01.2012

Number of records: 443

Search:

#	Query	Limiters/Expanders	Last Run Via	Results	
S7	S1 or S2 or S3 or S4 or S5 or S6	Search modes - Boo- lean/Phrase	Interface - EBSCOhost Search Screen - Advanced Search Database - CINAHL	534	Edit S7
S6	TI ( sunna or clitoridectom* or clitorectom* or infibulat* reinfibulat* or deinfibulat* ) OR AB ( sunna or clitoridectom* or clitorectom* or infibulat* reinfibulat* or deinfibulat* )	Search modes - Boo- lean/Phrase	Interface - EBSCOhost Search Screen - Advanced Search Database - CINAHL	4	Edit S6
S5	TI pharaonic W0 circumcision* OR AB pharaonic W0 circumcision*	Search modes - Boo- lean/Phrase	Interface - EBSCOhost Search Screen - Advanced Search Database - CINAHL	2	Edit S5
S4	TI ( (removal* or alteration* or exci- sion*) N6 (female W0 genital*) ) OR AB ( (removal* or altera- tion* or excision*)	Search modes - Boo- lean/Phrase	Interface - EBSCOhost Search Screen - Advanced Search Database - CINAHL	4	Edit S4

	N6 (female W0 genital*))				
S3	TI "fgm/c" OR AB "fgm/c"	Search modes - Boo- lean/Phrase	Interface - EBSCOhost Search Screen - Advanced Search Database - CINAHL	1	Edit S3
S2	TI ( (female* or wom#n or girl*) N3 (mutilation* or circumcis* or cutting*) ) OR AB ( (female* or wom#n or girl*) N3 (mutilation* or circumcis* or cutting*) )	Search modes - Boo- lean/Phrase	Interface - EBSCOhost Search Screen - Advanced Search Database - CINAHL	345	Edit S2
S1	(MH "Circumcision, Female")	Search modes - Boo- lean/Phrase	Interface - EBSCOhost Search Screen - Advanced Search Database - CINAHL	443	Edit S1

## **The Cochrane Library**

Databases in The Cochrane Library:

- Cochrane Database of Systematic Reviews (CDSR): Issue 12 of 12, Dec 2011
- Cochrane Central Register of Controlled Trials (CENTRAL),
- Database of Abstracts of Reviews of Effects (DARE)
- Health Technology Assessment Database (HTA): Issue 4 of 4 Oct 2011

Date: 09.01.2012

Number of records: CDSR: 1; CENTRAL: 12; DARE: 0; HTA: 3

Search:

#1 MeSH descriptor Circumcision, Female, this term only

or circumcis\* or cutting\*)) or "fgm/c" or ((removal\* or alteration\* or excision\*) near/6 (female next genital\*)) or (pharaonic next circumcision\*) or sunna or clitoridectom\* or clitorectom\* or infibulat\* or reinfibulat\* or deinfibulat\*:ti or ((female\* or woman or women or girl or girls) near/3 (mutilation\* or circumcis\* or cutting\*)) or "fgm/c" or ((removal\* or alteration\* or excision\*) near/6 (female

((female\* or woman or women or girl or girls) near/3 (mutilation\*

next genital\*)) or (pharaonic next circumcision\*) or sunna or <u>clitoridectom\* or clitorectom\* or infibulat\* or reinfibulat\* or</u>

deinfibulat\*:ab

#3 (#1 OR #2)

#### **EMBASE**

Database: Ovid Embase 1980 to 2012 Week 02

Date: 20.01.2012

Number of records: 1442

#### Search:

- 1. female circumcision/ or female genital mutilation/ or female genital cutting/ or infibulation/
- 2. ((female\$ or wom#n or girl\$1) adj3 (mutilation\$ or circumcis\$ or cutting\$)).tw.
- 3. "fgm/c".tw.
- 4. ((removal\$ or alteration\$ or excision\$) adj6 female genital\$).tw.
- 5. pharaonic circumcision\$.tw.
- 6. sunna.tw.
- 7. (clitoridectom\$ or clitorectom\$).tw.
- 8. (infibulat\$ or reinfibulat\$ or deinfibulat\$).tw.
- 9. or/1-8

## **MEDLINE(R) In-Process & Other Non-Indexed Citations**

Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 to Present (1946 to January Week 2 2012; January 19, 2012)

Date: 20.01.2012

Number of records: 1299

Search:

- 1. Circumcision, Female/
- 2. ((female\$ or wom#n or girl\$1) adj3 (mutilation\$ or circumcis\$ or cutting\$)).tw.
- 3. "fgm/c".tw.
- 4. ((removal\$ or alteration\$ or excision\$) adj6 female genital\$).tw.
- 5. pharaonic circumcision\$.tw.
- 6. sunna.tw.
- 7. (clitoridectom\$ or clitorectom\$).tw.
- 8. (infibulat\$ or reinfibulat\$ or deinfibulat\$).tw.
- 9. or/1-8

#### **PILOTS**

Database: CSA Illumina: PILOTS database (1871-Current)

Date: 02.03.2011

Number of records: 17

Search:

((DE=("genital mutilation")) or (TI=(((female\* or woman or women or girl or girls) within 3 (mutilation\* or circumcis\* or cutting\*)) or fgm or ((removal\* or alteration\* or excision\*) within 6 female genital\*) or pharaonic circumcision\* or sunna or clitoridectom\* or clitorectom\* or infibulat\* or reinfibulat\* or deinfibulat\*)) or (AB=(((female\* or woman or women or girl or girls) within 3 (mutilation\* or circumcis\* or cutting\*)) or fgm or ((removal\* or alteration\* or excision\*) within 6 female genital\*) or pharaonic circumcision\* or sunna or clitoridectom\* or clitorectom\* or infibulat\* or reinfibulat\* or deinfibulat\*)))

## **POPLINE**

Database: POPLINE® (POPulation information onLINE)

Date: 03.03.2011

Number of records: 1331

Search:

**KEYWORDS:** 

FEMALE GENITAL CUTTING

## **PsycINFO**

Database: Ovid PsycINFO 1806 to January Week 3 2012

Date: 20.01.2012

Number of records: 574

Search:

1. Circumcision/

- 2. ((female\$ or wom#n or girl\$1) adj3 (mutilation\$ or circumcis\$ or cutting\$)).tw.
- 3. "fgm/c".tw.
- 4. ((removal\$ or alteration\$ or excision\$) adj6 female genital\$).tw.
- 5. pharaonic circumcision\$.tw.
- 6. sunna.tw.
- 7. (clitoridectom\$ or clitorectom\$).tw.
- 8. (infibulat\$ or reinfibulat\$ or deinfibulat\$).tw.
- 9. or/1-8

#### **Social Services Abstracts**

Database: ProQuest: Social Services Abstracts (1979-Current)

Date: 25.01.2012

Number of records: 94

Search:

su.EXACT("Genital Mutilation" OR "Circumcision") OR ti((female\* NEAR/3 (mutilation\* OR circumcis\* OR cutting\*))) OR ab((female\* NEAR/3 (mutilation\* OR circumcis\* OR cutting\*)))

## **Sociological Abstracts**

Database: ProQuest: Sociological Abstracts (1952-Current)

Date: 25.01.2012

Number of records: 436

Search:

su.EXACT("Genital Mutilation" OR "Circumcision") OR ti((female\* NEAR/3 (mutilation\* OR circumcis\* OR cutting\*))) OR ab((female\* NEAR/3 (mutilation\* OR circumcis\* OR cutting\*)))

## **WHOLIS**

Database: WHO Library & Information Networks for Knowledge Database

(WHOLIS)

Date: 03.03.2011

Number of records: 72

Search:

words or phrase "((female\$ or wom?n or girl or girls) near3 (mutilation\$ or circum-

cis\$ or cutting\$))"

OR

words or phrase ""fgm/c""

OR

words or phrase "((removal\$ or alteration\$ or excision\$) near6 (female adj genital\$))"

OR

words or phrase "(pharaonic adj circumcision\$)"

OR

words or phrase "sunna"

OR

words or phrase "(clitoridectom\$ or clitorectom\$)"

OR

words or phrase "(infibulat\$ or reinfibulat\$ or deinfibulat\$)"

## **Appendix 3: Excluded studies**

**Table 1.1: Excluded studies read in full text and reason for exclusion** 

Study first author (ref no.)	Cause for exclusion of study
NN 1994 (97)	Not empirical study
NN 2007 (98)	Not empirical study
NN 1996 (99)	Not empirical study
NN 1997 (100)	Not empirical study
Abariga 2009 (101)	No physical consequences/complications following FGM/C reported
Abubakar 2004 (102)	No physical consequences/complications following FGM/C reported
Abu-Shamma 1949 (103)	Not empirical study
Adanu 2005 (104)	Population not girls/women subjected to FGM/C
Adelusi 1975 (105)	No physical consequences/complications following FGM/C reported
Adeneye 2006 (106)	No physical consequences/complications following FGM/C reported
Adeokun 2006 (107)	No physical consequences/complications following FGM/C reported
Adeyinka 2009 (108)	No physical consequences/complications following FGM/C reported
Adinma 1999 (109)	No physical consequences/complications following FGM/C reported
Afifi 2007 (110)	No physical consequences/complications following FGM/C reported

Study first author (ref no.)	Cause for exclusion of study
Ahmed 2000 (111)	Not empirical study
Ahmed 2005 (112)	Not empirical study
Ahnaimugan 1978 (113)	No physical consequences/complications following FGM/C reported
Al-Krenawi 1999 (114)	No physical consequences/complications following FGM/C reported
Al-Krenawi 1999 (115)	No physical consequences/complications following FGM/C reported
Allag 2001 (116)	No physical consequences/complications following FGM/C reported
Ahmed Allam 1999 (117)	Population not girls/women subjected to FGM/C
Allam 2001 (118)	Population not girls/women subjected to FGM/C
Almroth-Berggren 2001 (119)	No physical consequences/complications following FGM/C reported
Amusan 2006 (120)	No physical consequences/complications following FGM/C reported
Anderson 1929 (121)	No extractable physical consequences following FGM/C reported
Applebaum 2008 (122)	No physical consequences/complications following FGM/C reported
Archibong 1987 (123)	No physical consequences/complications following FGM/C reported
Arthur 1942 (124)	Not empirical study
Asali 1995 (125)	No physical consequences/complications following FGM/C reported (qual)
Azadeh 1997 (126)	Not empirical study
Baasher 1982 (127)	Not empirical study
Badri 1992 (128)	Not empirical study
Badri 1984 (129)	Not empirical study (review)
Baido 2004 (130)	No physical consequences/complications following FGM/C reported
Baido 2007 (131)	No physical consequences/complications following FGM/C reported
Baker 1993 (132)	No physical consequences/complications following FGM/C reported
Bakr 1985 (133)	Not empirical study
Balogun 2001 (134)	Not empirical study
Barber 2010 (135)	Not empirical study
Beck 2008 (136)	Not empirical study
Behrendt 2005 (137)	No physical consequences/complications following FGM/C reported
Belmaker 2011 (138)	No physical consequences/complications following FGM/C reported
Bender 1999 (139)	Not empirical study
Bikoo 2008 (140)	Not empirical study
Boddy 1982 (141)	No physical consequences/complications following FGM/C reported (qual)
Bonilla 1997 (142)	Not empirical study
Brady 1999 (143)	Not empirical study
Briggs 2002 (144)	No physical consequences/complications following FGM/C reported
Brotmacher 1955 (145)	Not empirical study
Burkina Faso DHS 1999 (146)	No physical consequences/complications following FGM/C reported

Study first author (ref no.)	Cause for exclusion of study
Caldwell 1983 (147)	No physical consequences/complications following FGM/C reported
Campbell 1995 (148)	No physical consequences/complications following FGM/C reported (qual)
Cameron DHS 2004 (149)	No physical consequences/complications following FGM/C reported
Cannon 1964 (150)	No physical consequences/complications following FGM/C reported
Capraro 1972 (151)	No physical consequences/complications following FGM/C reported
Carton 2008 (152)	Not empirical study
Certinkurşun 2009 (153)	No physical consequences/complications following FGM/C reported
Cohen 1992 (154)	Population not girls/women subjected to FGM/C
Coker 1998 (155)	No physical consequences/complications following FGM/C reported
Cook 1979 (156)	Not empirical study
Damas 1972 (157)	No physical consequences/complications following FGM/C reported
Dattijo 2010 (158)	No physical consequences/complications following FGM/C reported
Davis 1999 (159)	No physical consequences/complications following FGM/C reported
Daw 1970 (160)	No physical consequences/complications following FGM/C reported
Dekou 2002 (161)	Population not girls/women subjected to FGM/C
De Villeneuve 1937 (162)	Not empirical study
Dirie 1991 (163)	No physical consequences/complications following FGM/C reported
Ebomoyi 1987 (164)	No physical consequences/complications following FGM/C reported
Ebong 1997 (165)	No physical consequences/complications following FGM/C reported
Egypt DHS 2008 (166)	No physical consequences/complications following FGM/C reported
Egypt DHS 2005 (167)	No physical consequences/complications following FGM/C reported
Egypt DHS 2003 (168)	No physical consequences/complications following FGM/C reported
Egypt DHS 2000 (169)	No physical consequences/complications following FGM/C reported
Ehigiegba 1998 (170)	No physical consequences/complications following FGM/C reported
Eke 2006 (171)	Not empirical study
Ekwueme 2010 (172)	No physical consequences/complications following FGM/C reported
Elmusharaf 2009 (173)	No physical consequences/complications following FGM/C reported
Elmusharaf 2006 (94)	No physical consequences/complications following FGM/C reported
Elnashar 2007 (174)	No physical consequences/complications following FGM/C reported
Epelboin 1979 (175)	No physical consequences/complications following FGM/C reported (qual)
Ericksen 1995 (176)	No physical consequences/complications following FGM/C reported
Essen 2002 (177)	Consequences/complications following FGM/C not reported for women
Ethiopia DHS 2005 (178)	No physical consequences/complications following FGM/C reported
Ethiopia DHS 2000 (179)	No physical consequences/complications following FGM/C reported
Fahmy 2010 (180)	No physical consequences/complications following FGM/C reported
Feyi-Waboso 2006 (181)	No physical consequences/complications following FGM/C reported

Study first author (ref no.)	Cause for exclusion of study
Fleischer 1975 (182)	No physical consequences/complications following FGM/C reported
Gage 2006 (183)	No physical consequences/complications following FGM/C reported
Gallo 1985 (184)	No physical consequences/complications following FGM/C reported
Gallo 1985 (185)	No physical consequences/complications following FGM/C reported
Ghana DHS 2003 (186)	No physical consequences/complications following FGM/C reported
Gillian 1929 (187)	Not empirical study
Gilson 1995 (188)	Not empirical study
Githiora 2011 (189)	No physical consequences/complications following FGM/C reported
Gordon 2007 (190)	Not empirical study
Grisaru 1997 (191)	No physical consequences/complications following FGM/C reported
Gruenbaum 2006 (192)	No physical consequences/complications following FGM/C reported
Gurunluoglu 1999 (193)	Population not girls/women subjected to FGM/C
Hanselmann 2011 (194)	No physical consequences/complications following FGM/C reported
Harris 1951 (195)	No physical consequences/complications following FGM/C reported
Harrison 1983 (196)	Not empirical study
Hassan 1995 (197)	Not empirical study
Hassanin 2008 (198)	No physical consequences/complications following FGM/C reported
Henrion 2007 (199)	Not empirical study
Herieka 2003 (200)	No physical consequences/complications following FGM/C reported
Hezekiah 1989 (201)	Not empirical study
Hosken 1978 (202)	Not empirical study
Hosken 1993 (203)	Not empirical study (review)
Hrdy 1987 (204)	Not empirical study
Huber 1966 (205)	Not empirical study
Hulverscheidt 2009 (206)	Not empirical study
Igwegbe 2000 (207)	No physical consequences/complications following FGM/C reported
Isa 1999 (208)	No physical consequences/complications following FGM/C reported
Ismail 2009 (209)	No physical consequences/complications following FGM/C reported
Ivory Coast DHS 1999 (210)	No physical consequences/complications following FGM/C reported
Jackson 2003 (211)	No physical consequences/complications following FGM/C reported
Jaffer 2006 (212)	No physical consequences/complications following FGM/C reported
Jirovsky 2010 (213)	No physical consequences/complications following FGM/C reported
Johansen 2002 (214)	No physical consequences/complications following FGM/C reported (qual)
Junaid 1981 (215)	Population not girls/women subjected to FGM/C
Kangoum 2004 (216)	No physical consequences/complications following FGM/C reported
Karmaker 2011 (217)	No physical consequences/complications following FGM/C reported

Study first author (ref no.)	Cause for exclusion of study
Kassegne 2010 (218)	No physical consequences/complications following FGM/C reported
Kästner 2005 (219)	Not empirical study
Keita 2001 (220)	No physical consequences/complications following FGM/C reported
Kenya DHS 2009 (221)	No physical consequences/complications following FGM/C reported
Kenya DHS 2003 (222)	No physical consequences/complications following FGM/C reported
Kenya DHS 1998 (223)	No physical consequences/complications following FGM/C reported
Khadivzadeh 2009 (224)	No physical consequences/complications following FGM/C reported
Khan 1997 (225)	No physical consequences/complications following FGM/C reported
Khanam 1977 (226)	Population not girls/women subjected to FGM/C
Khisa 2011 (227)	No physical consequences/complications following FGM/C reported
Kingston 1957 (228)	Not empirical study
Kiragu 1995 (229)	Not empirical study
Kun 1997 (230)	Not empirical study
Lagarde 2003 (231)	No physical consequences/complications following FGM/C reported
Lax 2000 (232)	Not empirical study
Levin 1980 (233)	Not empirical study
Liberia DHS 2007 (234)	No physical consequences/complications following FGM/C reported
Lightfoot-Klein 1983 (235)	No physical consequences/complications following FGM/C reported
Lightfoot-Klein 1989 (236)	No physical consequences/complications following FGM/C reported
Lightfoot-Klein 1989 (237)	No physical consequences/complications following FGM/C reported
Lightfoot-Klein 1993 (238)	Not empirical study
Lister 1960 (239)	No physical consequences/complications following FGM/C reported
Longo 1964 (240)	Not empirical study
Lowenstein 1978 (241)	No physical consequences/complications following FGM/C reported
Lundberg 2008 (242)	No physical consequences/complications following FGM/C reported
Mahran 1981 (243)	Not empirical study
Mali DHS 1996 (244)	No physical consequences/complications following FGM/C reported
Marin 1980 (245)	Not empirical study
Marinho 2009 (246)	Population not girls/women subjected to FGM/C
Masho 2009 (247)	No physical consequences/complications following FGM/C reported
Mboto 2010 (248)	No physical consequences/complications following FGM/C reported
McLintock 1985 (249)	Population not girls/women subjected to FGM/C
Melhado 2006 (250)	Not empirical study
Menage 2006 (251)	Not empirical study
Meniru 1994 (252)	Not empirical study
Missailidis 2000 (253)	No physical consequences/complications following FGM/C reported (qual)

Study first author (ref no.)	Cause for exclusion of study
Mitike 2009 (254)	No physical consequences/complications following FGM/C reported
Mohamud 1991 (255)	Consequences/complications following FGM/C not reported for women
Momoh 2004 (256)	No physical consequences/complications following FGM/C reported
Momoh 2010 (257)	Not empirical study
Momoh 2011 (258)	Not empirical study
Monjok 2007 (259)	Not empirical study
Morgan 2006 (260)	Not empirical study
Morison 2003 (261)	Not empirical study
Morris 1996 (262)	No physical consequences/complications following FGM/C reported
Morris 1999 (263)	Not empirical study
Mseddi 2007 (264)	No physical consequences/complications following FGM/C reported
Mustafa 1972 (265)	No physical consequences/complications following FGM/C reported
Ncayiyana 2003 (266)	Not empirical study
Ng 2000 (267)	Not empirical study
Niger DHS 2006 (268)	No physical consequences/complications following FGM/C reported
Niger DHS 1998 (269)	No physical consequences/complications following FGM/C reported
Nigeria DHS 2008 (270)	No physical consequences/complications following FGM/C reported
Nigeria DHS 2003 (271)	No physical consequences/complications following FGM/C reported
Nigeria DHS 1999 (272)	No physical consequences/complications following FGM/C reported
Nkrumah 1999 (273)	Not empirical study
Nnodum 2002 (274)	Only sexual and psychological consequences following FGM/C reported
No 2004 (275)	Not empirical study
Nour 2004 (276)	Not empirical study
Nour 2006 (277)	Reports on effect of defibulation
Nour 2008 (278)	Not empirical study
Ntiri 1993 (279)	No physical consequences/complications following FGM/C reported
Obermeyer 1999 (280)	Not empirical study (review paper)
Obermeyer 1999 (281)	Not empirical study (review paper)
Obermeyer 2005 (282)	Not empirical study (review paper)
Odimegwu 2001 (283)	No physical consequences/complications following FGM/C reported
Odimegwu 2000 (284)	No physical consequences/complications following FGM/C reported
Odu 2008 (285)	No physical consequences/complications following FGM/C reported
Odujinrin 1989 (286)	No physical consequences/complications following FGM/C reported
Ogunlola 2003 (287)	No physical consequences/complications following FGM/C reported
Olamijulo 1983 (288)	No physical consequences/complications following FGM/C reported
Onuigbo 1976 (289)	No physical consequences/complications following FGM/C reported

Study first author (ref no.)	Cause for exclusion of study
Osinowo 2003 (290)	No physical consequences/complications following FGM/C reported
Oyeledun 1997 (291)	No data for physical consequences following FGM/C reported
Paul 1993 (292)	No physical consequences/complications following FGM/C reported
Penna 2002 (293)	Reports on effect of defibulation with laser surgery
Peterman 2009 (294)	No data for physical consequences following FGM/C reported
Philp 1925 (295)	Not empirical study
Preston 1942 (296)	Population not girls/women subjected to FGM/C
Preston 1951 (297)	No physical consequences/complications following FGM/C reported
Preston 1954 (298)	Not empirical study
Rasheed 2011 (299)	No physical consequences/complications following FGM/C reported
Renaud 1968 (300)	Not empirical study
Reyners 2004 (301)	Not empirical study
Roberts 1944 (302)	Population seems not to be girls/women subjected to FGM/C
Roles 1966 (303)	Not empirical study
Ronge 2006 (304)	Not empirical study
Rouzi 2001 (305)	Reports on effect of defibulation
Satti 2006 (306)	No physical consequences/complications following FGM/C reported
Senegal DHS 2011 (307)	No physical consequences/complications following FGM/C reported
Sequeira 1931(308)	Not empirical study
Shah 2009 (309)	Not empirical study
Shay 2010 (310)	No physical consequences/complications following FGM/C reported
Sierra Leone DHS 2008 (311)	No physical consequences/complications following FGM/C reported
Silberstein 1977 (312)	Not empirical study (review)
Snow 2002 (96)	No physical consequences/complications following FGM/C reported
Stewart 2002 (313)	No physical consequences/complications following FGM/C reported
Suardi 2010 (314)	No physical consequences/complications following FGM/C reported
Sudan DHS 1990 (315)	No physical consequences/complications following FGM/C reported
Tanganelli 1989 (316)	Not empirical study
Tanzania DHS 2010 (317)	No physical consequences/complications following FGM/C reported
Tanzania DHS 2004 (318)	No physical consequences/complications following FGM/C reported
Tanzania DHS 1996 (319)	No physical consequences/complications following FGM/C reported
Tegman 1990 (320)	Not empirical study
Thabet 2003 (321)	Only sexual consequences/complications following FGM/C reported
Thabet 2009 (322)	No physical consequences/complications following FGM/C reported
Thomas 2010 (323)	No physical consequences/complications following FGM/C reported
Ugboma 2004 (324)	No physical consequences/complications following FGM/C reported

Study first author (ref no.)	Cause for exclusion of study
Utz-Billing 2008 (325)	Not empirical study
Vaizey 1955 (326)	Not empirical study
Van Roosmalen 2000 (327)	Not empirical study
Van Rossem 2009 (328)	No physical consequences/complications following FGM/C reported
Vangen 2006 (329)	Not empirical study
Verzin 1975 (330)	Not empirical study
Wagner 2000 (331)	Not empirical study
WHO 2000 (18)	Not empirical study (review)
Williams 1999 (332)	Not empirical study
Wilson 1955 (333)	No physical consequences/complications following FGM/C reported
Worsley 1938 (334)	Not empirical study
Yemen DHS 1992 (335)	No physical consequences/complications following FGM/C reported
Yoder 2004 (336)	Not empirical study
Yoong 2005 (337)	Population mix of girls/women subjected to FGM/C and not
Young 1949 (338)	Not empirical study
Yount 2004 (339)	Not empirical study

## **Appendix 4: Quality assessment**

Description of assessment of study quality for all studies:

High quality (few limitations): All or almost all of the criteria from the checklist are met. If some of the criteria are not met, it must be unlikely that the study conclusions will change.

Moderate quality (some limitations): Some of the criteria are not met and/or the study does not adequately address the criteria. It is unlikely that the study conclusions will change.

Low quality (serious limitations): Few or no criteria are met and/or the study does not adequately address the criteria. It is likely that the study conclusions will change.

#### Quality assessment of comparative studies

Quality assessment questions for comparative studies.

All questions are answered 'yes', 'unclear/somewhat', or 'no' (na= not applicable):

- 1. Was the population from which the sample was drawn clearly defined?
- 2. Was the sample representative of the population?
- 3. Is it explained whether (and how) the participants who agreed to participate are different from those who refused to participate?
- 4. Is the response rate adequate?
- 5. Were standardized data collection methods used?

- 6. Were measures shown to be reliable and valid?
- 7. Were the statistical methods appropriate?
- 8. Was the non-exposed group selected from the same population as the exposed group?
- 9. Were the groups comparable with respect to important background factors?
- 10. Were exposure and outcome measured in the same way and reliably in the two groups?
- 11. Was the person who assessed the outcome blind to whether participants were exposed or not.
- 12. Have known, potential confounders been considered in the study design and/or analyses?

Table 2.1: Results of quality assessment of comparative studies

Study	1	2	3	4	5	6	7	8	9	10	11	12	Assessment
Adinma 1997	yes	unclear	no	yes	unclear	no	unclear	yes	unclear	unclear	unclear	unclear	Low
Berardi 1985	unclear	unclear	no	unclear	yes	yes	yes	yes	unclear	yes	unclear	no	Low
Bohoussou 1986	unclear	unclear	no	unclear	yes	unclear	yes	yes	unclear	unclear	unclear	unclear	Low
Browning 2010	yes	unclear	na	na	yes	yes	yes	yes	yes	yes	unclear	yes	High
Chibber 2011	yes	yes	unclear	unclear	yes	unclear	yes	yes	unclear	unclear	unclear	unclear	Low
De Silva 1989	unclear	unclear	no	unclear	yes	unclear	yes	yes	unclear	unclear	unclear	unclear	Low
Diop 1998	unclear	unclear	no	unclear	yes	no	yes	yes	unclear	unclear	unclear	unclear	Low
Elnashar 2007	yes	yes	no	yes	unclear	no	unclear	yes	unclear	unclear	no	unclear	Low
Eritrea DHS 2002	yes	yes	no	yes	yes	no	yes	yes	unclear	unclear	no	unclear	Low
Eritrea DHS 1995	yes	yes	no	yes	yes	no	yes	yes	unclear	unclear	no	unclear	Low
Essén 2005	yes	unclear	na	na	yes	yes	yes	no	unclear	yes	unclear	yes	Moderate
Hakim 2001	yes	unclear	no	unclear	unclear	unclear	no	yes	unclear	unclear	unclear	no	Low
Johnson 2005	yes	yes	na	na	yes	yes	yes	no	no	no	unclear	yes	Low
Jones 1999 a	yes	unclear	no	unclear	yes	no	yes	yes	unclear	unclear	unclear	yes	Low
Jones1999 b	yes	unclear	na	yes	yes	no	yes	yes	unclear	unclear	unclear	yes	Moderate
Larsen 2002	yes	unclear	no	yes	yes	no	yes	yes	no	unclear	unclear	yes	Low
Lupo 1999	no	unclear	no	na	unclear	unclear	yes	no	no	unclear	unclear	unclear	Low
MillTraore 2007	yes	unclear	no	unclear	yes	unclear	yes	yes	unclear	unclear	unclear	unclear	Low
Ndiaye 2010	yes	unclear	no	yes	yes	unclear	yes	yes	unclear	unclear	yes	no	Low
Oduro 2006	yes	yes	na	na	yes	yes	yes	yes	no	yes	unclear	unclear	High
Orji 2006	yes	unclear	no	unclear	yes	no	yes	yes	no	unclear	unclear	no	Low

Slanger 2002	yes	unclear	no	yes	yes	no	yes	yes	yes	unclear	unclear	yes	Moderate
Small 2008	unclear	unclear	na	na	unclear	no	yes	no	no	no	unclear	yes	Low
Vangen 2002	yes	yes	na	na	yes	yes	yes	no	no	no	unclear	yes	Low
WHO sg. 2006	yes	unclear	no	yes	yes	yes	yes	yes	unclear	yes	unclear	yes	High
Wuest 2009	yes	unclear	na	na	yes	yes	yes	unclear	no	yes	unclear	no	Low
Yount 2007	yes	yes	no	yes	yes	no	yes	yes	no	unclear	unclear	yes	Moderate
Yount 2006	yes	yes	no	unclear	unclear	no	yes	yes	unclear	unclear	no	yes	Low

Legend: Jones 1999 a = Study in Burkina Faso; Jones 1999b = Study in Mali; na= not applicable.

#### Quality assessment of cross-sectional descriptive studies (one group)

Quality assessment questions for cross-sectional studies.

All questions are answered 'yes', 'unclear/somewhat', or 'no' (na= not applicable):

- 1. Was the population from which the sample was drawn clearly defined?
- 2. Was the sample representative of the population?
- 3. Is it explained whether (and how) the participants who agreed to participate are different from those who refused to participate?
- 4. Is the response rate adequate?
- 5. Were standardized data collection methods used?
- 6. Were measures shown to be reliable and valid?
- 7. Were the statistical methods appropriate?

Table 3.1: Results of quality assessment of cross-sectional descriptive studies

Study	1	2	3	4	5	6	7	Assessment
Abor 2006	yes	no	no	yes	yes	no	yes	Low
Al-Hussaini 2003	yes	unclear	unclear	no	yes	yes	yes	Moderate
Bayoudh 1995	no	no	no	unclear	yes	no	yes	Low
CAR DHS 1995	yes	yes	no	yes	yes	unclear	yes	High
Chalmers 2000	yes	unclear	no	unclear	yes	no	yes	Low
Litorp 2008	yes	unclear	no	yes	yes	no	yes	Low
McCaffrey 1995	yes	unclear	na	na	unclear	unclear	unclear	Low

#### Quality assessment of case series

Quality assessment questions for case series.

All questions are answered 'yes', 'unclear/somewhat', or 'no' (na= not applicable):

- 1. Was the study based on a series of individuals from a suitable group of patients?
- 2. Were measures taken to ensure that the sample was not too selective?
- 3. Were the inclusion criteria for the sample clearly defined?
- 4. Is the response rate adequate?
- 5. Were all included patients at the same stage of disease progression?
- 6. Was the follow-up adequate (type/extent/time) to account for outcomes?
- 7. Were objective criteria used to assess the outcome?
- 8. If case series are compared, were the series adequately described and was the distribution of prognostic factors described?
- 9. Was registration of data prospective?

Table 4.1: Results of quality assessment of case series

Study	1	2	3	4	5	6	7	8	9	Assessment
Akotionga 2001	yes	yes	unclear	na	unclear	yes	yes	na	yes	High
Awuah 2008	yes	unclear	no	unclear	unclear	na	no	na	no	Low
Bonessio 2001	unclear	unclear	no	unclear	yes	na	yes	na	unclear	Low
Dörflinger 2000	yes	unclear	no	unclear	no	yes	yes	na	unclear	Low
Osifo 2009	yes	unclear	yes	unclear	no	yes	yes	na	yes	High

# **Appendix 5: Outcome tables**

The following tables present results from the non-comparative studies. The tables are organized according to outcomes, in line with the results chapter.

#### **Prolonged labor**

Table 5.1: Study outcomes for non-comparative studies that reported on pro-

longed labor

10118041141401			
Author	Study design	Outcome	Result
Awuah 2008	Case series	Prolonged 1 <sup>st</sup> stage labour Prolonged 2 <sup>nd</sup> stage labour	26/70 (37.0%) 6/70 (9.0%)
Bohoussou 1986	Cross-sectional+	Prolonged delivery	88/1097 (8.0%)
Bonessio 2001	Case series	Prolonged labor	1/4 (25.0%)
Dörflinger 2000	Case series	Prolonged stage 1 Prolonged stage 2	2/29 (6.9%) 7/29 (24.1%)

Legend: Cross-sectional+ = comparative cross-sectional study.

Table 6.1: Included studies that reported on prolonged labor and their description of prolonged labor

Author	Study design	Outcome	Description
Awuah 2008	Case series	Prolonged 1 <sup>st</sup> stage labour Prolonged 2 <sup>nd</sup> stage labour	24-72 hrs
Bohoussou 1986	Cross- sectional	Prolonged delivery	•
Bonessio 2001	Case series	Prolonged labor	
Browning 2010	Cross- sectional+	Days in labor	Continous
Chibber 2011	Cross- sectional+	Prolonged labor	Not defined
De Silva 1989	Cross- sectional+	Prolonged stage 1 Prolonged stage 2	>12 hours >60 min for multiparous and >90 minutes for primiparous women
Dörflinger 2000	Case series	Prolonged stage 1 Prolonged stage 2	>7 hrs >1 hr
Essén 2005	Cross- sectional+	Prolonged stage 2 Prolonged labor	>60 min "second stage of labour was defined as the period from complete cervical dilatation to delivery. Prolongation of labour was defined as a second stage of labour exceeding 60 min." (p) Continous
Hakim 2001	Cross- sectional+	Duration of labor stage 1 Duration of labor stage 2 Duration of labor stage 3	Continous Continous Continous
Larsen 2002a	Cross- sectional+	Prolonged labor	>24 hrs/2 days (self reported based on the interviewer question: did you have "strong and

			regular labor pains that lasted longer than 24 h/ 2 days") (p)
Millogo-Traore 2007	Cross- sectional+	Prolonged labor	>8 hours for multiparous and >12 hours for primiparous women
Vangen 2002	Cross- sectional+	Prolonged 2nd stage of labor	The time from the baby's head reaching the pelvic floor until the birth exceeded two hours (p318)
Wuest 2009	Cross- sectional+	Duration of 1st stage of labor Duration of 2nd stage of labor	Continous Continous

Legend: Cross-sectional+ = comparative cross-sectional study.

#### **Obstetric tears**

Table 7.1: Study outcomes for non-comparative studies that reported on obstetric tears/lacerations

Author	Study design	Outcome	Result
Al-Hussaini 2003	Cross-sectional	Vaginal/perineal tears	4/254 (1.6%)
Awuah 2008	Case series	Massive vaginal tears Damage to rectal wall	16/70 (23.0%) 9/70 (13.0%)
Dörflinger 2000	Case series	Tear degree IV	2/29 (6.9%)
McCaffrey 1995	Cross-sectional	Perineal laceration or episiotomy	13/13 (100%)
McSwiney 1992	Case report	Perineal and vaginal tears	Led to rapid hemorrhage (>6 I blood loss)
Osifo 2009	Case series	Perineal tear during delivery	2/51 (3.9%) led to uncontrolled bleeding

Table 8.1: Included studies that reported on obstetric tears and their description of obstetric tears

Author	Study design	Outcome	Description
Al-Hussaini 2003	Cross- sectional	Vaginal/perineal tears	
Awuah 2008	Case series	Massive vaginal tears Damage to rectal wall	
Berardi 1985	Cross- sectional+	Perineal injury	Not specified
Bohoussou 1986	Cross- sectional+	Perineal tears	Not specified
De Silva 1989	Cross- sectional+	2nd tear Urethral tear	Second degree tear of the perineum Tear of the urethra
Diop 1998	Cross- sectional+	Tears	Tearing of the perineum
Dörflinger 2000	Case series	Tear degree IV	
Elnashar 2007	Cross- sectional+	Tears (1st baby)	Perineal tear
Hakim 2001	Cross- sectional+	Lacerations/tear	Perineal laceration with 1st degree tear, 2nd degree tear, 3rd degree tear
Johnson 2005	Cross- sectional+	1st-4th degree tears	Perineal lacerations (none, 1º/2º, 3º/4º/cervical/vaginal

Larsen 2002a	Cross- sectional+	Tear (1st pregnancy, 2nd pregnancy, all pregnancies)	Self reported based on the interviewer question: did you have "a large tear that needed stitching" (p 258)
Lupo 1999	Cross- sectional+	Perineal laceration 3rd degree	"perineal laceration of 3rd degree of greater" (p19S)
McCaffrey 1995	Cross- sectional	Perineal laceration or episiotomy	•
McSwiney 1992	Case report	Perineal and vaginal tears	Perineal and vaginal tears (led to rapid hemorrhage)
Millogo-Traore 2007	Cross- sectional+	Perineal tears	First degree tears (tearing of vulvar tissue), second degree tears (bulbocavernosus muscle tear and anterior part of the central fibrous tissue)
Ndiaye 2010	Cross- sectional+	Perineal tear	Not specified
Osifo 2009	Case series	Perineal tear during delivery	Perineal tear during delivery (led to uncontrolled bleeding)
Slanger 2002	Cross- sectional+	Perineal tear	A large tear (perineal tear)
Vangen 2002	Cross- sectional+	Perineal injury degree 2-4	"perineal injury was diagnosed by the obstetrician and comprised of perineum laceration, anal sphincter or vaginal wall degree 2-4" (p 318)
WHO study grop 2006	Cross- sectional+	Perineal tear	Not specified
Wuest 2009	Cross- sectional+	Any tear, 1st degree, 2nd degree, 3rd degree	"The severity of any perineal tear was classified at the time of delivery using the 9th International Classification of Disease. A first-degree vaginal tear was defined as damage to the superficial vaginal epithelium; a second-degree tear as involving the vaginal epithelium and deeper muscles, but excluding the anal sphincters. A third-degree perineal tear was defined as a partial or complete anal sphincter rupture without the involvement of the anal mucosa and a fourth-degree tear as a rupture of the anal sphincter and mucosa" (p 1205).

Legend: Cross-sectional+ = comparative cross-sectional study.

## **Cesarean section**

Table 9.1: Study outcomes for non-comparative studies that reported on cesarean section

Author	Study design	Outcome	Result
Abor 2006	Cross-sectional	Cesarean section	4/24 (16.7%)
Al-Hussaini 2003	Cross-sectional	Cesarean section	52/306 (17.0%)
Bonessio 2001	Case series	Cesarean section	1/4 (25.0%)
Chalmers 2000	Cross-sectional	Cesarean section	218/432 (50.5%)
McCaffrey 1995	Cross-sectional	Cesarean section	6/23 (26.1%)

# **Episiotomy**

Table 10.1: Study outcomes for non-comparative studies that reported on episi-

otomy

Author	Study design	Outcome	Result
Abor 2006	Cross-sectional	Episiotomy	7/24 (29.2%)
Al-Hussaini 2003	Cross-sectional	Mediolateral episiotomy	241/254 (94.9%)
Awuah 2008	Case series	Large episiotomies	10/70 (14.0%)
Bayoudh 1995	Cross-sectional	Double episiotomy	10/300 (3.3%)
Bohoussou 1986	Cross-sectional	Episiotomy	276/1097 (25.2%)

Table 11.1: Included studies that reported on episiotomy and their description

of episiotomy

Author	Study design	Description
Abor 2006	Cross-sectional	Episiotomy
Adinma 1997	Cross-sectional+	Episiotomy 1st delivery Episiotomy all deliveries
Al-Hussaini 2003	Cross-sectional	Mediolateral episiotomy
Awuah 2008	Case series	Large episiotomies
Bayoudh 1995	Cross-sectional	Double episiotomy
Berardi 1985	Cross-sectional+	Episiotomy
Bohoussou 1986	Cross-sectional	Episiotomy
De Silva 1989	Cross-sectional+	Episiotomy
Diop 1998	Cross-sectional+	Episiotomy
Elnashar 2007	Cross-sectional+	Episiotomy (1st baby)
Hakim 2001	Cross-sectional+	Episiotomy
Larsen 2002a	Cross-sectional+	Episiotomy (1st pregnancy, 2nd pregnancy, all pregnancies)
Millogo-Traore 2007	Cross-sectional+	Episiotomy
Ndiaye 2010	Cross-sectional+	Episiotomy
Orji 2006	Cross-sectional+	Episiotomy
Slanger 2002	Cross-sectional+	Episiotomy
WHO study grop 2006	Cross-sectional+	Episiotomy
Wuest 2009	Cross-sectional+	Episiotomy

Legend: Cross-sectional+ = comparative cross-sectional study.

## **Instrumental delivery**

Table 12.1: Study outcomes for non-comparative studies that reported on in-

strumental delivery

Author	Study design	Outcome	Result
Abor 2006	Cross-sectional	Vacuum extraction	2/24 (8.3%)
Chalmers 2000	Cross-sectional	Vacuum extraction Forceps	28/432 (6.5%) 13/432 (3.0%)
McCaffrey 1995	Cross-sectional	Instrumental delivery	3/23 (13.0%)

## **Obstetric hemorrhage**

Table 13.1: Study outcomes for non-comparative studies that reported on ob-

stetric hemorrhage

Stoti to Homori Hugo			
Author	Study design	Outcome	Result
Awuah 2008	Case series	Severe intrapartum haemorrhage	19/70 (27.1%)
Dörflinger 2000	Case series	Hemorrhage >500 ml	4/29 (13.8%)

Table 14.1: Included studies that reported on obstetric hemorrhage and their

description of obstetric hemorrhage

Author	Study design	Outcome	Description
Awuah 2008	Case series	Severe intrapartum haemorrhage	
Chibber 2011	Cross-sectional+	Post-partum hemorrhage	Not specified
De Silva 1989	Cross-sectional+	Post-partum hemorrhage	≥500ml
Diop 1998	Cross-sectional+	Hemorrhage	Not specified
Dörflinger 2000	Case series	Hemorrhage	>500 ml
Hakim 2001	Cross-sectional+	Shock/bleeding	Not specified
Johnson 2005	Cross-sectional+	Post-partum hemorrhage	Postpartum hemorrhage (yes, no)
Ndiaye 2010	Cross-sectional+	Obstetric hemorrhage	Not specified
Slanger 2002	Cross-sectional+	Hemorrhage	Self-report question "so much bleeding that they feared they would die" (p176)
Vangen 2002	Cross-sectional+	Post partum hemorrhage	≥500ml
WHO study group 2006	Cross-sectional+	Post-partum blood loss	≥500ml
Wuest 2009	Cross-sectional+	Maternal blood loss	Continous

Legend: Cross-sectional+ = comparative cross-sectional study.

## **Difficult delivery**

Table 15.1: Study outcomes for non-comparative studies that reported on dystocia/difficult labor

Author Study design		Outcome	Result		
Akotionga 2001 Case series		Difficult delivery	5/40 (12.5%)		
Pritchard 1969	Case report	Dystocia (difficult labor)	3 patients		

 ${\bf Table~16.1: Studies~that~reported~difficult~delivery~and~their~description~of~difficult~delivery~and~their~description~of~difficult~delivery~and~their~description~of~difficult~delivery~and~their~description~of~difficult~delivery~and~their~description~of~difficult~delivery~and~their~description~of~difficult~delivery~and~their~description~of~difficult~delivery~and~their~description~of~difficult~delivery~and~their~description~of~difficult~delivery~and~their~description~of~difficult~delivery~and~their~description~of~difficult~delivery~and~their~description~of~difficult~delivery~and~their~description~of~difficult~delivery~and~their~description~of~difficult~delivery~and~their~description~of~difficult~delivery~and~their~description~of~difficult~delivery~and~delive$ 

cult delivery

Study design	Outcome	Description		
Case series	Difficult delivery			
Cross-sectional+	Obstructed labor	Not specified		
Cross-sectional+	Difficult delivery	Not specified		
Cross-sectional+	Problems during delivery (because of circumcision)	Self-report question "Women who had had at least one birth were also asked whether they had had any problem at the time of delivery." (p.214)		
Cross-sectional+	Problems during delivery (because of circumcision)	Self-report question "all female respondents who had ever had sex were asked whether they had had any problems or complications due to circumcision during sexual intercourse or at the time of delivery" (p.168)		
Cross-sectional+	Difficulties with delivery	Not specified, except "all women included in the study who had ever given birth were asked whether they had experienced any difficulties during any of their deliveries, and if so, to describe the type of complication" (p 222)		
Cross-sectional+	Observable difficulties with delivery	Not specified, except "any difficulties in childbirth were noted on the data-collection form" (p 222)		
Cross-sectional+	Obstructed labor/dystocia	Not specified		
Case report	Dystocia (difficult labor)			
Cross-sectional+	Obstructed labor	Not specified		
	Cross-sectional+ Cross-sectional+ Cross-sectional+  Cross-sectional+  Cross-sectional+  Cross-sectional+  Cross-sectional+  Cross-sectional+  Cross-sectional+  Cross-sectional+	Cross-sectional+ Obstructed labor  Cross-sectional+ Difficult delivery  Cross-sectional+ Problems during delivery (because of circumcision)  Cross-sectional+ Problems during delivery (because of circumcision)  Cross-sectional+ Difficulties with delivery  Cross-sectional+ Observable difficulties with delivery  Cross-sectional+ Obstructed labor/dystocia  Case report Dystocia (difficult labor)		

Legend: Cross-sectional+ = comparative cross-sectional study.

#### Other obstetrical and antenatal complications

Table 17.1: Study outcomes for non-comparative studies that reported on other obstetrical and antenatal complications

Author	Study design	Outcome	Result
Awuah 2008	Case series	Fistulae	10/70 (14.0%)

Bonessio 2001	Case series	Infection	1/4 (25.0%)
CAR DHS 1995	Cross-sectional	Obstetric complications	7/677 (1.1%)
Litorp 2008	Cross-sectional	Obstetric difficulties	18/37 (48.6%)
McCaffrey 1995	Cross-sectional	Not normal vaginal delivery	1/17 (7.1%)
Philp 1927	Case report	Death (after childbirth after FGM/C)	1 patient
Preston 1937	Case report	Birth per rectum	1 patient

# **Appendix 6: GRADE Evidence profile tables**

The following three GRADE Evidence profile tables (tables 18.1-20.1) present our assessment of the quality of the evidence, organized according to comparison.

Table 18.1: GRADE Evidence profile table for the comparison cut vs non-cut

			Quality asso	essment			Summary of findings				
			quarty asso				No of patients E			Effect	
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considera- tions	FGM/C	non-FGM/C	Relative (95% CI)	Absolute	Quality
Prolonge	d labor										
5 <sup>1</sup>	observational studies	serious <sup>2</sup>	serious³	no serious indi- rectness	no serious imprecision	none	471/6324 (7.5%)	33345/708755 (4.7%)	RR 1.69 (1.03 to 2.77)	3 more per 100 (from 0 more to 8 more)	⊕OOO VERY LOW
Obstetric	tears										
144	observational studies	serious <sup>5</sup>	serious <sup>6</sup>	no serious indi- rectness	no serious imprecision	none	1789/18572 (9.6%)	24703/720871 (3.4%)	RR 1.39 (1.07 to 1.82)	1 more per 100 (from 0 more to 3 more)	⊕OOO VERY LOW
Cesarean	section				L						
15	observational studies	serious <sup>7</sup>	serious <sup>8</sup>	no serious indi- rectness	serious <sup>9</sup>	none	5123/41306 (12.4%)	439456/999999 (43.9%)	RR 1.18 (0.99 to 1.4)	8 more per 100 (from o fewer to 18 more)	⊕OOO VERY LOW
Episioto	ny										
<b>11</b> <sup>10</sup>	observational studies	serious <sup>11</sup>	serious <sup>12</sup>	no serious indi- rectness	serious <sup>13</sup>	none	10911/23869 (45.7%)	3672/11598 (31.7%)	RR 1.19 (0.98 to 1.44)	6 more per 100 (from 1 fewer to 14 more)	⊕OOO VERY LOW
Instrume	ental delivery (	cross-section	al studies)	1							
5	observational	serious <sup>14</sup>	no serious incon-	no serious indi-	no serious	none	94/2234 (4.2%)	240/6649 (3.6%)	RR 1.65 (1.29	2 more per 100 (from 1	⊕000

	studies		sistency	rectness	imprecision				to 2.12)	more to 4 more)	VERY LOW
Obstetr	ic hemorrhage										
815	observational studies	serious¹6	serious <sup>17</sup>	no serious indi- rectness	no serious imprecision	none	2043/26840 (7.6%)	31427/719827 (4.4%)	RR 2.04 (1.36 to 3.05)	5 more per 100 (from 2 more to 9 more)	⊕OOO VERY LOW
Difficul	t delivery (cross	-sectional s	tudies)								
3	observational studies	serious <sup>18</sup>	serious <sup>19</sup>	no serious indi- rectness	serious <sup>20</sup>	none	222/2673 (8.3%)	75/3588 (2.1%)	RR 3.35 (1.71 to 6.55)	5 more per 100 (from 1 more to 12 more)	⊕OOO VERY LOW
Fever											
3	observational studies	serious <sup>21</sup>	no serious incon- sistency	no serious indi- rectness	serious <sup>22</sup>	none	42/1110 (3.8%)	4/536 (0.75%)	RR 1.61 (0.31 to 8.41)	o more per 100 (from 1 fewer to 6 more)	⊕OOO VERY LOW
Induction	on of labor			<u>'</u>	<b>.</b>		<u> </u>		'		
3	observational studies	serious	serious <sup>23</sup>	no serious indi- rectness	no serious imprecision	none	1803/9451 (19.1%)	382889/999999 (38.3%)	RR 1.17 (1.01 to 1.36)	7 more per 100 (from 0 more to 14 more) 0 more per 100 (from 0 more to 0 more)	⊕OOO VERY LOW

<sup>&</sup>lt;sup>1</sup> One additional study includes this outcome, but we have not received the data.

<sup>&</sup>lt;sup>2</sup> 5 of 5 studies had low methodological study quality.

 $<sup>^{3}</sup>$  Considerable heterogeneity indicated by I2 (I2=92%) showed inconsistency across studies.

<sup>&</sup>lt;sup>4</sup> One additional study includes this outcome, but we have not received the data.

 $<sup>^{\</sup>rm 5}$  12 of 14 studies had low methodological study quality.

<sup>&</sup>lt;sup>6</sup> Considerable heterogeneity indicated by I2 (I2=89%) showed inconsistency across studies.

<sup>&</sup>lt;sup>7</sup> 11 of 15 studies had low methodological study quality.

<sup>&</sup>lt;sup>8</sup> Considerable heterogeneity indicated by I2 (I2=97%) showed inconsistency across studies.

<sup>&</sup>lt;sup>9</sup> CI is wide, crosses limitations of precision (CI=0.94, 1.51).

<sup>&</sup>lt;sup>10</sup> One additional study includes this outcome, but we have not received the data.

<sup>&</sup>lt;sup>11</sup> 8 of 11 studies had low methodological study quality.

<sup>&</sup>lt;sup>12</sup> Considerable heterogeneity indicated by I2 (I2=96%) showed inconsistency across studies.

<sup>&</sup>lt;sup>13</sup> CI is wide, crosses limitations of precision (CI=0.98, 1.44).

<sup>&</sup>lt;sup>14</sup> 4 of 5 studies had low methodological study quality.

<sup>&</sup>lt;sup>15</sup> One additional study includes this outcome, but we have not received the data.

<sup>&</sup>lt;sup>16</sup> 6 of 8 studies had low methodological study quality.

<sup>&</sup>lt;sup>17</sup> Considerable heterogeneity indicated by I2 (I2=92%) showed inconsistency across studies.

<sup>&</sup>lt;sup>18</sup> 2 of 3 studies had low methodological study quality.

<sup>&</sup>lt;sup>19</sup> Considerable heterogeneity indicated by I2 (I2=77%) showed inconsistency across studies.

<sup>&</sup>lt;sup>20</sup> CI is wide (CI=1.71, 6.55) and number of events is less than 300.

<sup>&</sup>lt;sup>21</sup> 2 of 3 studies had low methodological study quality.

<sup>&</sup>lt;sup>22</sup> Total number of events is less than 300.

<sup>&</sup>lt;sup>23</sup> Considerable heterogeneity indicated by I2 (I2=91%) showed inconsistency across studies.

Table 19.1: GRADE Evidence profile table for the comparison FGM/C type I vs II

			Quality ass	ocemont		Summary of findings						
			Quanty ass	essment	No of patients		Effect					
No of studies	Design	Limitations	imitations Inconsistency Inc		Indirectness Imprecision Other		FGM/C type	FGM/C type II	Relative (95% CI)	Absolute	Quality	
Obstetric	tears											
2	observational studies		no serious incon- sistency	no serious indi- rectness	serious <sup>2</sup>	none	457/6315 (7.2%)		RR 0.70 (0.47 to 1.04)	3 fewer per 100 (from 6 fewer to 0 more)	⊕OOO VERY	
					-,	0%		0 fewer per 100 (from 0 fewer to 0 more)	LOW			
Cesarean	section											
3	observational studies		no serious incon- sistency	no serious indi- rectness	no serious impre- cision	none	489/7466 (6.5%)	499/7929 (6.3%)	RR 1.07 (0.94 to 1.2)	o more per 100 (from o fewer to 1 more)	⊕OOO VERY LOW	
Episioton	ny											
3	observational studies	serious <sup>4</sup>	serious <sup>5</sup>	no serious indi- rectness	very serious <sup>6</sup>	none	2005/7928 (25.3%)	2209/7125 (31%)	RR 0.92 (0.61 to 1.4)	2 fewer per 100 (from 12 fewer to 12 more)	⊕OOO VERY LOW	

<sup>&</sup>lt;sup>1</sup> 1 of 2 studies had low methodological study quality.

<sup>&</sup>lt;sup>2</sup> CI is wide, crosses limitations of precision (CI=0.47, 1.04).

<sup>&</sup>lt;sup>3</sup> 2 of 3 studies had low methodological study quality.

<sup>&</sup>lt;sup>4</sup> 2 of 3 studies had low methodological study quality.

 $<sup>^{\</sup>rm 5}$  Considerable heterogeneity indicated by I2 (I2=78%) showed inconsistency across studies.

<sup>&</sup>lt;sup>6</sup> CI is wide, crosses limitations of precision (CI=0.61, 1.40).

Table 20.1: GRADE Evidence profile table for the comparison FGM/C type I-II vs III

		_	Quality assess	sment	Summary of findings							
quanty assessment								atients		Effect		
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considera- tions	FGM/C type I-II	FGM/C type III	Relative (95% CI)	Absolute	Quality	
Problems	Problems during delivery											
	observational studies		_	no serious indi- rectness	serious	none	189/2443 (7.7%)	947/3602 (26.3%)	RR 0.24 (0.21 to 0.28)	20 fewer per 100 (from 19 fewer to 21 fewer)	⊕OOO VERY LOW	

<sup>&</sup>lt;sup>1</sup> Number of events is less than 300.